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Abstract
Detection of biomarker genes play a crucial role in disease detection and treatment. Bioin-
formatics offers a variety of approaches for identification of biomarker genes which play
key roles in complex diseases. These computational approaches enhance the insight de-
rived from experiments and reduce the efforts of biologists and experimentalists. This is
essentially achieved through prioritizing a set of genes with certain attributes.
In this thesis, we show that understanding the regulatory mechanisms underlying stem
cells helps to identify cancer biomarkers. We got inspired by the regulatory mechanisms
of the pluripotency network in mouse embryonic stem cells and formulated the prob-
lem where a set of master regulatory genes in regulatory networks is identified with two
combinatorial optimization problems namely as minimum dominating set and minimum
connected dominating set in weakly and strongly connected components. Then we applied
the developed methods to regulatory cancer networks to identify disease-associated genes
and anti-cancer drug targets in breast cancer and hepatocellular carcinoma (chapter 3).
As not all the nodes in the solutions are critical, we developed a prioritization method to
rank a set of candidate genes which are related to a certain disease based on systematic
analysis of the genes that are differentially expressed in tumor and normal conditions
(chapter 5). Moreover, we demonstrated that the topological features in regulatory net-
works surrounding differentially expressed genes are highly consistent in terms of using
the output of several analysis tools (chapter 6). We compared two randomization strate-
gies for TF-miRNA co-regulatory networks to infer significant network motifs underlying
cellular identity. We showed that the edge-type conserving method surpasses the non-
conserving method in terms of biological relevance and centrality overlap (chapter 7).
We presented several web servers and software packages that are publicly available at no
cost. The Cytoscape plugin of minimum connected dominating set identifies a set of key
regulatory genes in a user provided regulatory network based on a heuristic approach.
The ILP formulations of minimum dominating set and minimum connected dominating
set return the optimal solutions for the aforementioned problems. Our source code is
publicly available (chapter 3). The web servers TFmiR and TFmiR2 construct disease-,
tissue-, process-specific networks for the sets of deregulated genes and miRNAs provided
by a user. They highlight topological hotspots and offer detection of three- and four-node
FFL motifs as a separate web service for both organisms mouse and human (chapter 4,8).
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Kurzfassung
Die Gendetektion von Biomarkern spielt eine wesentliche Rolle bei der Erkennung und Be-
handlung von Krankheiten. Die Bioinformatik bietet eine Vielzahl von Ansätzen zur Iden-
tifizierung von Biomarker-Genen, die bei komplizierten Erkrankungen eine Schlüsselrolle
spielen. Diese computerbasierten Ansätze verbessern die Erkenntnisse aus Experimenten
und reduzieren den Aufwand von Biologen und Forschern. Dies wird hauptsächlich erre-
icht durch die Priorisierung einer Reihe von Genen mit bestimmten Attributen. In dieser
Arbeit zeigen wir, dass die Identifizierung von Krebs-Biomarkern leichter gelingt, wenn wir
die den Stammzellen zugrunde liegenden regulatorischen Mechanismen verstehen. Dazu
angeregt wurden wir durch die regulatorischen Mechanismen des Pluripotenz-Netzwerks
in embryonalen Maus-Stammzellen. Wir formulierten und haben das Problem der Identi-
fizierung einer Reihe von Master-Regulator-Genen in regulatorischen Netzwerken mit zwei
kombinatorischen Optimierungsproblemen, nämlich als minimal dominierende Menge und
als minimal zusammenhängende dominierende Menge in schwach und stark verbundenen
Komponenten. Die entwickelten Methoden haben wir dann auf regulatorische Krebsnet-
zwerke angewandt, um krankheitsassoziierte Gene und Zielproteine für Medikamenten
gegen Brustkrebs und hepatozelluläres Karzinom zu identifizieren (Kapitel 3). Im Hin-
blick darauf, dass nicht alle Knoten in den Lösungen wesentlich sind, haben wir basierend
auf der systematischen Analyse von Genen, die unterschiedlich bei Tumor- und Normalbe-
dingungen reagieren, eine Priorisierungsmethode entwickelt, um einen Satz von Kandi-
datengenen in eine Reihenfolge zu bringen, die einer bestimmten Krankheit zugeordnet
sind (Kapitel 5). Darüber hinaus haben wir gezeigt, dass die topologischen Eigenschaften
in regulatorischen Netzwerken, die die deregulierte Gene umgeben, sehr einheitlich in
Bezug auf den Einsatz verschiedener Analysewerkzeuge sind (Kapitel 6). Wir haben zwei
Randomisierungsstrategien für TF-miRNA-Co-regulatorische Netzwerke verglichen, um
signifikante Netzwerkmotive herauszufinden, welche zellulärer Identität zugrunde liegen.
Wir haben gezeigt, dass die Edge-Type-Erhaltungsmethode, die nicht-erhaltende Meth-
ode in Bezug auf biologische Relevanz und zentrale Überlappung übertrifft (Kapitel 7).
Wir haben mehrere Softwarepakete und Webserver vorgestellt, die allgemein und kosten-
los zugänglich sind. Das Cytoscape Plugin für die Identififizierung, der minimal verbun-
dener dominierenden Mengen identifiziert einen Satz von regulatorischen Schlüsselgenen
in einem vom Benutzer bereitgestellten regulatorischen Netzwerk basierend auf einem
heuristischen Ansatz. Die ILP Formulierungen, der minimal dominierenden Menge und
der minimal verbundenen dominierenden Menge liefern die optimalen Lösungen für die
oben vorgenannten Probleme. Unser Quellcode hierfür ist öffentlich verfügbar (Kapitel3).
Die Webserver TFmiR und TFmiR2 erzeugen Krankheits-, Gewebe- und prozessspezifis-
che Netzwerke für die von einem Benutzer bereitgestellten deregulierten Gene und miR-
NAs. Außerdem verwenden die Webserver topologische Merkmale, um Hotspot-Knoten
ix
xhervorzuheben und bieten die Erkennung von drei und vier Knoten FFL Motiven als
separaten Web-Service für beide Organismen, Maus und Mensch (Kapitel 4,8).
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Chapter 1
An Introduction to Cellular Regulatory
Networks
Cancer is a disease that affects a very large number of people around the world with the po-
tential to cause death. Being diagnosed with cancer has profound emotional effects on the
patients and their families (de Leeuw et al., 2000; Cook et al., 2018). There are a variety
of treatments to address this disease such as chemotherapy, radiotherapy, immunotherapy
and etc, (Urruticoechea et al., 2010). Reprogramming of terminally differentiated cells
to induced pluripotent stem cells (IPSCs) has recently become feasible by inducing over-
expression of a few transcription factors (TFs) Oct4, Sox2, Myc and Klf4 (Takahashi and
Yamanaka, 2006). This finding opened promising strategies for patient-specific regener-
ative medicine (Robinton and Daley, 2012). Understanding the regulatory mechanisms
underlying reprogramming events helps to increase the reprogramming efficiency (Arty-
omov et al., 2010). To achieve this goal, we worked from the opposite direction with the
aim to first understand the regulatory mechanisms underlying stem cells and the hope
that this may help to identify cancer biomarkers and dominating pathways in the can-
cer networks. This chapter provides a basic introduction to cellular regulatory networks,
specifically underlying the cellular identity in embryonic stem cells (ESCs). Then I de-
scribe the common characteristics between the behaviours of stem cells and that of cancer
stem cells. Finally I provide an overview over the databases that collected regulatory
interactions between TFs, miRNAs and target genes.
1.1 Regulatory networks
Gene expression is the basis of cellular identity. Basically, genes are transcribed into
mRNA molecules under regulation of TFs and the resulting mRNAs are translated sub-
sequently into the proteins. There are other regulators in the cell that affect the gene
expression such as miRNAs. miRNAs are small non-coding RNAs which bind to mRNAs
after transcription, leading usually to translational repression or target degradation and
gene silencing (Kusenda et al., 2006; Bartel, 2009; Le et al., 2013), see Figure 1.1. Inside
the cell, TFs interact with other TFs, as well as with their target genes. These interactions
form a cell-specific gene regulatory network (GRN) which governs the particular cellular
identity. TFs affect the transcription level of their target genes either in form of activation
1
2Figure 1.1: A graphical description of the regulatory effects of TFs and miRNAs on the
target genes. The regulatory interactions are TF→ miRNA, TF→ gene, miRNA→ gene
and miRNA → TF. The figure is from the publication by (Xu et al., 2013).
or repression.
Modern GRNs consider the regulatory effect of miRNAs in the network. In TF-miRNA
co-regulatory networks, target genes can be regulated by TFs and miRNAs. Therefore,
four types of edge types corresponding to four regulatory interactions (TF → miRNA,
TF → gene , miRNA → gene and miRNA → TF) are considered between TFs, miRNAs
and their target genes in these networks.
1.2 Stem cells
In multicellular organisms, there are different cell types, expressing different sets of pro-
teins with different functions. Stem cells are distinguished from other cells in the body,
mainly based on the two characteristics of self-renewal and the potential for cellular dif-
ferentiation. Stem cells are classified into several groups based on their different potential
for cellular differentiation. Totipotent stem cells have the maximum capability of cellular
differentiation. They can generate any type of cells in the body. Unipotent stem cells
have the least capacity. They can generate solely cells of the same type. The reason
such cells are termed stem cells is mainly based on the self-renewal ability. In between,
there are pluripotent stem cells mainly in embryos that contain pluripotency networks.
Pluripotency networks in mouse ESCs are maintained by a few directly interacting TFs
which share many target genes (Kim et al., 2008), see Figure 1.2. Slight changes in the
expression level of these TFs lead the stem cells to differentiation (Kim et al., 2008).
There is hope that understanding the genetic and epigenetic states of the pluripoteny
networks may help to enhance the efficiency of reprogramming, facilitating a treatment
for cancer. Using this treatment strategy, terminally differentiated cells can be repro-
grammed into IPSCs under the over-expression of few TFs. Creating IPSCs is essential
for creating patient-specific stem cells for the purpose of regenerative medicine (Artyomov
et al., 2010). Moreover, understanding the mechanisms underlying stem cells might help
to target the key regulators and pathways which are responsible for tumor growth in
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Figure 1.2: A graphical description of the pluripotency network in a mouse ESC. The
nodes colored blue display the pluripotency nodes. The other colors show the lineage
markers. Arcs indicate that the node at the tail regulates the expression of the head
node. The figure is from the publication by (Xu et al., 2014).
cancer stem cells (Nazari et al., 2018).
1.3 Cancer
Cancer constitutes a group of diseases involving abnormal cell-growth with the potential
of causing metastasis, see Figure 1.3. These diseases are generally divided into benign
tumors as well as malignant tumors. Malignant tumors are usually progressive. It has
been shown that a minimal set of deregulated biological processes such as deregulated
cell proliferation and suppression of apoptosis are enough to render the cancer progressive
(Evan and Vousden, 2001). There is a hypothesis that malignant cancers originate either
from tissue-specific cells or progenitors that have abnormal indefinite divisions (Cohnheim,
1867).
Cancer stem cells are special stem cells mainly because they can generate an indefinite
number of cancer cells and they can also generate different types of tumors (Reya et al.,
2001). Based on cancer stem cell hypothesis that a subpopulation of tumor cells have
characteristic similar to ESCs and cause the tumor growth (Reya et al., 2001; Rahman
et al., 2011), researchers and therapists target the cancer stem cells than the whole tumors
(Tan et al., 2006). Therefore, identification of key regulators of the cancer stem cells which
are responsible for tumor growth is a promising strategy for cancer treatment (Nazari
et al., 2018).
In this thesis, I worked mainly on two types of cancers, breast cancer (breast neoplasms)
and liver cancer (hepatocellular carcinoma). Breast cancer is the most common invasive
group of diseases in women that develops from breast tissue (McGuire et al., 2015). It
occurs due to abnormal proliferation of abnormal breast cells. Damaged cells can infect
4Figure 1.3: Illustration of tumor forming. The figure is from the (Cancer research UK)
other tissues by spreading through the body. Hepatocellular carcinoma is one of the most
common cancers which occurs in the liver and affects more men than women (Seton-
Rogers, 2014).
1.4 Regulatory Databases
To construct TF-miRNA co-regulatory disease networks, TFmiR and TFmiR2 web servers
use a variety of regulatory interaction databases for the case of TF → gene, TF →
miRNA, miRNA → gene, miRNA → miRNA and gene-gene interactions. The networks
constructed based on these databases are filtered to disease-specific networks using disease
databases.
Transcription factor-target gene interaction (TF → gene)
TRANSFAC is a manually curated database of TFs, their target genes and regulatory
binding sites for a variety of eukaryotic organisms including mouse and human (Matys
et al., 2003, 2006).
OregAnno is an open-source and open-access TF → gene interaction database which uti-
lizes a literature curation system for annotation of experimentally identified regulatory
binding sites from published papers for a variety of species including mouse and human
(Griffith et al., 2008; Lesurf et al., 2016).
TRED is a database of TF-target gene pairs providing experimentally-validated and com-
putationally predicted regulatory elements such as promoters and binding motifs for rat,
mouse and human (Jiang et al., 2007).
Transcription factor-miRNA interaction (TF → miRNA)
TransmiR is a regulatory database of TF → miRNA interactions. It compiles manually
curated experimentally validated interactions from a wide variety of publications deter-
mining their associations in tumors or other diseases (Wang et al., 2010).
ChIPBase employs the ChIP-Seq technology which combines chromatin immunoprecipi-
tation with next-generation DNA sequencing to identify transcription factor binding site
with high sensitivity in diverse tissues and cell lines for six organisms including mouse and
human. Based on these predictions a large database of regulatory interactions between
TFs and miRNAs were compiled (Yang et al., 2013; Zhou et al., 2017).
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miRNA-target gene interaction (miRNA → gene)
TarBase (Sethupathy et al., 2006; Vergoulis et al., 2012), miRTarBase (Hsu et al., 2010;
Chou et al., 2018) and miRecords (Xiao et al., 2009) are manually curated databases for
miRNA-target interactions with experimentally tested resources derived from the litera-
ture for different species including mouse and human.
StarBase utilizes high-throughput CLIP-Seq and degradome sequencing methods to iden-
tify the sites of Argonaute interaction and miRNA cleavage sites to detect the miRNA
target interactions for six organisms including mouse and human (Yang et al., 2011; Li
et al., 2014a).
miRNA-miRNA interaction (miRNA → miRNA)
PmmR infers miRNA-miRNA interactions for human from the induced miRNA-TF regu-
latory network that was constructed by combining all possible regulations between miR-
NAs and TFs. Topological analysis of the network reveals many TF modules that are
enriched in different functional categories. Many of the identified miRNAs modules are
significantly associated with common diseases. A putative miRNA inter-regulatory net-
work is derived from the induced regulatory miRNA-TF network (Sengupta and Bandy-
opadhyay, 2011).
gene-gene interaction
Mentha integrates manually curated experimental detection of physical protein-protein
interactions data avoiding genetic and inferred interactions for many species including
mouse and human (Calderone et al., 2013). In contrast, STRING is a database that
integrates information extracted by text mining and prediction methods. The database
contains functional links between proteins that are inferred from genomic associations in
form of gene-gene interactions. In addition to direct interactions, STRING takes into
account the functionally associated interactions whose genes were regulated at the same
time. The third group are genes whose protein products aggregate in the cell to form
protein complexes. STRING integrates the three types of interactions and assigns a con-
fidence score to each interaction indicating the significance of the interaction predictions
(von Mering et al., 2003; Szklarczyk et al., 2017).
1.5 Topological Measures in Disease-specific Networks
Identification of disease genes among lots of candidates is a very challenging task. A
disease network is defined by a set of potential disease genes that are connected with each
other to make a specific disease while carrying known phenotypes of the disease (Goh
et al., 2007). Although the effect of hub-degree genes in disease networks is considerable,
a large number of disease genes are not among the hubs (Goh et al., 2007; Liu et al.,
2011; Nazarieh et al., 2016). Therefore a prioritization method which identifies the most
promising disease genes with considering the disease network and giving priority to both
hubs as well as non-hubs is very necessary. This idea is the base of our TopControl method
which we describe later in chapter 5.
61.5.1 Disease databases: DisGeNET, HMDD
DisGeNET (Bauer-Mehren et al., 2010; Piñero et al., 2017) is a Cytoscape plugin that
provides access to a gene-disease database. The database is built by integrating several
public databases. It enables the user to query and analyze the gene-disease networks for
human. The gene-disease network is represented by undirected bipartite graphs of two
disjoint independent sets of genes and diseases, respectively. DisGeNET allows multiple
edges between two set of nodes representing different source types. The networks are
constructed from the bipartite graph by connecting the nodes via edges if the two genes
or diseases share a disease or gene in the bipartite graph.
The human miRNA disease database (HMDD) provides manually collected miRNA-
disease associations from the literature. Similar to DisGeNET, a miRNA-disease network
is represented by a bipartite graph that connects two sets of nodes that represent miR-
NAs and diseases. The network is constructed from the bipartite graph by connecting
two disease nodes with an edge if the respective two diseases share at least one common
associated miRNA (Lu et al., 2008; Li et al., 2014b).
1.5.2 Centrality Measures
Centrality is a measure of importance of a node in a network. There are several ways to
measure centrality in regulatory networks. Degree centrality in PPI networks describes
the number of interactions that a protein has. In case of GRNs which are modeled with
directed graphs, degree centrality can refer to either indegree (the number of incoming
edges) or outdegree (the number of outgoing edges) or both of them, see equation 1.1.
Cdegree(u) = deg(u) (1.1)
Betweenness centrality describes the number of times that a gene acts as a connector
along the shortest path between any pair of nodes in the network as shown in equation
1.2. σst(u) stands for the number of times that node u stands on the shortest path from
node s to node t and σst shows the number of shortest paths between nodes s and t.
Cbetweenness(u) =
∑
s 6=u6=t∈V
σst(u)
σst
(1.2)
Closeness centrality in the connected network describes the inverse of the sum of the dis-
tances denoted by d(u, v) based on the shortest path between node u and all other nodes
in the network, see equation 1.3.
Ccloseness(u) =
1∑
v d(u, v)
(1.3)
Chapter 2
Computational Methods
Although deterministic algorithms with high speed are very demanding for the complex
structure of computational systems, biological systems require simple interpretable mod-
els. The corresponding algorithms need to make a trade-off between speed, robustness
and accuracy (Navlakha and Bar-Joseph, 2014). The robustness of the biological algo-
rithms is affected by the topology of biological networks. Dense topologies like cliques
are preferred to sparser topologies for the networks with little noise (Milo et al., 2002; Yu
et al., 2007). We discuss in chapter 3 more in detail about these issues.
This chapter begins with an explanation of optimization problems which I used for the
mathematical modeling of topological features in regulatory networks. Then I describe
the network motifs and the recent perspectives for considering these network modules.
I explain differentially expressed (DE) genes as I took them into account as potential
candidates for detecting disease-associated genes.
2.1 Combinatorial Optimization Problems
An optimization problem is a problem of minimizing (or maximizing) a function (called
the objective function) given a set of constraints. In optimization problems, we search
for the best solution among all the feasible solutions. An optimization problem can be
written in this form:
minimize f(x)
subject to gi(x) ≤ 0, i = 1, . . . ,m
hi(x) = 0, i = 1, . . . , p
(2.1)
where f(x) : Rn → R is the objective function to be minimized over the variable x,
gi(x) ≤ 0 are called inequality constraints, and hi(x) = 0 are called equality constraints.
A maximization problem can be turned into a minimization problem by negating the
objective function −f(x). If the objective function is a linear function of the variables
and the equality and inequality constraints are also linear, it is called linear problem. In an
integer linear program (ILP), the objective function and the constraints are linear and all
the variables are restricted to be integers. In a mixed integer linear program (MILP) some
variables are restricted to be integer. If a problem is solvable in polynomial time in the
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8worst case, then it is contained in the class P. The class NP contains all problems that are
solvable in polynomial time by a non-deterministic Turing machine (Cormen et al., 2003).
The solution of these problem are verifiable in polynomial time. Optimization problems
relate to decision problems, where a given optimization problem can be considered also
as a decision problem (answer yes or no) by setting bound on the optimal value (Cormen
et al., 2003). A decision problem is NP-hard if every problem in class NP can reduce to
it by polynomial time reduction (Gross and Yellen, 2005). A problem is NP-complete if
it is NP-hard and also contained in NP.
NP-complete Problems
Since the algorithms which solve NP problems can take a long time to execute, other
types of algorithms exist which search for a close to optimal solution in shorter time.
• Approximation: The cost of the solution is within a factor of optimal.
• Fixed parameter tractability: Such an algorithm solves the problem more quickly if
certain parameters are fixed than in general case.
• Heuristic: Such an algorithm returns a reasonably good result in a short time.
• Randomization: Such an algorithm reduces the running time using random numbers.
2.2 Network Motifs
Network motifs are recurring patterns of interactions between a predefined number of
elements in regulatory networks which occur at higher frequencies in the real biological
network than in random networks with the same size and connectivity characteristics
(Alon, 2007). Regulatory motifs have been found in a variety of organisms from bacteria
to human. The importance of network motifs is principally due to their biological func-
tion. Autoregulation motifs where a TF activates or represses the transcription of its own
gene modulate the speed of response to biological signals by facilitating the synthesis of
the amount of proteins that is required at the appropriate time. Positive autoregulation
motifs speed up the process and increase cell-cell variation in protein levels whereas nega-
tive autoregulation motifs slow down the process and decrease cell-cell variation in protein
levels (Alon, 2007). In contrast to autoregulation motifs, feedforward loops (FFLs) com-
prise of at least two regulators and one target gene which is regulated by both regulators,
see Figure 2.1. Since the regulatory interactions correspond to upregulator and down-
regulator regulatory factors, therefore eight FFLs exist in the transcriptional regulatory
networks (Alon, 2007).
In case of two target genes for the regulators, FFLs of size four are generated. Com-
posite FFLs, in which two regulators regulate each other were found in developmental
networks. Cascade motifs in which the target gene is activated by a regulator in which
the regulator itself is regulated by another regulator are useful for passing and processing
the information (Alon, 2007).
The computational process of network motif detection typically consists of three steps.
The first step is to detect all predefined structural subgraphs in the network. To find the
overrepresented subgraphs which occur in real network, more frequently than in random
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Figure 2.1: 3-node motifs in miRNA & TF synergistic regulatory networks. In FFLs the
gene is regulated via two paths: (1) a direct regulation by a main regulator (TF/miRNA)
and (2) an indirect regulation through an intermediate regulator (miRNA/TF) which is
itself regulated by the main regulator. Composite-TF/miRNA-mediated: mutual reg-
ulation of TF and miRNA besides regulation of the target gene by only one of them.
Cascade-TF/miRNA-mediated: are non-loop forms, including an indirect effect of the
main regulator (TF/miRNA) on the target gene only via another type of regulator (miR-
NA/TF). The 3rd row shows two non-cooperative motifs where the target gene is not
cooperatively regulated. The figure is from (Sadegh et al., 2017).
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networks, a large number of randomized networks need to be generated. The random-
ization strategy affects the significance of the motifs (Sadegh et al., 2017). p-value and
z-score are the statistical tests which may be used to indicate the significance of the find-
ings.
A novel challenge in this area is to identify network motifs underlying cellular identity
(Liang et al., 2015). (Megraw et al., 2013) detected sustained input switches among TFs
and miRNAs that constitute composite FFLs in TF-miRNA co-regulatory networks in
Arabidopsis network. When two regulators are activators, then the gene circuit ensures
stable downstream gene expression and functions and as a noise repression role when
both regulators are repressors (Megraw et al., 2013). To identify the network motifs that
underlie cellular identity, we considered the network motifs that involve a considerable
number of master regulators and key drivers detected by MCDS method (Sadegh et al.,
2017).
The meaningfulness of the network motifs relies on the strategy which generates random-
ized networks. Reliable results come from randomized networks that do not generate
a certain random network more often (Megraw et al., 2013). Variances of count dis-
tributions of subgraphs in randomized networks are an indicator for inferring uniform
sampling. The best randomization strategy is the one that is capable of detecting a few
significant motifs with high biological relevance. Fast network motif detection (FAN-
MOD) method applies the edge-switching method with considering both edge-conserving
and non-conserving variations maintains the in/out degree of the nodes during the ran-
domization. Edge switching works by selecting two edges from the biological network,
swap their endpoints and repeat this process for a predefined number of times. In case
of the conserving approach, edge switching is performed on edges of same type of in-
teraction. The non-conserving method has no obligation regarding the choice of edges.
The number of required edge swaps is described by Q ∗ L, where L is the number of
edges and Q is the number of iterations. Some tools like TFmiR (Hamed et al., 2015a)
suggest a default number for the number of iterations. (Liang et al., 2015) suggested max-
imum difference between a given network and each of the randomized networks. To avoid
under-shuﬄing, we suggested the number of edge swaps should satisfy minimum similar-
ity between the biological network and each of the randomized networks (Sadegh et al.,
2017). The goal in both the approaches is to generate randomized networks which are
fully shuﬄed (Liang et al., 2015; Sadegh et al., 2017). Unlike the edge-switching method
which swaps the edges with potential of under-shuﬄing and over-shuﬄing, weighted and
reverse swap (WaRSwap) method generates randomized networks without replacement
(Megraw et al., 2013). This way of randomization creates a trade-off between uniform
sampling and speed. To generate randomized networks, WaRSwap breaks the biological
network into multiple layers corresponding to different edge types. For each layer, it ap-
plies the WaRSwap algorithm which preserves the target indegree distribution (Megraw
et al., 2013). The algorithms consists of mainly three steps, see Figure 2.2. 1) it sorts the
source nodes in each layer based on their out-degrees in descending order. For each source
node Si, it computes attraction weight for each target Tj. 2) it matches the source node
Si to target nodes Tj using edges if they are weighted proportionally to sampling weights
if the degree of Si is less than the number of unsaturated target nodes. 3) if the degree
of Si is greater than the number of unsaturated target nodes, then it matches the source
node to each target that has available capacity. In case of unplaced edges, it performs
swapping (Megraw et al., 2013).
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Figure 2.2: A graphical description of WaRSwap (Weighted-and-Reverse-Swap) algo-
rithm. The algorithms comprises of two main strategies A) weighted selection B) reverse
swap to resolve conflicts. The figure is from (Megraw et al., 2013).
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2.3 Identification of DE Genes
There are mainly two ways to measure the expression of a gene using the RNA-Seq tech-
nology. Read counts refer to the number of reads mapping to gene segments in the DNA
sequence. The data are not comparable across the samples, due to different sequencing
depth, total number of reads, and sequencing biases (Conesa et al., 2016). Therefore
normalization of the data would be the first step before any downstream analysis. In
contrast, measures which remove the dependency of the data on the library size and gene
length such as read per kilobase of exon model per million reads (RPKM) and fragments
per kilobase of exon model per million mapped reads (FPKM) and transcript per mil-
lion (TPM) are most commonly used for the comparison of gene expression values across
different conditions (Conesa et al., 2016). In this dissertation, we focused on the read
count data for the purpose of inferring DE genes. The main reason for this was that the
TCGA data are available in the form of read counts. We exploited the four differential
gene expression analysis methods DESeq, edgeR, voom and VST which take read counts
as input and return p-values as an indicator of statistically significant DE gene. The
above-mentioned methods use DESeq and TMM normalization methods.
To identify DE genes, which are transcripts with different abundances between two sam-
ples, differential gene expression analysis methods get RNA-Seq reads from two different
samples and transcript sequences. To identify statistically significant DE genes, a statical
test is necessary which is based on modelling of the data distribution.
Since RNA-Seq data have discrete values, it is not possible to model the data with a
normal distribution. The Poisson distribution has just one parameter, µ which does not
allow for dealing with overdispersed data. Thus, it has been proposed to model RNA-Seq
count data with a negative binomial distribution (NB) with the two parameters mean µ
and variance σ2 as follows Kij ∼ NB(µij, σ2ij), where µij is the mean of the gene i in sam-
ple j and variance is σ2ij = µij + µijφij where φij is the dispersion parameter, controlling
the overdispersion level (Soneson and Delorenzi, 2013).
Poisson Distribution
Count data are modeled naturally by the Poisson distribution (Cameron and Trivedi,
2007). The Poisson distribution is described by the following formula where E[K] = µ
and V [K] = µ which imposes that mean and variance are equal.
Pr(K = k) = e
−µ ∗ µk
k! (2.2)
Negative Binomial Distribution
Sampling data from an appropriate Poisson distribution is challenging due to the problem
of accurately estimating µ (Cameron and Trivedi, 2007). Moreover, there is overdispersion
in count data due to unobserved heterogeneity which makes the model very restrictive to
model the read count (Cameron and Trivedi, 2007). An integer-valued random variable K
follows a NB distribution with parameters p ∈ (0, 1) and r ∈ (0,∞) if it follows equation
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2.3 as mentioned in (Cameron and Trivedi, 1998; Anders and Huber, 2010).
Pr(K = k) =
(
k + r − 1
r − 1
)
pr(1− p)k (2.3a)
p = µ
σ2
(2.3b)
r = µ
2
σ2 − µ (2.3c)
2.3.1 Differential Gene Expression Analysis Methods
A gene with observed difference in read counts between two conditions is termed a DE
gene. To decide whether, for a given gene, an observed difference in read counts is
statistically significant and did not occur due to random chance, a p-value is used. To
find the set of DE genes from RNA-Seq data, mean and variance need to be estimated for
distribution of expression values for each gene. But since the number of samples is often
too small, it is difficult to measure these parameters reliably.
DESeq
DESeq is a DE analysis method which takes the read count data as input. The data
are given as an n ∗ m table of counts kij, where i = 1, . . . , n relate to indexes of the
genes, and j = 1, . . . ,m relate to indexes of the samples. DESeq models count data with
a negative binomial distribution (NB) Kij ∼ NB(µij, σ2ij), where Kij is the number of
reads in sample j that are mapped to gene i with two parameters of mean µij and variance
σ2ij. µij is proportional to the mean of the of read counts of gene i under experimental
condition ρ(j) and size factor sj as denoted by µij = qi,ρ(j)sj . The size factor sj denotes
sampling depth of sample j. The variance denoted by σ2ij = µij + s2jνi,ρ(j) shows a linear
relationship between the two parameters of the NB model. With respect to the low
number of replicates which does not lead to a reliable estimate of the variance for gene i
from just the data available for this gene, DESeq assumes that the per-gene raw variance
parameter νi,ρ(j) = νρ(qi,ρ(j)) is a smooth function of qi and ρ (Anders and Huber, 2010).
To derive the set of statistically significant DE genes from the data, DESeq estimates
mean and variance for each gene separately. It applies a normalization step ahead, since
the samples have been generated with different sequencing depth. DESeq calculates a
size factor for m times related to m samples in the data. The size factor is estimated by
taking the median of the ratios of read counts 2.4.
sˆj = median(i)
kij
(∏mν=1 kiν) 1m (2.4)
For each experimental condition ρ, there are n read counts qiρ. They reflect the read
counts for gene i under condition ρ. That is, the mean of gene i is proportional to qiρ as
illustrated below in equation 2.5, where mρ is the number of samples of condition ρ and
the sum runs over these samples.
qˆiρ =
1
mρ
∑
j:ρ(j)=ρ
kij
sˆj
(2.5)
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To calculate variance νρ, DESeq calculates at first sample variances on the common scale
as in equation 2.6.
wiρ =
1
mρ − 1
∑
j:ρ(j)=ρ
(kij
sˆj
− qˆiρ)2 (2.6)
and defines ziρ = qˆiρmρ
∑
j:ρ(j)=ρ
1
sˆj
. It was shown that wiρ− ziρ is an unbiased estimator for
the raw variance parameter νiρ (Anders and Huber, 2010).
DESeq uses a test statistic similar to Fisher’s exact test (nbinomTest) to obtain statis-
tically significant results. The null hypothesis is qiA = qiB, where qiA is the read count
for the samples of condition A and qiB for condition B. To this end, (Anders and Huber,
2010) define the total counts in each condition, KiA =
∑
j:ρ(j)=A kij, KiB =
∑
j:ρ(j)=B kij
and their overall sum KiS = KiA +KiB. Then it uses any pairs (a, b), where KiA = a and
KiB = b and a+ b = kiS to calculate the p-value. The p-value of a pair of observed count
sums (kiA, kiB) is then the sum of all probabilities less or equal to p(kiA, kiB), given that
the overall sum is kiS (Anders and Huber, 2010). The probability is calculated using the
formula 2.7.
pi =
∑
a+b=kiS ,p(a,b)≤p(kiA,kiB) p(a, b)∑
a+b=kiS p(a, b)
(2.7)
VST + limma
The Variance Stabilizing Transformation (VST) takes the variance-mean dependence w(q)
computed by DESeq and applies a transformation function 2.8 to remove the dependency.
The monotonous mapping function produces data whose variance is independent from the
mean (Anders and Huber, 2010).
τ(K) =
∫ K dq√
w(q)
(2.8)
VST uses the limma package for performing the statistical tests and inferring the set of
DE genes.
edgeR
edgeR assumes a NB distribution for modelling the count data (Robinson et al., 2010).
Before the analysis, TMM normalization (Robinson and Oshlack, 2010) is applied to the
data. To calculate µij, edgeR considers total number of reads in sample j and the relative
abundance of gene i in the sample (Robinson et al., 2010). edgeR estimates common
dispersion before gene-wise dispersion by accounting the values of all genes. Gene-wise
dispersion is estimated from common dispersion φ as shown in equation 2.9 in (Robinson
and Smyth, 2007, 2008). Gene-wise dispersion gives a unique dispersion value to each gene.
edgeR estimates the gene-wise dispersion by conditional maximal likelihood, conditioning
on the total count zi =
∑ni
j=1 Yij, where ni is the total number of samples for gene i and
yij denotes the observed count for gene i in sample j.
lg(φ) =
2∑
j=1
(
ni∑
j=i
logΓ(yij + φ−1) + logΓ(niφ−1)− logΓ(zi + niφ−1)− nilogΓ(φ−1)) (2.9)
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Figure 2.3: Mean-variance modelling of voom (Law et al., 2014).
Gene-wise dispersions is shrunk towards a common dispersion using an empirical Bayes
procedure. The common dispersion estimator maximizes the common likelihood lC =∑G
g=1 lg(φ) where G is the number of genes (Robinson and Smyth, 2008). Finally, differ-
ential expression is assessed for each gene using an exact test similar to Fisher’s exact
test, but adapted for data that have overdispersion (Robinson and Smyth, 2008; Robinson
et al., 2010).
voom+limma
voom (variance modelling at the observation level) attempts to estimate the mean-variance
relationship robustly and without any parameter from data at the level of individual
observations. It transforms count data to log-cpm(counts per million) values for the
purpose of normalization (Law et al., 2014). This transformation is performed because
read counts show increasing variance with increasing count size, while log-counts typically
show a decreasing mean-variance trend. To estimate the mean-variance trend at level
of individual observation, it computes a residual standard deviation for each gene, See
Figure 2.3 panel (a). After fitting a robust trend to the residual standard deviations,
see Figure 2.3 panel (b), standard deviation for an individual observation is predicted by
interpolating the standard deviation trend based on its predicted count size, see Figure
2.3 panel (c). Finally, the inverse square of the predicted standard deviation for each
observation and log-cpm values are given to limma’s standard differentiation pipeline as
input to obtain the set of statistically significant DE genes (Law et al., 2014).
2.4 Applied Programming Languages
I used a variety of programming languages to develop softwares, process and analyze the
data and develop web servers including R, Java, Perl, PHP, JavaScript and SageMath.
• SageMath: it is a free open-source software system under the terms of GNU general
public license which was developed initially by William Stein, at the University
of Washington (The Sage Developers, 2015). The software uses many open-source
packages such as NumPy, SciPy. It is accessible either through Python language
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or directly through interfaces of wrappers. I implemented the ILP formulations of
minimum dominating set and minimum connected dominating set in SageMath.
• Java: it is a general-purpose class-based and object oriented language. The platform
independent language lets the Java programs run on any combination of software and
hardware systems because of the java virtual machine. I implemented the heuris-
tic approximate approaches of minimum dominating set and minimum connected
dominating set in Java.
• R: it is a free programming language and software environment for statistical com-
puting and graphics which is widely used for analysis of large data sets. I imple-
mented the backend programs of TFmiR2 web server in R. Moreover, I used the
language for TCGA data analysis.
• Perl: it is a scripting language facilitating easy manipulation of text files and defining
and searching string patterns. I used these facilities to download the YPA data from
the web and to process the files.
• PHP: it is a server-side scripting language mainly designed for web development
and usually embedded into HTML. I implemented the front-end of the TFmiR2
web server (server-side) in PHP.
• JavaScript: it is a client-side scripting language developed to run in web browsers
which is embedded usually with HTML and CSS. I implemented the front-end of
TFmiR2 web server (client-side) in JavaScript.
Chapter 3
Identification of Key Regulatory Genes in
Gene Regulatory Networks
This chapter is based on our paper entitled "Identification of Key Regulatory Genes in
Gene Regulatory Networks " by Maryam Nazarieh, Andreas Wiese, Thorsten Will, Mo-
hamed Hamed and Volkhard Helms published in the journal of BMC Systems Biology
(Nazarieh et al., 2016).
Maryam Nazarieh mapped the problem to minimum dominating set and minimum con-
nected dominating set, designed and implemented the algorithms, performed data analysis
and wrote the manuscript. Dr. Andreas Wiese extended the established the ILP formu-
lations and edited the manuscript. Thorsten Will developed the Cytoscape plugin for the
heuristic approach of MCDS and improved the implementation of the algorithm. Mo-
hamed Hamed assisted with the functional enrichment analysis. Prof. Volkhard Helms
proposed the biological motivation of the paper and helped with designing the study, data
analysis and the manuscript.
The initial results of the mathematical modelling was presented at the German Stem
Cell Network conference in Nov.2014 in Heidelberg http://www.gscn.org/Conferences/
2014/Program.aspx.
Identifying the gene regulatory networks governing the workings and identity of cells is
one of the main challenges in understanding processes such as cellular differentiation, re-
programming or cancerogenesis. One particular challenge is to identify the main drivers
and master regulatory genes that control such cell fate transitions. In this work, we re-
formulate this problem in terms of the optimization problems of computing a Minimum
Dominating Set (MDS) and a Minimum Connected Dominating Set (MCDS) for directed
graphs.
Both MDS and MCDS are applied to the well-studied gene regulatory networks of the
model organisms E. coli and S. cerevisiae and to a pluripotency network for mouse ESCs.
The results show that a MCDS can capture most of the known key player genes identified
so far in the model organisms. Moreover, this method suggests an additional small set
of TFs as novel key players for governing the cell-specific gene regulatory network which
can also be investigated with regard to diseases. To this aim, we investigated the ability
of MCDS to define key drivers in breast cancer. The method identified many known drug
targets as members of the MDS and MCDS.
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The Java implementation of the heuristic algorithm explained in this chapter is available
as a Cytoscape plugin at http://apps.cytoscape.org/apps/mcds. The SageMath pro-
grams for solving integer linear programming formulations used in the paper are available
at
https://github.com/maryamNazarieh/KeyRegulatoryGenes and as supplementary ma-
terial.
3.1 Background
Although all the cells in multicellular organisms basically share the same DNA sequence
with the same set of genes, in each cell type only a particular set of genes is actively
expressed which then defines its specific morphology and function. Thus, different types
of cells are controlled by different sets of active genes and by the interactions between
them (Chen and Rajewsky, 2007; Bossi and Lehner, 2009; Neph et al., 2012; Will and
Helms, 2014). Inside each cell, a set of target genes and regulatory genes, namely the TFs,
interact with each other and form a gene regulatory network (GRN). Typically, GRNs
topologically comprise a highly connected component and a few nodes with low connectiv-
ity (Barabasi and Oltvai, 2004). ESCs, for example, can be distinguished from other cells
mainly based on their pluripotency network. This network in ESCs is spanned up by few
connected TFs which share many target genes (Kim et al., 2008). A slight change in the
expression levels of such a tightly interwoven network of TFs leads to ESC differentiation
(Kim et al., 2008).
Of particular interest are the groups of key driver genes and master regulatory genes in
condition-specific and unspecific gene regulatory networks. Key driver genes are basically
those genes that control the state of the network (Liu et al., 2011; Zhang et al., 2015b;
Hamed et al., 2015b). The term master regulatory gene was introduced by Susumu Ohno
over 30 years ago. According to his definition, a master regulator is a gene which stands
at the top of a regulatory hierarchy and is not regulated by any other gene (Ohno, 1979).
Later on, this term was redefined to involve a set of genes which either directly govern the
particular cellular identity or are at the inception of developmental lineages and regulate
the expression of a cascade of genes to form specific lineages (Ohno, 1979).
To address the problem of computational identification of key and master regulatory
genes, we have used the notion of network controllability (Liu et al., 2011) in terms of
dominating set, modeled and solved two optimization problems named Minimum Domi-
nating Set (MDS) and Minimum Connected Dominating Set (MCDS) on the GRNs. We
compared these sets against well-known centrality measures such as degree, betweenness
and closeness centrality as described in (Freeman, 1978). These attribute the importance
of genes to their centrality in the networks. However, it is unclear whether high centrality
genes exercise a full control over the underlying network.
A recent study derived a minimum input theorem based on structural control theory
which can be applied to directed graphs to fully control the network (Liu et al., 2011).
For this purpose, the authors introduced a deep relation between structural controllabil-
ity and maximum matching. The idea is to control the whole network by covering all
the regulatory interactions with a minimum number of genes. Their results show that
a few nodes are sufficient to control dense and homogeneous networks, but this number
increases dramatically when the nodes in the network are sparsely connected.
An MDS is a related concept in which the goal is to control the network by covering all
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Figure 3.1: A graphical representation that illustrates the MDS and MCDS solutions of
an example network. The network can be controlled by MDS and MCDS nodes. In the
case of a GRN, directed arcs symbolize that a TF regulates a target gene. In panel (a), the
MDS nodes {A,B} are the dominators of the network. Together, they regulate all other
nodes of the network (C, E, D). Panel (b) visualizes the respective set of MCDS nodes
(black and gray). Here, node C is added in order to preserve the connection between the
two dominators A and B to form an MCDS.
expressed genes with a minimum number of TFs. Since each node that does not belong
to the MDS is adjacent to at least one node in the MDS, full control over the network is
provided by the MDS solution. Our group has previously applied the concept of MDS to
the area of complex diseases. The results showed that this method can capture several
important disease and drug target genes (Hamed et al., 2015b,a). The MDS method can
be applied to any connected or disconnected regulatory network to identify key dominator
nodes. In this work, we use MDS in directed graphs to identify key driver genes. Be-
sides the MDS concept, we suggest to also consider the task of identifying a set of master
regulatory genes in terms of another optimization problem, namely that of constructing
an MCDS. We suggest to apply MCDS mainly to networks that are related to cell fate
transitions such as the pluripotency network of an ESC. This idea is motivated by the ob-
servation that the pluripotency network in mouse ESCs is maintained by a few connected
TFs which share many target genes (Kim et al., 2008). The concepts of MDS and MCDS
are visualized for a small toy network in Figure 3.1.
The concept of MCDS has already been applied to protein-protein interaction networks
(which are represented by undirected graphs). There, the proteins which compose a
MCDS solution contributed significantly to related biological processes (Milenković et al.,
2011). In this work, we show how the MCDS concept can be applied to GRNs (represented
by directed graphs) to detect the TFs and target genes which determine a specific cellu-
lar identity. We start with the model organisms E. coli and S. cerevisiae because their
GRNs have been extensively characterized in experimental studies. Then, we present
applications to a mouse pluripotency network and to a breast cancer regulatory network.
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3.2 Methods
3.2.1 Minimum Dominating Set
A dominating set (DS) in an undirected graph G = (V,E) is a subset of nodes D ⊆ V
with the property that for each node v ∈ V we have that v ∈ D or that there is a node
u ∈ D and an edge {u, v} ∈ E. We call a set D ⊆ V a minimum dominating set (MDS)
if it is a dominating set and it has minimum cardinality among all dominating sets for G.
Computing a MDS is known to be an NP-complete problem (Garey and Johnson, 1979).
In biological networks, the set of dominators can provide full control over the whole net-
work. Since each node that does not belong to the MDS is at least adjacent to one node in
the MDS, full control over the network can be obtained by the MDS solution. To address
GRNs which are represented by directed graphs, we define an MDS for a directed graph
G = (V,E) to be a set D ⊆ V of minimum cardinality such that for each node v ∈ V
we have that v ∈ D or that there is a node u ∈ D and an arc (u, v) ∈ E. The integer
linear programming (ILP) formulation of MDS for directed graphs is given below. Here,
for each node v ∈ V we denote by δ−(v) the set of incoming nodes of v, i.e., the set of
nodes u such that (u, v) ∈ E.
minimize
∑
v∈V
xv
subject to xu +
∑
v∈δ−(u)
xv ≥ 1 ∀u ∈ V
xv ∈ {0, 1} ∀v ∈ V
(3.1)
Here, variables xu and xv are binary variables associated to the nodes u and v in the
graph. Using this formulation, we select a node v as a dominator if its binary variable xv
has value 1 in the computed solution and otherwise we do not select it. Since our objective
function is to minimize
∑
v∈V xv this yields a minimum dominating set. For all networks
considered here, MDS solutions were constructed in less than 1 minute of running time.
3.2.2 Minimum Connected Dominating Set
A minimum connected dominating set (MCDS) for a directed graph G = (V,E) is a set
of nodes D ⊆ V of minimum cardinality that is a dominating set and that additionally
has the property that the graph G[D] induced by D is weakly connected, i.e., such that
in the underlying undirected graph between any two nodes v, v′ ∈ D there is a path using
only vertices in D. Computing an optimal MCDS in undirected graphs is known to be
NP-hard (Garey and Johnson, 1979). Since GRNs are represented by directed graphs, we
are interested in MCDSs for directed graphs.
Optimal Solution via ILP
To this end, we modified the existing integer linear programming (ILP) formulation of
MCDS in undirected graphs (Simonetti et al., 2011) to determine a MCDS for directed
graphs. This work introduced a set of valid inequalities for the undirected graphs which
can be modified to be used for the directed MCDS on the directed graphs (Simonetti
et al., 2011).
As before, the set V is the set of vertices and E is the set of edges in the input graph.
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For a set S ⊆ V , the set E(S) stands for all the edges connecting two vertices u, v with
u, v ∈ S. The binary valued yv variables indicate whether node v is selected to belong to
the minimum connected dominating set. The binary variables xe for the edges then yield
a tree that contains all selected vertices and no vertex that was not selected. Thus, the
selected vertices form a connected component. The first constraint guarantees that the
number of edges is one unit less than the number of nodes. This is necessary for them
to form a (spanning) tree but is not sufficient. The second constraint guarantees that
the selected edges imply a tree. The third constraint guarantees that the set of selected
nodes in the solution forms a dominating set of the graph. For dense undirected graphs,
this formulation provides a quick solution, but in the case of sparse graphs, finding the
optimal solution may take considerable running time (Simonetti et al., 2011).
minimize
∑
v∈V
yv
subject to
∑
e∈E
xe =
∑
i∈V
yi − 1∑
e∈E(S)
xe ≤
∑
i∈S\{j}
yi ∀S ⊂ V, ∀j ∈ S
yu +
∑
v∈δ−(u)
yv ≥ 1 ∀u ∈ V
yv ∈ {0, 1} ∀v ∈ V
xe ∈ {0, 1} ∀e ∈ E
(3.2)
The above IP formulation contains an exponential number of constraints since it has one
constraint for each subset S ⊆ V . Therefore, already for relatively small instances it is
impractical to generate all its inequalities. Instead, we used the following approach: we
generate the first constraint and all constraints of the third type (i.e.,
∑
e∈E
xe =
∑
i∈V
yi − 1
and yu+
∑
v∈δ−(u)
yv ≥ 1 for each u ∈ V ). Then we compute the optimal IP solution subject
to these constraints. Then we check whether the found solution satisfies all constraints
of the above IP (even those that we did not add to our formulation). This is the case
if and only if the computed set of vertices yields a connected dominating set. If this is
the case then we found the optimal solution and we stop. Otherwise, we add (violated)
constraints of the second type (i.e.,
∑
e∈E(S)
xe ≤ ∑
i∈S\{j}
yi for some subset V and some node
j) to our formulation and compute the optimal IP solution to this stronger formulation
and repeat. If the computed set of vertices has more than one connected component then
we add such a constraint for each connected component S and for each vertex j ∈ S. In
order to improve the running time of our procedure, we added some valid inequalities to
our initial formulation. These inequalities discard all the solutions that select an edge
e = {u, v} (i.e., xe = 1) such that not both of its incident vertices were selected (i.e., not
both yu = 1 and yv = 1). Formally, for each edge e = {u, v} we added the inequalities
xe ≤ yu
xe ≤ yv
(3.3)
Despite adding these valid inequalities, some problem instances were not solved in ap-
propriate time. To overcome this problem, we also considered a heuristic approach. It
22
is known that an approximate MCDS in undirected graphs can be found by heuristic
approaches in polynomial time (Wightman et al., 2011; Rai et al., 2009). For graphs with
low number of nodes and high node degree, the optimal ILP solution can be found at
comparable running times as such heuristic solutions (Wightman et al., 2011). However,
the heuristic solution outperforms the ILP for graphs with high node density and low node
degree in terms of running time (Wightman et al., 2011). In this work, all computations
were conducted on a single threaded Intel XEON CPU at 2.2 Ghz. We determine the ILP
solution using the glpk solver version 4.35 (Makhorin, 2008). In cases where the network
is very sparse we used the heuristic algorithm (see next section).
Heuristic Solution
In this study, we computed the heuristic solution for all networks except for the modules
of a breast cancer network. There, the optimal MCDS solution could be obtained within
a few minutes to several hours of compute time. We adapted the heuristic algorithm
presented in (Rai et al., 2009) that was inspired by one of the two general approximation
approaches mentioned in (Guha and Khuller, 1998) to find solutions for MCDS. We mod-
ified the algorithm to determine a MCDS for directed graphs rather than an undirected
graph. The algorithm has three main phases as described in the following. Initially, all
nodes are white. In the first phase, a white node with the highest outdegree is selected as
a dominator and colored black. In cases where multiple nodes have the same outdegree,
we select the node with the highest indegree. This selection guarantees higher connectiv-
ity compared to nodes with smaller indegree. Its (directed) child neighbors are colored
gray to indicate that they are already dominated. This step is repeated until all nodes
are either black or gray. From these, we check if the (black) set of dominators forms a
connected dominating set. If yes, we move to the third phase, otherwise we move to the
second phase. In the second phase, a node with maximum number of arcs to black nodes,
that we term a connector, is colored dark gray. This dark gray node is then added to the
connected dominating set if it belongs to a path between two connected components that
are not connected so far. This step is repeated until all black and dark gray nodes form
a connected component in the underlying undirected graph. In the third phase, the size
of the connected dominating set is reduced as much as possible by repeatedly removing
a node with smallest outdegree while making sure that the dominating set remains con-
nected and the graph remains covered by the connected dominating set. In cases where
multiple nodes have the same outdegree, we again select the node with highest indegree.
One can also interpret the algorithm biologically in the context of GRNs. We start by
selecting a TF with the most target genes as a dominator. This process is repeated until
all the genes are either selected as dominators or as target genes. If the dominating set is
not connected, the next step is to connect the dominators by adding a few number of con-
nector genes. This step is motivated by the modularity of cellular networks (Singh et al.,
2008). We will investigate below whether defining a connected set of dominator nodes
is beneficial for the biological interpretability of the control hierarchy. As connectors,
we consider TFs as well as target genes. The last step is to reduce the size of the con-
nected dominating set. Then, the connected dominating set comprises of dominators and
connectors, whereby all dominators are TFs and the connectors comprise of TFs and/or
target genes. Note that the set of MCDS identified as dominators or connectors provides
potential candidates for key drivers and master regulatory genes.
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For the networks considered here, the running time for the heuristic MCDS solution was
less than 1 minute.
3.2.3 Components
Unlike MDS, the task of computing an MCDS only makes sense for input graphs that
are connected since otherwise there can be no solution. Therefore, if we are given a
disconnected undirected graph, we compute MCDSs for connected components of the
graph. For directed graphs, we distinguish between strongly connected components and
(weakly) connected components.
Strongly Connected Component
A component is called a strongly connected component (SCC) in a directed graph if each
of its nodes is reachable via directed edges from every other node in the component. In a
SCC, there is a path between each pair of nodes in the component. Here, we implemented
Tarjan’s algorithm to find SCCs as described in (Tarjan, 1972).
Largest Connected Component
A component is a (weakly) connected component if in the underlying undirected graph,
there exists a path between any pair of nodes of this component. The connected compo-
nent of highest cardinality is termed the largest connected component (LCC). The con-
nected components were found by breadth first search (BFS) as described in (Hopcroft
and Tarjan, 1973). Note that each strongly connected component is also a (weakly) con-
nected component but the converse is not necessarily true. Since a MCDS does not exist
in graphs that are not connected, we consider the LCC and the largest strongly connected
component (LSCC) in such cases, see Figure 3.2. We compared the results of MCDS
when the network has only one connected component to those obtained with a directed
version of MDS in terms of the size of the result set and enrichment analysis.
Criteria to Select the Component
MDS is always applied to the whole network. If the input network is not connected, we
select either LCC or the LSCC as the input for MCDS. If the cardinality of the network
is equal to the LCC of the network, we select the whole network. Otherwise, we consider
the component density of LCC (the number of other components were few with very small
size for the considered GRNs in this study) and LSCC. For a directed graph G = (V,E),
the component density is defined as |E||V |(|V |−1) , where E denotes the set of edges and V
denotes the set of nodes in the component. The component density is equal to the ra-
tio of existing edges (interactions) |E| in the component to the total number of possible
edges (interactions). According to the definitions in (Sant, 2004), in a dense graph the
number of edges is close to the maximal number of edges which is in contrast to a sparse
graph. In this study, an MCDS is then derived for the component (LCC or LSCC) with
highest density, as we were interested to find the minimum number of genes. High density
components are more promising in this regard, because they need a smaller number of
connectors to connect the dominators.
Enrichment Analysis
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Figure 3.2: A graphical representation that illustrates the concept of MDS on a toy
network. In addition, the MCDS nodes are colored black on three types of components
(LSCC, LCC of the underlying directed graph and LCC of the underlying undirected
graph) in the toy network. The above toy network includes 14 nodes and 14 edges as
shown in yellow in panel (a). The nodes {J, B, C, H, L} are the dominators of the network
obtained by computing a MDS (right panel). The nodes colored blue in panel (b), make
up the LCC of the underlying undirected graph. MCDS nodes for this component are {J,
D, B, C, G, H}. Green colored nodes in panel (c) are elements of the LCC underlying the
directed graph. The two nodes {B, C} form the MCDS for this component. The nodes
colored orange in panel (d) show the LSCC in the network. Here, the node A is the only
element of the MCDS.
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The biological relevance of the results obtained by the directed forms of MDS and MCDS
was evaluated using the enrichment analysis tool provided at the DAVID portal of NIH
(Huang et al., 2009). p-values below the threshold 0.05 obtained by the hypergeometric
test were adjusted for multiple testing using the Benjamini & Hochberg (BH) procedure
(Benjamini and Hochberg, 1995).
Functional Similarity
Functional similarity was examined based on Gene Ontology (GO) Biological Process
(BP) terms among the pairs of MCDS nodes. This was then compared to the functional
similarity of gene pairs from the entire network as described in (Hamed et al., 2012). The
permutation test was repeated 100 times and Kolmogorov-Smirnov test was applied to
get the p-value.
Hypergeometric Test
The statistical significance of the results was assessed using the hypergeometric test which
is based on sampling without replacement. The p-value for the test is calculated from the
following formula:
p-value = 1 - ∑xi=0 (ki)(M−kN−i)(MN)
where M is the total number of genes in the network, N is the sample size which is equal
e.g. to the size of the MCDS, k is the number of genes in M with a specific property and
x is the number of genes in the MCDS having that property. The cutoff value was set to
p = 0.05 to report a set obtained by MCDS as a significant result. To apply the test, we
used the online tool (GeneProf) which is described in (Halbritter et al., 2011).
Data and software
We tested the presented approaches to identify key player and master regulatory genes
in several GRNs for E. coli, S. cerevisiae, a human breast cancer network and for the
pluripotency of mouse ESC. We will present the obtained results one by one in the next
section.
The dataset of E. coli is a GRN of the Escherichia coli strain K-12 that was downloaded
on 22-July-2014 from RegulonDB (Salgado et al., 2013). It contains curated data for 1807
genes, including 202 TFs.
The dataset of S. cerevisiae was taken from the Yeast Promoter Atlas (YPA) downloaded
on 26-March-2014 (Chang et al., 2011). It contains 5026 genes including 122 TFs. In this
database, the target genes for each TF is a set of genes whose promoter regions contain
the associated TF binding site for the TF binding motif.
The dataset for mouse is a manually curated GRN of mouse (Mus musculus) ESCs. It
consists of 274 mouse genes/proteins and 574 molecular interactions, stimulations and
inhibitions (Som et al., 2010). The network consists of genes that are involved in either
induction, maintenance or loss of the pluripotency state and is thus termed pluripotency
network throughout the text.
The breast cancer network used here was generated in (Hamed et al., 2015b) using a
Bayesian learning approach that was coupled to an integrative network-based approach
based on whole-genome gene expression profiling, DNA methylome, and genomic mu-
tations of breast cancer samples from TCGA. The GRN networks were constructed via
three steps: first the co-expression network was generated based on the topological overlap
matrix as a distance measure. Then, we connected the co-expression interactions to reg-
ulatory information retrieved from publicly available regulatory databases accompanied
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with motif search for all known binding motifs of the TFs represented in the co-expression
network against the promoter regions of all genes in the network. Finally, a causal prob-
abilistic Bayesian network was inferred from the co-expression modules utilizing the di-
rected edges obtained from the previous step as a start search point to infer directionality
between nodes. Clustering yielded ten network modules of dysregulated genes (Hamed
et al., 2015b). Each module turned out to have distinct functional categories, cellular
pathways, as well as oncogene and tumor suppressor specificity. We also extracted breast
cancer specific subnetworks from the human genome regulatory interactome induced by
the dysregulated mRNAs.
We implemented the ILP formulas for the directed forms of MDS and MCDS in the
SageMath software system (The Sage Developers, 2015) version 6.8 using the glpk solver
(Makhorin, 2008). We implemented the heuristic algorithm in Java and made it avail-
able as a plugin for the popular biological network analysis platform Cytoscape (Shannon
et al., 2003). It is available at http://apps.cytoscape.org/apps/mcds.
3.3 Results
3.3.1 Global E. coli GRN
The GRN for E. coli studied here contains 1807 genes, including 202 TFs and 4061 regu-
latory interactions. This set of regulatory interactions in E. coli forms a general network
which controls all sorts of responses which are needed in different conditions. With net-
work density 0.001, the network can be considered as sparse. Due to this sparsity, MDS
deems 199 TFs to be necessary to control the network. The network does not have any
SCC with size larger than 5 nodes. For computing an MCDS, we therefore used the LCC
underlying directed graph that contains 1198 genes. Based on the directed form of the
LCC, target genes are placed at the bottom level and a set of TFs comprises the MCDS. In
the LCC, the algorithm identified an heuristic MCDS containing 34 genes (11 dominators
and 23 connectors) that cover the entire component, see Table S1.
Figure 3.3 illustrates the hierarchical structure between the 34 TFs contained in the
MCDS. The hierarchical structure was drawn based on generalized hierarchies using
breadth-first search as described in (Yu and Gerstein, 2006). A previous study that
was based on an earlier version of RegulonDB identified 10 global regulators that regulate
operons in at least three modules (Ma et al., 2004). Two of them, H-NS and CspA, do not
belong to the LCC considered here. Two other global TFs identified previously (RpoS and
RpoN) are no longer contained in the list of regulators in the version of RegulonDB used
here. Out of the six remaining genes, the five genes IHF, CRP, FNR, ArcA and NarL are
among the nine top genes in Table S1 and the sixth gene OmpR is found a bit further
below in the list. Table S2 lists enriched KEGG and GO terms for the 34 genes in the
MCDS of the E. coli gene regulatory network. As expected, the strongest enrichment is
found for processes related to transcriptional regulation. The second most enriched term
is related to two-component systems which enables E. coli to respond to changes arising
from different environmental conditions (Stock et al., 2000).
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Figure 3.3: Connectivity among the genes in the connected dominating set of the LCC of
the E.coli GRN. In this component, TFs construct the set of dominators and connectors.
The red nodes are master regulatory genes identified as global regulators in [32].
3.3.2 Cell-cycle specific S. cerevisiae GRN
Next, we retrieved regulatory interactions in S. cerevisiae involving 122 TFs from the YPA
(Chang et al., 2011). From this set of regulatory interactions, we extracted a cell-cycle
specific subnetwork of 302 genes that are DE along the cell cycle of yeast as described in
(Spellman et al., 1998). The 302 genes already form the LCC of this subnetwork. This
set of genes is controlled by a MDS including 12 TFs and a heuristic MCDS including
14 TFs and 3 target genes. The MDS and MCDS elements are listed in Tables S3 and
S4, respectively. Most of the TFs identified to belong to the MDS and MCDS have been
identified before by experimental methods to be associated with the cell cycle (Lee et al.,
2002). Figure 3.4 shows the GRN of the cell cycle activity of S. cerevisiae controlled
by these 14 TFs. Table S5 lists enriched KEGG and GO terms for the 17 genes in this
MCDS. As expected and similar to what we found for the E. coli network, the strongest
enrichment was found for processes related to transcriptional regulation. 9 of the 17
genes (PMA2, YOX1, ACE2, SWI5, SWI4, ORC1, STB1, FKH1, TID3) are annotated
to cell-cycle related GO terms, namely GO:0051329 ∼ interphase of mitotic cell cycle and
GO:0000278 ∼ mitotic cell cycle and to the KEGG pathway sce04111:Cell cycle.
3.3.3 Pluripotency Network in Mouse ESCs
Next, we applied the MDS and MCDS methods to a manually curated GRN of mouse
ESCs that consists of 274 mouse genes/proteins and 574 molecular interactions, stimula-
tions and inhibitions (Som et al., 2010). We found that the heuristic MCDS of the LSCC
(80 genes) of this network contains 29 TFs. The connectivity among these 29 TFs is
displayed in Figure 3.5. The MCDS elements are listed in Table S6, respectively. Among
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Figure 3.4: Tightly interwoven network of 17 TFs and target genes that organize the
cell cycle of S. cerevisiae. Shown on the circumference of the outer circle are 164 target
genes that are DE during the cell cycle. The inner circle consists of the 14 TFs from the
heuristic MCDS and of 123 other target genes that are regulated by at least two of these
TFs.
the set of regulators, 7 TFs including Pou5f1, Nanog, Sox2, Stat3, Esrrb, Tcf3, Sall4 are
in common with an experimentally validated regulatory network controlling pluripotency
that consists of 15 experimentally validated TFs (Xu et al., 2014). Such a result is unlikely
to be obtained by chance (hypergeometric test p-value = 0.004 ) in a network with 176
TFs.
Next, we evaluated the ability of the MCDS method to detect a cooperative biologi-
cally functional backbone within the entire network. For this, we examined the functional
similarity according to the Wang measure in the GoSemSim R package (Yu et al., 2010)
(explained in chapter 4), among the pairs of MCDS nodes and compared this to the func-
tional similarity of gene pairs from the mouse network, see Figure S1. This figure shows
the cumulative distribution of the functional similarity scores between pairs of MCDS
nodes of the mouse pluripotency network (in red) compared to the similarity scores of all
possible pairs between genes of this network (in black). The Kolmogorov-Smirnov test
revealed that the MCDS genes were functionally significantly more homogeneous than the
randomly selected gene pairs of the whole network with p-value of 6.41e-05. This hints at
the ability of the MCDS method to extract a functionally homogeneous network backbone
that is expected to have an important role in maintaining the pluripotency state in early
developmental stages. Table S7 lists enriched KEGG and GO terms for the 29 genes in
the MCDS of the mouse ESC pluripotency network. In this case, GO terms related to
developmental processes are stronger enriched than GO terms related to transcriptional
regulation. The set of genes (Nanog, Cdx2, Esrrb, Pou5f1, Sox2 and TCl1) annotated
with GO:0019827 are responsible for stem cell maintenance. The genes annotated with
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Figure 3.5: Connectivity among TFs in the heuristic MCDS in the LSCC of a GRN for
mouse ESCs. The red circle borders mark the 7 TFs belonging to the set of master
regulatory genes identified experimentally in (Xu et al., 2014).
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Figure 3.6: Percentage overlap of the genes of the MDS and MCDS with the list of top
genes (same size as MCDS) according to 3 centrality measures. Shown is the percentage
of genes in the MDS or MCDS that also belong to the list of top genes with respect to
degree, betweenness and closeness centrality.
other GO terms are mainly related to embryonic development and other tissue-specific
development.
To check the centrality significance of the MCDS genes in the LSCC, we selected the same
number of genes as the size of MCDS with respect to degree, betweenness and closeness
centrality. The centralities were measured using the igraph package (Csardi and Nepusz,
2006). We considered only outdegree nodes in the directed network. The results show that
most of the genes contained in the heuristic MCDS are among the top nodes according
to at least one centrality (degree, betweenness, closeness), see Figure 3.6. Among them,
the top nodes of the MCDS have the highest overlap with the top nodes of the degree
centrality and the betweenness centrality. Six out of 10 connector nodes in MCDS belong
to the top 29 nodes with highest betweenness centrality according to Jaccard’s index.
3.3.4 Human Disease Network
Finally, we applied the MCDS method to the LCC of ten breast cancer network modules
where each LCC covers the whole module (Hamed et al., 2015b), see methods section.
Table 3.1 lists the identified MDS and MCDS sets for the nine out of ten modules. One
module (grey) could not be solved in appropriate time using ILP. In total, the MDS and
MCDS sets of the nine modules contain 68 and 70 genes, respectively. Then, we looked
up the known anti-cancer drugs that target any of the 70 proteins coded for by these
genes based on experimentally validated drug-target databases as described in (Hamed
et al., 2015b). In the network with 1169 genes including 228 drug target genes, we found
that 20 of the 70 drug target genes belong to the genes identified using the MCDS. This
is statistically significant with a p-value of 0.03 obtained from the hypergeometric test.
Sixteen out of the 68 proteins belonging to the MDS genes are binding targets of at least
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Figure 3.7: Number of MCDS genes determined by the heuristic approach or by the ILP
formulation and in the MDS. Shown are the results for 9 modules of the breast cancer
network.
one anti-breast cancer drug, see Table 3.1.
Next, we compared the set size of the optimal and heuristic solutions of MCDS and
MDS for 9 out of the 10 modules. One module (grey) could not be solved in appropriate
time using ILP. Table S8 displays the density and running time for the ILP solutions for
the mentioned modules implemented in Sage. The running time was not correlated with
the size or density of the networks. Figure 3.7 shows that the optimal solutions of MCDS
and MDS contain almost the same number of genes for all modules. In comparison, the
heuristic MCDS solutions (see, Table S9) contain 10-50 % more genes than the solutions
of the other two approaches. We also compared the heuristic approach with the optimal
solution in terms of overlapped identified genes. Table 3.2 indicates that according to
Jaccard’s index the solutions overlap approximately by about 60% in a range from 40%
to 75%. Table S9 shows the results obtained by the heuristic approach of MCDS. Table
S10 lists enriched GO BP terms and KEGG pathways in the MCDS genes obtained by
heuristic approach. 12 genes (AKT1, RASSF5, WNT5B, ETS1, PDGFA, TP53, SPI1,
NFKB1, TCEB1, MYC, TGFB1, DAPK1) belong to a known cancer pathway (p-value =
0.004). We hypothesize that the products of the some of the remaining identified MCDS
protein coding genes may open up new avenues for novel therapeutic drugs.
3.3.5 Directed Random Networks
To characterize the size of problems which can be solved using the MCDS ILP formulation,
multiple Erdos-Renyi random digraphs were generated using the Java code DigraphGen-
erator available in (Sedgewick and Wayne, 2015) with different sizes and densities. We
discarded the networks whose running times exceeded 2 days. Table 3.3 shows that the
size of MCDS reduces when the network density increases. A low density for networks of
size more than 110 nodes leads to a dramatic increase in the computation time.
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Table 3.1: Identified genes in the MDS and MCDS (ILP) for 10 modules of the breast
cancer network.
Method Mod-
ule
Net-
work
Size
Re-
sult
size
Key driver genes
MCDS black 41 5 ZNF254, KIAA1632, ZNF681, SEC24B, ZNF615
MDS 5 ZNF254, KIAA1632, ZNF681, SEC24B, ZNF615
MCDS blue 247 3 FAM54A,ACAN, GLDC
MDS 2 ACAN, FAM54A
MCDS brown 195 1 AATK
MDS 1 AATK
MCDS green 110 18 ADPRHL2, AKT1, LTBR, MAN2C1, SH3GLB2, UTP14A, WDR55, MADD,
B4GALT7, OS9, MYO1C, CDC34, CDC37, RBM19, MARS, CCDC22,
MAP2K2, DAP
MDS 17 ADPRHL2, LTBR, HMG20B, HK1, SH3GLB2, UTP14A, ELK1, MED6,
B4GALT7, OS9, MYO1C, CDC34, CLN3, INPPL1, DAP, PLXNB1, TIMM44
MCDS ma-
genta
26 4 ILF2, BGLAP, POGK, ATF6
MDS 4 ILF2, BGLAP, ATF6, VPS72
MCDS pink 30 5 TCEB1, RAB2A, ZNF706, TMEM70, ATP6V1C1
MDS 5 TCEB1, RAB2A, TMEM70, TCEA1, ATP6V1C1
MCDS red 93 13 SIX4, SP1, ATP1B1, PCGF1, SUMF2, EPN3, GTF3A, RAP1B, FHL3, RPS3A,
ABCB8, GFAP, ANXA5
MDS 13 LSM11, SIX4, PCGF1, SUMF2, EPN3, ZNRF2, GTF3A, RAP1B, FHL3, RPS3A,
ABCB8, GFAP, NAGA
MCDS tur
quoise
295 1 ABHD10
MDS 1 ABHD10
MCDS yel-
low
132 20 CASP10, TSPAN2, ACSL6, HDAC11, SLC7A7, TRAF3IP3, GZMK, PAG1, LAP3 ,
HTRA4, CD79B, SPI1, GCET2, WAS, DFNA5, LRRC33, FCRL2, LCP2,
TCTEX1D1, FUT4
MDS 20 CASP10, TSPAN2, ACSL6, HDAC11, TLR9, SLC7A7, FAM129C, TRAF3IP3,
HTRA4,SPI1, CPXM2, GCET2, FASN, SLFN11, DFNA5, ETS1, PLS3, LCP2,
TCTEX1D1, FUT4
The genes, whose protein products are known to be targeted by drugs, are marked in bold.
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Table 3.2: Overlapping genes between the heuristic and optimal solutions of MCDS for
modules of the breast cancer network. The names of the modules were introduced in the
original ref. (Hamed et al., 2015b).
Module shared genes count
black SEC24B, ZNF254, ZNF681 3
green UTP14A, LTBR, SH3GLB2, OS9, CDC34, CDC37, AKT1 7
magenta BGLAP, ATF6, ILF2 3
pink ZNF706, TCEB1, TMEM70 3
red FHL3, SUMF2, RPS3A, PCGF1, EPN3, GTF3A, ATP1B1 7
yellow FUT4, SPI1, DFNA5, CASP10, PAG1, HDAC11, LCP2, TRAF3IP3, HTRA4, TSPAN2, GZMK 9
blue ACAN, FAM54A 2
The modules brown and turquoise have only 1 mcds gene and give 100% overlap.
3.4 Summary and Discussion
Experimental identification of a set of key regulatory genes among large sets of genes is
very time-consuming and costly. Therefore, computational methods such as the ones pre-
sented here are helpful to condense and shape a list of candidate genes to more promising
candidates before planning and starting expensive experimental work. Such follow-up
works could e.g. validate the regulatory roles of these genes by siRNA knockdown ex-
periments, by over-expressing genes e.g. under the control of the highly inducible GAL1
promoter in yeast, or by CRISPR-type genome editing of promoter sequences containing
TF binding sites. We presented three novel approaches (ILP formulation for the directed
form of MDS, ILP formulation for the directed form of MCDS and heuristic algorithm
for the directed form of MCDS) to identify driver genes and master regulatory genes re-
sponsible for a particular cellular identity. In the notion of network controllability, MDSs
and MCDSs of biological networks are likely enriched in key regulatory genes. The results
of these optimization problems can thus aids in pruning the network to the potentially
more important nodes. We applied our method to the established GRNs of E. coli and S.
cerevisiae and also to a pluripotency network of mouse ESC. The characteristics of these
methods appear to be well suited, on the one hand, to the topology of approximately
scale-free biological networks that contain a small number of high degree hub nodes and,
on the other hand, to the observed tendency of these hubs to interact with each other.
We showed that the networks can be controlled by a fairly small set of dominating TFs.
A notable number of known master regulatory genes are detected in the connected dom-
inating set of the components.
The number of driver genes obtained by the directed form of MDS and MCDS depends on
the connectivity of the network. Networks with low connectivity yield a higher number
of driver genes compared to networks with higher connectivity. The application of the
MCDS method to modules of a regulatory network for a breast cancer network identified
70 key driver genes that could possibly drive the tumorigenesis process. Twenty of them
are already known targets of available cancer drugs. The remaining dominating genes
may be suitable candidates as news drug targets that may warrant further experimental
validation.
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Table 3.3: Runtime to determine an optimal solution for generated directed random
networks with differing number of nodes and edges. Listed is also the resulting component
density. All computations were conducted on a single threaded Intel XEON machine
running at 2.2 Ghz. The networks whose running times exceeded 2 days were discarded.
nodes edges density mcds_size mcds_time (s)
10 9 0.1 6 1.94
10 27 0.3 4 2.00
10 45 0.5 2 1.81
10 63 0.7 2 1.80
10 81 0.9 1 1.85
30 87 0.1 9 2.53
30 261 0.3 4 2.21
30 435 0.5 3 2.03
30 609 0.7 2 2.07
30 783 0.9 1 2.17
50 245 0.1 11 4.43
50 735 0.3 5 3.83
50 1225 0.5 3 8.77
50 1715 0.7 2 4.47
50 2205 0.9 1 3.03
70 483 0.1 11 5.69
70 1449 0.3 5 25.56
70 2415 0.5 3 19.89
70 3381 0.7 3 61.69
70 4347 0.9 2 43.32
90 801 0.1 12 35.16
90 2403 0.3 6 1467.69
90 4005 0.5 4 1022.77
90 5607 0.7 3 137.33
90 7209 0.9 2 42.01
110 1199 0.1 13 497.21
110 3597 0.3 5 1761.15
110 5995 0.5 4 3132.90
110 8393 0.7 3 455.06
110 10791 0.9 2 27.90
130 1677 0.1 13 4706.06
130 5031 0.3 6 8625.99
130 8385 0.5 4 9903.08
130 11739 0.7 3 959.93
130 15093 0.9 2 279.81
150 2235 0.1 13 5902.89
150 6705 0.3 6 21610.52
150 11175 0.5 4 24067.34
150 15645 0.7 3 1994.68
150 20115 0.9 2 810.58
170 2873 0.1 - -
170 8619 0.3 - -
170 14365 0.5 4 44398.62
170 20111 0.7 3 2867.04
170 25857 0.9 2 675.49
190 3591 0.1 - -
190 10773 0.3 - -
190 17955 0.5 4 85180.81
190 25137 0.7 3 4738.96
190 32319 0.9 2 854.05
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3.5 Remarks
(Golipour et al., 2012) showed that distinct sets of TFs are required for the transition of
somatic cells to induced pluripotent stem cells (IPSCs) versus the maintenance. At this
point, I proposed the hypothesis that the underlying networks define the role of domina-
tors, whether they control the network in order to maintain the cellular identity or they
are responsible for cellular transition. To check the hypothesis, I suggested Thorsten Will
to apply the set cover approach on the hematopoiesis network to identify the set of tran-
scriptomes that are responsible for cellular differentiation (Will and Helms, 2017). This
suggestion was based on the one-to-one correspondence of MDS for directed graphs with
the set cover problem by considering only the outgoing edges (Chlebík and Chlebíková,
2008) with respect to the constraints of protein complexes.
3.6 Availability of Data and Software
• MDS: This file includes the implementation of ILP formulation for MDS problem
using glpk solver.
available at https://github.com/maryamNazarieh/KeyRegulatoryGenes.
• MCDS: This file includes the implementation of ILP formulation for MCDS prob-
lem using glpk solver.
Available at https://github.com/maryamNazarieh/KeyRegulatoryGenes.
• User guide: This guide (in the supplementary) contains instructions for users to
use the MDS and MCDS programs to find the optimal solution in a directed network.
It also includes two GRNs for modules of the breast cancer networ which can be
used as input networks for ILP programs.
Available at https://github.com/maryamNazarieh/KeyRegulatoryGenes.
• Cytoscape plugin: The Java implementation of the heuristic algorithm explained
in this paper is available as a Cytoscape plugin at http://apps.cytoscape.org/
apps/mcds, see Figure S2 with three examples, see Figures S3, S4, S5. Based on
the request by Cytoscape users, see Figures S6, S7, we were informed by Cytoscape
organizers that there is a need for an updated version of MCDS Cytoscape. This
update will be available soon, which enables users to call Cytoscape from Python
and R workflows.
• Data: This folder contains GRN files for E. coli, S. cerevisiae, pluripotency net-
work of mouse ESC and breast cancer network modules.
Available at https://github.com/maryamNazarieh/KeyRegulatoryGenes.
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Chapter 4
TFmiR: A Web server for Constructing and
Analyzing Disease-specific Transcription
factor and miRNA co-regulatory Networks
This chapter is based on our paper entitled "TFmiR: A web server for constructing and
analyzing disease-specific transcription factor and miRNA co-regulatory networks" by Mo-
hamed Hamed, Christian Spaniol, Maryam Nazarieh and Volkhard Helms (Hamed et al.,
2015a) published in the journal of Nucleic Acids Research.
Mohamed Hamed compiled the regulatory databases for human, developed the backend
of the web server in R language and wrote the manuscript. Christian Spaniol developed
the frontend of the web server in PHP and Java-script. Maryam Nazarieh modelled the
problem of identifying hotspot nodes with a MDS problem and introduced the effect of
centrality measures in regulatory networks as an alternative approach to the controllabil-
ity approach via a minimum dominating set and implemented the heuristic approach of
dominating set in Java for TF-miRNA co-regulatory networks and wrote the text of the
paper in Latex. Prof. Volkhard Helms proposed the biological motivation of the paper,
helped in designing the study and edited the manuscript.
TFmiR is a freely available web server for deep and integrative analysis of combinatorial
regulatory interactions between TFs, microRNAs and target genes that are involved in
disease pathogenesis. Since the inner workings of cells rely on the correct functioning
of an enormously complex system of activating and repressing interactions that can be
perturbed in many ways, TFmiR helps to better elucidate cellular mechanisms at the
molecular level from a network perspective. The provided topological and functional
analyses promote TFmiR as a reliable systems biology tool for researchers across the
life science communities. TFmiR web server is accessible through the following URL:
http://service.bioinformatik.uni-saarland.de/tfmir
4.1 Introduction
Among many genetic regulators, TFs and microRNAs (miRNAs) are the essential key
players for regulating gene expression (Hobert, 2008). Together they play important roles
in regulating virtually all cellular processes such as differentiation, proliferation, survival,
and apoptosis (Esquela-Kerscher and Slack, 2006). Also genetic disorders and complex
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diseases including cancer are mostly associated with perturbations of the interwoven reg-
ulatory circuit between TFs and miRNAs (Hanahan and Weinberg, 2011; Poos et al.,
2013). TFs and miRNAs frequently form Feed Forward Loops (FFLs) and other network
motifs to regulate cellular transcription in a connective manner (Poos et al., 2013; Yan
et al., 2012). Therefore, utilizing the combined regulatory information on TFs and miR-
NAs as well as their target genes could shed light on key driver genes and miRNAs in
human diseases and, in turn, suggests novel therapeutic strategies in disease treatment
(Yan et al., 2012; Hamed et al., 2015b).
Several databases have been developed in order to facilitate research on transcriptional
and post-transcriptional interaction types between TFs, miRNAs and target genes. For
instance, TransFac (Matys et al., 2003), OregAnno (Griffith et al., 2008), and MsigDB
(Liberzon et al., 2011) provide compilations of TFs regulating genes (TF→ gene). Trans-
miR (Wang et al., 2010) provides information on which TFs regulate miRNAs (TF →
miRNA). mirTarBase(Hsu et al., 2010), TarBase (Sethupathy et al., 2006) and miRecords
(Xiao et al., 2009) collect target genes of miRNAs (miRNA → gene) in different organ-
isms. Although still little is known about miRNA-mediated miRNA regulations, recent
studies reported plausible evidences that miRNAs may regulate the expression of other
miRNAs as well as their target genes (Yan et al., 2012; Matkovich et al., 2013). Thus,
miRNA → miRNA interactions were computationally predicted and made available in
the PmmR database (Sengupta and Bandyopadhyay, 2011).
Despite the general availability of such databases, generalized repositories integrating
different kinds of molecular interactions and enabling to analyze their contributions to
diseases are still missing. To this end, we present TFmiR, a web server that allows for
integrative and comprehensive analysis of interactions between a set of deregulated TFs/-
genes and a set of deregulated miRNAs within the relevant pathways of a certain disease.
The tool unravels the disease-specific co-regulatory network between TFs and miRNAs
and performs over representation analysis (ORA) for the involved TFs/genes and miR-
NAs. Our web server also detects feed forward loops (FFLs) consisting of miRNAs, TFs,
and co-targeted genes (TF-miRNA co-regulatory motifs) and statistically assesses the
functional homogeneity between the co-regulated targets. Furthermore, TFmiR utilizes
seven different methods for identifying key network players that could possibly drive onco-
genic processes of diseases and thus could act as potential drug targets. Especially when
combined with experimental validation, these putative key players as well as the novel
TF-miRNA co-regulatory motifs could promote novel insights to develop new therapeutic
approaches for human diseases.
4.2 Materials and Methods
4.2.1 Description
TFmiR integrates genome-wide transcriptional and post-transcriptional regulatory inter-
actions to elucidate human diseases. For a specified disease and based on user-supplied
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Figure 4.1: A system level overview of the TFmiR architecture describing the incorporated
databases, data flows and output downstream analysis.
lists of deregulated genes/TFs and miRNAs, TFmiR investigates four different types of
interactions, TF→ gene, TF→ miRNA, miRNA→ miRNA, and miRNA→ gene. It also
unravels the circuitry between miRNAs, TFs and target genes with respect to specified
diseases. For each interaction type, TFmiR utilizes information provided by established
and curated regulatory databases of both predicted and experimentally validated interac-
tions (see Figure 4.1) whereby all duplicate interactions were removed. For TF→ miRNA
interactions, we also integrated manually curated regulatory relationships compiled by the
authors from (∼ 5000) published papers (Qiu et al., 2010). From the predicted miRNA
→ miRNA interactions in the PmmR database (Sengupta and Bandyopadhyay, 2011),
we considered only the best hits having score < 0.2, which was computed as the normal-
ized path length between the two involved miRNAs. The incorporated predicted miRNA
→ gene interactions were retrieved from starBase (Yang et al., 2011) by selecting only
those predictions confirmed by three out of five prediction algorithms (targetScan (Bartel,
2009), picTar (Krek et al., 2005), RNA22 (Miranda et al., 2006), PITA (Kertesz et al.,
2007), and miRanda (John et al., 2004)). Table S11 lists the included databases and
the number of regulations available for each interaction type. In total, TFmiR currently
integrates information on almost 10.000 genes, 1856 miRNAs, ∼ 3000 diseases including
subtypes, and more than 111.000 interactions.
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4.2.2 TFmiR user input Scenarios
TFmiR can be called in two ways. If the user submits two RNA sets (a set of deregu-
lated mRNAs/genes and a set of deregulated miRNAs), the tool will return regulatory
interactions based on the provided deregulated genes and deregulated miRNAs. In the
second scenario, a user submits only a set of deregulated genes. In this case, TFmiR
identifies the set of miRNAs whose target genes as well as regulator TFs are significantly
enriched within the input deregulated genes using the hypergeometric distribution func-
tion followed by the BH adjustment with a cutoff value of 0.001. Sample input files of
the deregulated genes and miRNAs are provided in the supplementary Figures S8 and S9.
The user can optionally set the p-value cutoff (default is 0.05) for ORA on the resulting
network nodes (genes/miRNAs). Finally, the user can control the evidence level (exper-
imentally validated, predicted, or both) for the constructed regulatory interactions that
will be used in the subsequent network analysis.
4.2.3 Functionality of TFmiR
TFmiR pools all four interactions types (TF → miRNA, miRNA → TF, miRNA →
gene, miRNA→ miRNA) based on the significant TF(gene)-miRNA pairs from the input
deregulated genes and miRNAs and accordingly generates the entire combinatorial reg-
ulatory network. If a disease was selected, TFmiR uses data retrieved from the human
miRNA disease database (HMDD) (Lu et al., 2008) as well as DisGeNET (a database
for gene-disease association) (Bauer-Mehren et al., 2010) as sources for disease-associated
miRNAs and genes, respectively. Interactions whose target nodes or regulator nodes are
known to be associated with the disease compose the putative disease-specific network.
TFmiR then offers three levels of downstream analysis: (1) the regulatory subnetwork of
the four interaction types, (2) the combined network of all interaction types, and (3) the
disease-specific network (if disease was selected).
For each interaction type subnetwork of regulator→ target links, we display the total num-
ber of targets and regulators in the corresponding interaction databases, a Venn diagram
depicting the overlap between the input deregulated targets (miRNAs/genes), and the
targets of the input deregulated regulators (genes/miRNAs) available from the database.
The significance of overlap is computed using the hypergeometric distribution test. To
avoid the effect of false-positives in the regulator → target databases and to account for
a different number of targets for the input deregulated regulators, a randomization test is
conducted (n=1000). Furthermore, TFmiR carries out ORA for both gene analyses and
miRNA sets comprising the interaction subnetwork.
For gene set analysis, TFmiR employs DAVID (Huang et al., 2009) to check for enrich-
ment of GO terms (BP subcategory), KEGG pathways, and OMIM diseases as well as for
clustering the genes based on their functional similarities. For miRNA set analysis, we
used the miRNA-functional association data and miRNA-disease association data from
HMDD to statistically relate the functional and disease terms to the miRNA set.
For the combined and disease-specific networks, TFmiR calculates for each network ba-
sic topological features, relevance to the disease-associated genes/miRNAs by testing the
overlap significance with the network nodes, degree distribution plot, ORA analyses for
both gene and miRNA nodes, network key nodes, and detects 3-node motifs. To mea-
sure the strength of correlation between the potential disease-specific network, the input
disease, and the input deregulated genes and miRNAs, we compute a coverage ratio CR
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between the nodes of the disease-specific network and the nodes of the entire combined
network.
CR = NdNt
Here, Nd represents the number of disease-specific network nodes, and Nt represents the
total number of nodes in the entire network. We also calculate the CR ratio between
the edges of the two networks. All resulting networks are visualized using the interactive
Cytoscape-web viewer (Lopes et al., 2010).
4.2.4 Identification of Network Key Nodes
We defined the key nodes as the top 10% highest centrality nodes of the TFs, miRNAs, and
genes in the disease-specific and whole network. TFmir uses degree centrality, closeness
centrality, betweenness centrality and eigenvector centrality as well as the common and
union sets of the key nodes identified by these four measures. We also determine the
minimal set of dominating nodes that regulate the entire network as explained in chapter
3. To solve such an optimization problem, we apply the directed version of the algorithm
presented by (Rai et al., 2009) to search for the dominating set on the directed graphs.
4.2.5 Identification of TF-miRNA co-regulatory Motifs
Feed Forward Loops (FFLs) are interconnection patterns that recur in many different
parts of a network and form key functional modules (Yan et al., 2012; Shen-Orr et al.,
2002). They have been demonstrated as one of the most important motif patterns in
transcriptional regulation networks (Shen-Orr et al., 2002) that govern many aspects of
normal cell functions and diseases (He et al., 2007; Li et al., 2009). Here, TFmiR identifies
four types of 3-nodes motifs (3 FFLs and 1 co-regulation motif) consisting of a TF, a
miRNA, and their co-targeted gene and defines them as TF-miRNA co-regulatory motifs,
see Figure 4.2. (1) The Coregulation-FFL includes only TF regulation of a target gene as
well as miRNA repression of that target gene. (2) The TF-FFL includes TF regulation of
the expression of both a miRNA and a target gene and it also includes miRNA repression
of that target gene. (3) The miRNA-FFL includes miRNA repression of both a TF and a
target gene, as well as TF regulation of this target gene. (4) The Composite-FFL describes
TF regulation of both a miRNA and a target gene as well as miRNA suppression of that
TF and that target gene.
1-Identifying significant TF-miRNA co-occuring pairs
We identified statistically significant TF and miRNA pairs that cooperatively regulate
the same target gene using the hypergeometric distribution and evaluated p-values:
p-value = 1 - ∑xi=0 (ki)(M−kN−i)(MN)
where k is the number of target genes of a certain miRNA, N is the number of genes
regulated by a certain TF, x is the number of common target genes between these TF
and miRNA, and M is the number of genes in the union of all human genes targeted by
human miRNAs and all human genes regulated by all human TFs in our databases. Then,
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Figure 4.2: Schematic illustration of the four motif types detected in TFmiR. All motifs
contain a TF, a miRNA, and a common target gene.
multiple test correction was performed by determining FDR according to BH (Benjamini
and Hochberg, 1995) method and only those pairs with a adjusted p-value less than 0.05
were selected as significant TF-miRNA pairs.
2-Construction of candidate TF-miRNA-gene FFLs
All interactions associated with the significant TF-miRNA pairs are represented as con-
nectivity matrix, M , such that Mij = 1 if regulator i regulates target j where i ∈ (TF,
miRNA) , and j ∈ (TF, miRNA, gene). Then, we scan all the 3 ∗ 3 submatrices of M
that represent each type of the four considered FFL topologies, see Figure 4.2.
3-Significance of the FFL motifs
To evaluate the significance of each FFL motif type, we compare how often they appear in
the real network to the number of times they appear in randomized ensembles preserving
the same node degrees. The random networks were constructed 100 times and compared
to the real network. The p-value is calculated as
p-value = Nh
Nr
where Nh is the number of random times that a certain motif type is acquired more than
or equal to its number in the real network, and Nr is 100. We also calculate the z-score
for each motif type to examine by how many standard deviations the observed real motif
was above or below the mean of the random ones.
z-score = No−Nm
σ
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Here No is the number of motifs observed in the real network, whereas Nm, and σ are the
mean and standard deviation of the motif occurrence in 100 random networks, respec-
tively.
4.2.6 Functional Homogeneity
In order to evaluate the biological evidence of the identified TF-miRNA co-regulatory
motifs and better understand their functional roles, TFmiR allows the user to analyze the
GO semantic similarity for all pairs of genes targeted by the same TF and miRNA pair
or for all pairs of genes regulated by the TF or the miRNAs of that TF-miRNA pair, see
Figure S10. The GoSemSim R package (Yu et al., 2010) is used to compute the semantic
similarity scores according to the GO annotations. Statistical significance is determined
by randomly selecting the same number of genes (co-targeted genes or co-regulated genes)
from all Entrez genes with GO annotations, and computing their similarity scores. The
permutation procedure is repeated 1000 times. Then, we carry out a Kolmogorov-Smirnov
test to check whether the functional similarity scores of all gene pairs from the FFL motif
are significantly higher than that of randomly selected pairs.
4.3 Results
4.3.1 Case Study
TFmiR was applied to several data sets related to complex diseases such as cancer,
Alzheimer and diabetes. In a recent study on breast cancer (Hamed et al., 2015b), the
authors identified 1262 deregulated genes and 121 deregulated miRNAs using gene and
miRNA expression data from the TCGA portal (https://tcga-data.nci.nih.gov/tcga/).
These two sets of deregulated genes and miRNAs are the default sample input files pro-
vided by the TFmiR web server. Next, TFmiR was used to reveal the co-regulation
network between the deregulated genes/TFs and deregulated miRNAs and to better un-
derstand the pathogenic mechanisms associated with breast tumorigenesis. As user input
parameters we set the p-value cut off to 0.05, disease was set to breast neoplasms, and
the evidence level was set to both experimentally validated and predicted interactions.
For this data set TFmiR constructed a total of 427 regulatory interactions comprising
263 nodes of deregulated miRNAs and deregulated TFs/genes. The breast cancer-specific
network involved 345 interactions and 212 nodes of deregulated miRNAs and genes with
node and edge coverage ratios CR of 80.6% and 80.8%, respectively. The provided ORA
analysis of the disease network nodes revealed their implications in many cancer types as
well as cancer-related KEGG pathways. Moreover, ORA analysis of the network miRNAs
showed their involvement in cancerogenesis of multiple organs such as lung neoplasms,
ovarian cancer, and adenocarcinoma, see Table S12. Additionally, TFmiR identified 22
key network players (10 genes and 12 miRNAs) based on the union set of four centrality
measures described above, see Table S13. Interestingly, some of the identified key genes
such as BRCA2, ESR1, AKT1, and TP53 were previously implicated and significantly
mutated in breast cancer samples (Koboldt et al., 2012). More importantly, the protein
products of the genes ESR1, TP53, TGFB1, AKT1, and BRCA2 are binding targets for
anti-breast cancer drugs (Hamed et al., 2015b), see Table S14.
The effect of MDS on the breast cancer co-regulatory network has been explored in
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(Hamed et al., 2015b). Next, we examined the TF-miRNA co-regulatory motifs that
were significantly enriched in the entire interaction network. We identified 53 FFL motifs
(3 composite-FFLs, 2 TF-FFLs, 6 miRNA-FFLs, and 42 coreg-FFLs). An interesting
motif involving the TF SPI1, the miRNA hsa-mir-155, and the target gene FLI1 reveals
how FFL motifs may help to better understanding the pathogenicity of breast cancer, see
Figure S11 from the tool. Recent studies reported that the oncogene SPI1 is involved in
tumor progression and metastasis (Guo et al., 2005; Rimmelé et al., 2010). However, the
co-regulation of the oncogene FLI1 (Sakurai et al., 1784) by both SPI1 and the oncomiR
hsa-mir-155 was not reported before. As the co-regulated genes of SPI1 and hsa-mir-
155 have significantly more similar cellular functions than randomly selected genes (see
Figure S12), this FFL motif provides novel insights on SPI1-miRNA network's alteration
in breast cancer and suggests a cooperative functional role between SPI1 and potential
miRNA partners.
4.4 Summary and Discussion
We developed TFmiR as a comprehensive web server for integrative analysis of the molec-
ular interactions between TFs/genes and miRNAs and their interwoven critical roles in the
pathology of human diseases. TFmiR provides an extended downstream analysis, a variety
of user parameters, use case scenarios, and incorporates information from various well-
established regulatory databases. TFmiR is based on user-provided sets of deregulated
genes and/or miRNAs regardless of the data producing technologies of either microarray
experiments, NGS, or PCR. We showed that unlike the traditional separate analysis of
gene expression profiles (Bertucci et al., 2004; Chang et al., 2003) or the aberration of
miRNA expression in cancer tissues (Yang et al., 2009; Xi et al., 2006), this integrated
molecular analysis of deregulated miRNAs and genes using TFmiR was able to uncover
literature confirmed core regulators as well as important new aspects of the TF/gene-
miRNA interactomes, their co-regulation mechanisms, and the underlying pathogenesis
of human breast cancer. The novel hub nodes of TFs/miRNAs could be further experi-
mentally investigated as new potential drug targets. TFmiR was also able to characterize
important TF miRNA co-regulatory motifs whose co-regulated genes form cooperative
functional modules in breast oncogenesis processes.
Compared to the web services of related databases and tools such as Transmir (Wang
et al., 2010), ChIPBase (Yang et al., 2013), CircuitsDB (Friard et al., 2010), starBase
(Yang et al., 2011), miR2Disease (Jiang et al., 2009), and cGRNB (Xu et al., 2013), our
TFmiR web server has several distinctive features: (1) TFmiR performs integrative anal-
ysis of molecular interactions between a set of deregulated genes and a set of deregulated
miRNAs within or without the pathogenic pathways of a certain disease. In contrast, the
above mentioned web tools only search the regulatory interactions of a single gene or a sin-
gle miRNA. (2) TFmiR performs a rich network analysis, TF-miRNA co-regulatory motif
detection, network visualization, statistical significance of the extracted interactions, and
ORA analysis for each interaction type, the combined interaction network, and the dis-
ease network. Such an integrated analysis is not provided by other web tools. (3) TFmiR
allows the user to retrieve either experimentally validated or predicted interactions or
both. Such an option is not available using the other tools. In a somehow similar fashion,
DisTMGneT (Sengupta and Bandyopadhyay, 2013) was developed for obtaining cancer-
specific network based on user-selected sets of deregulated genes and miRNAs. However,
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it lacks the downstream analysis, the varieties of user input parameters, and it is limited
to a predefined set of miRNAs and genes as well as cancer disease. Also miRTrail (Laczny
et al., 2012) performs ORA and Gene Set Enrichment (GSEA) analyses of interactions
of genes and miRNAs based on expression profiles. However, it explores only miRNA →
gene interactions.
4.5 Outlook and Perspective
TFmiR is planned to be integrated with other useful ORA tools such as KeyPathwayMiner
(Alcaraz et al., 2011), GiGA (Thomas, 2010), HotNet (Vandin et al., 2011) and jActive-
Modules (Ideker et al., 2002) to allow the user to benefit their advances within TFmiR.
We also intend to allow for submitting multi case expression data and times series data
as well as the currently supported case/control data. Finally, expanding the TFmiR to
elucidate the regulatory mechanisms of cellular processes (ex. stem cell differentiation) in
addition to diseases would sort TFmiR of great interest for wide range of researchers and
most of life science community.
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Chapter 5
TopControl: Candidate Disease Gene
Prioritization
This chapter is based on the manuscript entitled "Candidate Disease Gene Prioritization
based on Topological Features" written by Maryam Nazarieh. Prof. Volkhard Helms
edited the manuscript.
Potentially disease-associated genes are typically identified among those genes that are
DE between disease and normal conditions. This strategy typically yields thousands of
DE genes. Gene prioritizing schemes boost the power for identifying the most promis-
ing disease-causing genes among a set of candidates. We introduce a novel system for
prioritizing genes among those which are significantly DE between tumor and normal
samples. To achieve this goal, a TF-miRNA co-regulatory network is constructed for the
set of candidates, where the ranks of the candidates are determined by topological and
biological factors. We tested our prioritization system on breast invasive carcinoma and
liver hepatocellular carcinoma datasets to reveal the power of the system to detect sets of
disease-associated genes. Our experiments show that this novel prioritization technique
identifies a significant set of known disease-associated genes, while suggesting new candi-
dates which can be investigated later as potential disease-associated genes.
5.1 Introduction
RNA sequencing (RNA-Seq) generates an abundant number of sequencing reads, which
leaves a large number of experiments for identifying disease-associated genes. Candidate
gene prioritization helps experimentalists to focus their follow-up experiments on the most
promising candidates based on the relationship between known disease genes and candi-
dates.
Prioritizing tools typically produce their outputs either by filtering the candidates into
smaller subsets or by ranking the candidates from the most promising to least promising
ones. Some ranking techniques select the relevant candidates based on their similarities
with user-defined disease-associated genes (Moreau and Tranchevent, 2012).
Currently, ranking methods based on network analysis indicate most of what we already
know about the disease. They combine interaction networks with functional annota-
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tions to select disease related candidates. The tool ToppNet (Chen et al., 2009) takes
a different approach and ranks the candidate genes based on topological features in the
protein-protein interaction network. The tool utilizes three algorithms mainly developed
for social networks to prioritize candidate genes (Chen et al., 2009).
Other ranking approaches like text mining techniques select the candidates related to
a disease through retrieving related documents from literature focusing on certain key-
words (Moreau and Tranchevent, 2012). Since most prioritization methods require access
to multiple databases, they are available mostly in the form of web services, e.g Endeavor
(Tranchevent et al., 2016). Unlike Endeavor, NetworkPrioritizer (Kacprowski et al., 2013)
utilizes the central nodes of a network mainly based on betweenness and closeness as seed
nodes. It aggregates multiple node rankings derived according to the distance to central
nodes to prioritize the candidates. However, it is unclear whether high centrality genes
exercise a full control over the underlying network. FocusHeuristics aims to combine the
static knowledge on the PPI network with the dynamics of gene expression for the gene
ranking (Ernst et al., 2017). The software aggregates three features that are derived from
gene expression data and the biological network, namely fold change, the differential link
score and the interaction link score. Then the tool prunes the network to those nodes that
exceed at least one of the predefined thresholds of the mentioned features. Therefore, the
results vary based on different thresholds.
In this work, we present a prioritization system termed TopControl which finds a signifi-
cant set of disease genes among the candidates by considering the set of genes that control
the disease network. TopControl does not rely on any prior knowledge for prioritization
of candidate disease genes. No seed genes need to be provided by a user. TopControl
combines topological features and a biological factor to give an aggregated ranking to the
candidates. MDS, MCDS and hub degree nodes are the topological features and log2(fold
change) of expression is a biological factor that we considered in this work, see Figure 5.1.
In previous works, we demonstrated the power of MDS and MCDS in capturing the sig-
nificant set of drug target genes in the breast cancer network. Moreover, we showed that
a MCDS had high overlap with betweenness central nodes in the network, whereas the
closeness centrality was more dominant in the MDS in the mouse ESC network (Nazarieh
et al., 2016), see chapter 3. As explained earlier, MDS and MCDS genes in the regulatory
networks control the network through their interactions, whereas hub-degree nodes are
the top 10% high degree nodes in the network.
Here, we propose a novel candidate gene prioritization based on systematic analysis of DE
genes between tumor and normal conditions. Initially, DE genes are filtered out to yield
a set of candidates which form a network. The network candidates are prioritized based
on network topological features. The priority of the candidates by which we mean rele-
vance to a disease in disease networks increases when they are either in solutions derived
from computing MDS, MCDS or they are in the hub set. Since significant DE genes with
high fold change are the top candidates to experimentalists (Yang et al., 2016), the set of
candidates with equal topological priorities are sorted based on the log2(fold change) of
expression.
As explained earlier, MDS and MCDS are optimization problems. Solving the optimiza-
tion problems by exact algorithms returns optimal solutions, but these optimal solutions
are not unique. Different optimal solutions can be generated with different optimization
algorithms. To address this problem, (Zhang et al., 2015b) modified the ILP formula-
tion of MDS to return optimal solutions which are biased to hubs in the protein-protein
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Figure 5.1: Schematic illustration of TopControl method with describing its hierarchical
layers.
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interaction networks. This modification cannot be applied to ILP formulations which
address GRNs which are represented by directed graphs. (Liu et al., 2011) and (Nazarieh
et al., 2016) realized that key drivers tend not to be among hubs in GRNs. Moreover,
the heuristic approaches which are used when exact algorithms cannot find the solutions
in appropriate time (Rai et al., 2009; Wightman et al., 2011), affect the optimal solution.
The other problem is that not all nodes in MDS or MCDS are critical. We termed nodes
that are part of both MDS and MCDS as critical nodes. TopControl addresses these
issues by selecting the genes and miRNAs which are identified based on network control-
lability (the term was explained in chapter 3) by two different approaches. Although both
MDS and MCDS consider a set of nodes which can control the state of GRNs through
direct regulation of their target genes, only MCDS ensures that network controllability is
achieved by a dominating pathway in the LCC of the network. To select the most promis-
ing candidates, TopControl gives priority to the candidates that are identified by both
MDS and MCDS and have high degree of interactions. Therefore, the most promising
candidates according to TopControl are the set of genes and miRNAs which are selected
by all the three methods MDS, MCDS and hub set. They are sorted by log2(fold change)
in descending order.
5.2 Materials and Methods
In this work, we use a hierarchical model of five layers to prioritize a set of candidates
related to a certain disease. Genes at the first layer have the lowest priority and highest
priority when they reach to the fifth layer. Basically, the genes in each layer is a subset
of the genes in the lower layer. A set of miRNAs is introduced in the third layer if they
interact with the selected genes from the second layer.
TopControl considers the whole set of genes in the first layer whose expression levels
between two conditions have been provided. Then it selects the set of genes that are
DE between disease and normal conditions based on the high potential that this set of
genes carry to be associated with a related disease. With respect to the fact that disease
genes interact with each other and related miRNAs, a TF-miRNA co-regulatory network
is constructed for the set of DE genes. Therefore, the set of genes from the second layer
that interact with each other and a selected set of miRNAs by TFmiR (the process of
selection was explained in chapter 4) construct the disease-network in the third layer.
Priority in the fourth layer is given to the set of genes and miRNAs which have either
high interactions (hub-degree) or can control the network through their interactions. For
this purpose, we consider two methods MDS and MCDS as explained in chapter 3. Top
most candidates selected by TopControl in the fifth layer are the genes and miRNAs which
have three roles in the network. They are in the set of hubs as well as MDS and MCDS.
These genes and miRNAs are ranked up based on the absolute value of their fold changes
in descending order.
We tested our method on the processed RNA-Seq data taken from the cancer genome
atlas (TCGA) for matched tumor and normal samples of liver hepatocellular carcinoma
(LIHC) and breast invasive carcinoma (BRCA) datasets downloaded on 15-Jun-2015. We
exploited the DESeq method to identify the set of DE genes. TFmiR constructs a TF-
miRNA co-regulatory network for the set of DE genes. Then the genes and miRNAs in
the network were prioritized based on topological and biological factors.
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5.2.1 Candidates in the First Layer
The first layer contains the whole set of genes with the corresponding expression levels
across samples of tumor and normal conditions.
5.2.2 Candidates in the Second Layer
Potential disease-associated genes are typically identified among those genes that are DE
between disease and normal conditions. This strategy usually yields thousands of DE
genes, where the results are affected by various methods and sample size (Soneson and
Delorenzi, 2013; Ching et al., 2014). Therefore, we considered DE genes as the candidates
in the second layer. To identify the DE genes, we used the DESeq method (Anders and
Huber, 2010).
5.2.3 Candidates in the Third Layer
DE genes and miRNAs which interact with each other to construct a network form the
third layer of candidates. To construct the network, the TFmiR web server is used, see
chapter 4. The set of miRNAs is selected such that target genes and regulator TFs of
miRNAs are significantly enriched within the input deregulated genes using the hyperge-
ometric distribution function followed by the BH adjustment (Benjamini and Hochberg,
1995) with a cut off value of 0.001. A complete network includes all the experimentally
validated interactions between user-defined DE genes and retrieved miRNAs which are
extracted from a variety of regulatory databases (Hamed et al., 2015a). The interaction
types are TF→ gene, TF→ miRNA and miRNA→ gene. In this work, we just used the
complete network without specifying any disease.
5.2.4 Candidates in the Fourth Layer
Genes and miRNAs from the third layer are prioritized if they take part in one of the
three sets, MDS, MCDS or hub set. Therefore, hubs, dominators and the nodes on the
dominating pathway of the TF-miRNA co-regulatory network form the fourth layer. As
a basis for this, we used regulatory networks involving TFs, microRNAs, and target genes
that we predicted with our TFmiR web server from a set of DE genes. As hub-degree
genes the web server outputs the top 10% highest degree nodes. A MDS was calculated
based on the ILP formulation described in (Nazarieh et al., 2016), where MDS in a
regulatory network is the minimum number of regulatory genes and miRNAs that control
the whole network. A MCDS was computed based on the heuristic approach mentioned
in (Nazarieh et al., 2016), where MCDS in a co-regulatory network is a connected set
of genes and miRNAs that control the LCC of the network. A score is assigned to the
nodes in this layer based on the number of roles they play in the network. The maximum
score which is equal to three is given to a gene or miRNAs which is a hub, as well as a
dominator and is on the dominating pathway of the network. Genes and miRNAs with
the same score are sorted based on log2(fold changes) in descending order.
5.2.5 Candidates in the Fifth Layer
The set of candidates in the fourth layer which are selected by all three methods such
as MDS, MCDS, and hubs are selected in the fifth layer and sorted in descending order
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Figure 5.2: Histogram of p-values from the call to nbinomTest adjusted by BH derived
by DESeq method.
based on the log2(fold changes) of expression between two conditions.
5.2.6 Biological Relevance
The biological relevance of the results obtained by the hub set, MDS, and MCDS criteria
was evaluated using the enrichment analysis tool provided at the DAVID portal of NIH
(version 6.8) based on the functional categories in GO Direct (Huang et al., 2009). p-
values below the threshold 0.05 obtained by the hypergeometric test were adjusted for
multiple testing using the BH procedure (Benjamini and Hochberg, 1995).
5.3 Results
5.3.1 LIHC dataset
The LIHC data set consisting of 20501 genes for 100 matching tumor and normal sam-
ples were given as input to the DESeq method. We selected the set of DE genes whose
adjusted p-values were below 0.05. DESeq identified 3872 significant DE genes. Figure
5.2 shows the histogram of adjusted p-values visualized using the DESeq package (Anders
and Huber, 2016). This set of DE genes was given to the TFmiR web server, by setting
the p-value threshold to 0.05 and selecting experimentally validated resources. TFmiR
constructed a complete TF-miRNA co-regulatory network with 275 genes and miRNAs
and 383 regulatory interactions. 28 hub-degree nodes were obtained from the hotspot
section of the web server. 61 and 68 genes and miRNAs were the results of MDS and
MCDS, respectively. The union of hubs, MDS and MCDS were 82 distinct genes and
miRNAs, see Table S15.
Table 5.1 shows the set of genes and miRNAs associated with hepatocellular carcinoma
in the TFmiR complete network with the corresponding TopControl-assigned scores. 17
out of 33 genes and miRNAs associated with hepatocellular carcinoma (reported by Dis-
GeNET (Bauer-Mehren et al., 2010) and HMDD database (Lu et al., 2008)) in the net-
work were among the set selected by TopControl. This led to sensitivity = 52%, specificity
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= 73% and accuracy = 71%. The significance of the union of genes and miRNAs selected
by respective methods was assessed with the hypergeometric test, by returning a p-value
of 0.004 with (0.002, 0.035, 0.013) per each set of hub, MDS, MCDS.
Enrichment analysis for these sets (hub, MDS, MCDS) demonstrates the related enriched
GO terms and KEGG pathways, see Tables S16, S17 and S18. These three sets shared
several GO terms like GO:0051726, GO:0008285 and GO:0042493 for regulation of cell
cycle, negative regulation of cell proliferation and response to drug, respectively. More-
over, MDS and MCDS shared the GO:0010941 correspond to regulation of cell death.
Table 5.2 shows the top-most candidates in the fifth layer. 6 out of 18 proposed genes
and miRNAs were reported in DisGeNET and HMDD. To biologically assess the potential
of new candidates, we used LiverWiki (Chen et al., 2017), which is a comprehensive and
up-to-date database for liver data. All the 12 new candidates were significantly expressed
in hepatocellular carcinoma.
5.3.2 BRCA dataset
The breast invasive carcinoma (BRCA) data set with 20501 genes and 226 matching tu-
mor and normal samples were given as input to the DESeq method. 5231 significant
DE genes with adjusted p-values below 0.05 were selected by DESeq method. Figure 5.3
Figure 5.3: Histogram of p-values from the call to nbinomTest adjusted by BH derived
by DESeq method.
shows the histogram of adjusted p-values visualized using the DESeq package (Anders
and Huber, 2016).
The set of DE genes was given to the TFmiR web server, by setting the p-value thresh-
old to 0.05 and selecting experimentally validated resources. TFmiR constructed a co-
regulatory network with 463 nodes and 696 regulatory interactions. 47 hub-degree nodes
were obtained as the top 10% high-degree nodes in the network. 97 and 113 genes and
miRNAs were the results of MDS and MCDS, respectively. This led to a total 140 dis-
tinct genes and miRNAs. Table 5.3 shows the set of genes and miRNAs associated with
breast neoplasms with the corresponding TopControl-assigned scores. 33 out of 50 genes
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Table 5.1: TopControl-assigned scores of 33 disease-associated genes and miRNAs re-
ported in DisGeNET and HMDD databases and were in the constructed TFmiR complete
network for the LIHC dataset. The set of genes and miRNAs in the table were ranked
up first by their TopControl-assigned scores and then sorted by LFC in descending order.
D stands for the degree of the node and LFC for log2(fold change) of expression. The
HCC flag denotes whether a gene or miRNA is associated with this disease (1) or not (0)
according to DisGeNET and HMDD.
gene D hub mds mcds score LFC HCC
E2F1 25 1 1 1 3 3.76 1
ESR1 9 1 1 1 3 2.19 1
JUN 33 1 1 1 3 1.39 1
MYC 18 1 1 1 3 1.07 1
hsa-let-7b 47 1 1 1 3 - 1
hsa-mir-29a 21 1 1 1 3 - 1
FOXM1 3 0 1 1 2 3.69 1
FOS 23 1 0 1 2 2.93 1
CEBPD 1 0 1 1 2 1.3 1
PDGFB 1 0 1 1 2 1.11 1
SREBF2 3 0 1 1 2 0.68 1
NFE2L2 4 0 1 1 2 0.66 1
TERT 6 1 0 0 1 9.17 1
RRM2 2 0 0 1 1 2.98 1
AR 3 0 1 0 1 1 1
HTATIP2 2 0 0 1 1 0.68 1
CCND1 12 1 0 0 1 0.67 1
CYP17A1 1 0 0 0 0 5.22 1
BIRC5 1 0 0 0 0 4.2 1
CCNE1 2 0 0 0 0 3.69 1
PTGS2 1 0 0 0 0 2.73 1
MT2A 2 0 0 0 0 2.71 1
HGF 1 0 0 0 0 2.37 1
GLUL 2 0 0 0 0 2.26 1
ACSL4 1 0 0 0 0 2.26 1
TFPI2 1 0 0 0 0 1.79 1
HSPB1 1 0 0 0 0 1.75 1
TYMS 1 0 0 0 0 1.73 1
MMP9 1 0 0 0 0 1.57 1
APOA1 1 0 0 0 0 1.38 1
ACE 2 0 0 0 0 1.09 1
F2 1 0 0 0 0 0.88 1
PTK2 1 0 0 0 0 0.71 1
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Table 5.2: Top most candidates (genes and miRNAs) selected by TopControl in the
hepatocellular carcinoma network. D stands for the degree of the node and LFC for
log2(fold change) of expression. The HCC flag denotes whether a gene or miRNA is
associated with this disease (1) or not (0) according to DisGeNET and HMDD.
gene D hub mds mcds score LFC HCC
E2F1 25 1 1 1 3 3.76 1
EGR1 18 1 1 1 3 2.33 0
ESR1 9 1 1 1 3 2.19 1
JUN 33 1 1 1 3 1.39 1
NR1I2 9 1 1 1 3 1.37 0
MYC 18 1 1 1 3 1.07 1
JUND 6 1 1 1 3 0.99 0
STAT3 10 1 1 1 3 0.81 0
USF1 15 1 1 1 3 0.73 0
NR1H4 7 1 1 1 3 0.63 0
ETS1 9 1 1 1 3 0.61 0
IRF1 5 1 1 1 3 0.61 0
NR1I3 8 1 1 1 3 0.6 0
hsa-let-7b 47 1 1 1 3 NA 1
hsa-mir-29a 21 1 1 1 3 NA 1
hsa-mir-26a-
5p
16 1 1 1 3 NA 0
hsa-mir-29a-
3p
18 1 1 1 3 NA 0
hsa-mir-34a-
5p
28 1 1 1 3 NA 0
and miRNAs associated with breast neoplasms (reported by DisGeNET (Bauer-Mehren
et al., 2010) and HMDD database (Lu et al., 2008)) in the network were among the set
selected by TopControl. This led to sensitivity = 66%, specificity = 74% and accuracy
= 73%. The significance of the overlap was measured using the hypergeometric test with
p-value of 3.15 ∗ 10−8 with (6.68e-7, 2e-50, 6e-6) per each set (hub, MDS, MCDS) indi-
vidually.
Enrichment analysis for these sets (hub, MDS, MCDS) describes the related biological
process GO terms and KEGG pathways, see Tables S20, S21 and S22. These three sets
shared some GO terms such as GO:0008285 and GO:0042493 for negative regulation of
cell proliferation and response to drug, respectively. All of these sets shared several KEGG
pathways related to different cancers. Moreover, MDS and MCDS shared several terms
related to cell cycle and cell differentiation. Table S19 shows the candidates in the fourth
layer proposed by TopControl. Table 5.4 shows the top most candidates with the high-
est scores given by TopControl, where some of them such as ESR2, FOS, E2F1, ESR1,
JUN, STAT5A, ETS2, TFAP2A, hsa-mir-146a and hsa-mir-21 are disease-associated genes
based on DisGeNET and HMDD databases. We found experimental validations in the
literature mainly as drug target, metastasis promoter and tumor growth enhancer for
other candidates such as EGR1, RUNX2, STAT1, TRAP2, IRF1 and USF1 in (Weiwei
et al., 2013; Li et al., 2016; Hix et al., 2013; Reithmeier et al., 2017; Schwartz-Roberts
et al., 2015; Bouafia et al., 2014).
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Table 5.3: TopControl-assigned scores of 50 disease-associated genes and miRNAs re-
ported in DisGeNET and HMDD databases and were in the constructed TFmiR complete
network for the BRCA dataset. The set of genes and miRNAs in the table were ranked
up first by their TopControl-assigned scores and then sorted by LFC in descending order.
D stands for the degree of the node and LFC for log2(fold change) of expression. The
BC flag denotes whether a gene or miRNA is associated with this disease (1) or not (0)
according to DisGeNET and HMDD.
gene D hub mds mcds score LFC BC
ESR2 7 1 1 1 3 2.58 1
FOS 20 1 1 1 3 2.47 1
E2F1 25 1 1 1 3 2.34 1
ESR1 19 1 1 1 3 1.79 1
JUN 45 1 1 1 3 1.6 1
STAT5A 7 1 1 1 3 1.6 1
ETS2 6 1 1 1 3 1.15 1
TFAP2A 24 1 1 1 3 0.9 1
hsa-mir-
21
44 1 1 1 3 - 1
hsa-mir-
146a
31 1 1 1 3 - 1
WT1 2 0 1 1 2 5.39 1
IFNB1 9 1 0 1 2 4.13 1
FOXM1 1 0 1 1 2 3.54 1
KIT 6 1 0 1 2 2.79 1
IL6 7 1 0 1 2 2.76 1
FOXA1 3 0 1 1 2 1.87 1
RARB 6 1 1 0 2 1.1 1
TRERF1 1 0 1 1 2 1.08 1
HEY2 1 0 1 1 2 1.06 1
MEIS1 1 0 1 1 2 1.01 1
NR2F6 2 0 1 1 2 1 1
KRAS 1 0 1 1 2 0.83 1
AR 5 0 1 1 2 0.63 1
ERBB2 6 1 0 0 1 1.89 1
BRCA2 4 0 0 1 1 1.81 1
AFP 1 0 1 0 1 1.43 1
EGFR 8 1 0 0 1 1.4 1
PDGFA 2 0 0 1 1 1.33 1
BRCA1 5 0 0 1 1 1.24 1
PARP1 1 0 1 0 1 1.2 1
CCND1 15 1 0 0 1 1.01 1
PGR 5 0 0 1 1 0.87 1
ZEB1 1 0 1 0 1 0.72 1
CAV1 3 0 0 0 0 3.19 1
RAD54L 1 0 0 0 0 3.06 1
CCL20 1 0 0 0 0 2.93 1
CCNE1 1 0 0 0 0 2.5 1
MMP3 2 0 0 0 0 2.39 1
F3 2 0 0 0 0 1.77 1
STMN1 2 0 0 0 0 1.68 1
TFPI2 1 0 0 0 0 1.58 1
SYNE1 1 0 0 0 0 1.44 1
PTGS2 1 0 0 0 0 1.26 1
DLL1 1 0 0 0 0 1.09 1
ALDOA 1 0 0 0 0 0.92 1
SERPINB5 3 0 0 0 0 0.75 1
SNAI2 2 0 0 0 0 0.74 1
SOD2 1 0 0 0 0 0.74 1
CSF1 2 0 0 0 0 0.73 1
PIM1 4 0 0 0 0 0.61 1
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Table 5.4: Top most candidates (genes and miRNAs) selected by TopControl in the breast
neoplasms network. D stands for the degree of a node and LFC for log2(fold change).
The BC flag denotes whether a gene or miRNA is associated with this disease (1) or not
(0) according to DisGeNET and HMDD.
gene D hub mds mcds score LFC BC
EGR1 19 1 1 1 3 2.59 0
ESR2 7 1 1 1 3 2.58 1
FOS 20 1 1 1 3 2.47 1
E2F1 25 1 1 1 3 2.34 1
CEBPA 17 1 1 1 3 2.1 0
ESR1 19 1 1 1 3 1.79 1
JUN 45 1 1 1 3 1.6 1
STAT5A 7 1 1 1 3 1.6 1
RUNX2 5 1 1 1 3 1.4 0
STAT1 34 1 1 1 3 1.28 0
ETS2 6 1 1 1 3 1.15 1
MITF 8 1 1 1 3 0.94 0
TFAP2A 24 1 1 1 3 0.9 1
NR1H3 8 1 1 1 3 0.9 0
IRF1 16 1 1 1 3 0.65 0
ARHGEF7 11 1 1 1 3 0.62 0
USF1 16 1 1 1 3 0.61 0
SRF 5 1 1 1 3 0.58 0
TFDP1 10 1 1 1 3 0.58 0
hsa-mir-1 86 1 1 1 3 - 0
hsa-mir-21 44 1 1 1 3 - 1
hsa-mir-145-
5p
39 1 1 1 3 - 0
hsa-mir-21-
5p
32 1 1 1 3 - 0
hsa-mir-146a 31 1 1 1 3 - 1
hsa-mir-34a-
5p
27 1 1 1 3 - 0
5.4 Comparison of TopControl with Endeavor
We compared the results of TopControl with Endeavor (Tranchevent et al., 2016). The set
of DE genes for the LIHC and BRCA datasets derived using DESeq method were given
as input to Endeavor. We selected the same number of genes as the size of TopControl
from top selected genes by Endeavor based on p-value that stands for the significance of
a combination of rankings. In this comparison, we ignored the set of miRNAs from the
lists of top candidates by TopControl as Endeavor does not consider miRNAs. During the
training of Endeavor, we provided the minimum required number of genes for training the
model, as TopControl does not rely on any prior knowledge. We selected all data sources
to build models and prioritize the candidates from Endeavor. DisGeNET was used for
the evaluation of the results. For the case of hepatocellular carcinoma, both methods per-
formed equally well with detecting 15 related disease-associated genes among of 77 top
candidates, see Figure 5.4 panel (A). The overlap among the identified disease-associated
genes comprises seven genes (E2F1, MYC, JUN, CCND1, ESR1, TERT, SREBF2). In
the case of breast neoplasms, TopControl outperformed Endeavor with detecting 31 com-
pared to 26 related disease-associated genes out of 134. This led to an overlap of 20
genes including (ESR2, PGR, AR, JUN, CCND1, RARB, NR2F6, EGFR, FOXA1, FOS,
ERBB2, E2F1, WT1, BRCA1, KRAS, TFAP2A, ZEB1, STAT5A, TRERF1, PARP1),
see Figure 5.4 panel (B).
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Figure 5.4: A) Comparison of identified disease-associated genes between TopControl and
Endeavor for the LIHC dataset. B) Comparison of identified disease-associated genes
between TopControl and Endeavor for the BRCA dataset.
5.5 Summary and Discussion
This chapter introduced the tool TopControl as a new prioritizing method based on topo-
logical and biological factors to propose a new set of disease-associated candidate genes.
This led to the detection of a significant set (based on hypergeometric test) of disease-
associated genes and miRNAs, while introducing a new set of candidates. As a basis for
this, we used regulatory networks involving TFs, microRNAs, and target genes that we
predicted with our TFmiR web server from a set of DE genes and identified the hubs in a
similar way to this tool. Then we applied the ILP formulation of MDS and the heuristic
approach of MCDS to find MDS and MCDS in the underlying networks. Here, we pro-
cessed RNA-Seq data taken from TCGA for matched tumor and normal samples of LIHC
and BRCA. DE genes were identified by the DESeq tool. The BRCA dataset has more
than twice as many samples size as LIHC. This affected the sensitivity without changing
the specificity.
TopControl differs from other gene prioritization tools mainly in that it does not rely on
any prior knowledge to train and build models for prediction of disease-associated genes.
It suggests topological features as potential candidates and prioritizes them to target
critical ones.
Chapter 6
Topology Consistency of Disease Networks
This chapter is based on the manuscript entitled "Topology Consistency of Disease-specific
Networks".
Maryam Nazarieh discovered the topological consistency among different bioinformatics
tools, performed the experiments and wrote the manuscript. Hema Sekhar Reddy Rajula
preprocessed the LIHC dataset and applied the analysis tools for differential expression
under the guidance of Maryam Nazarieh (I was advisor of Hema, only on this work under
supervision of Prof. Helms). Prof. Volkhard Helms helped in designing the study and
edited the manuscript. The motivation of this investigation was that various methods
for identifying DE genes yield quite different results. Thus, we investigated whether this
affects the identification of key regulatory players in regulatory networks derived by down-
stream analysis from lists of DE genes that may be responsible for disease processes.
While the overlap between the sets of significant DE genes was only 26% in liver hepato-
cellular carcinoma and 28% in breast invasive carcinoma, we found that the topology of
the regulatory networks constructed using TFmiR for the different sets of DE genes was
highly consistent with respect to hub-degree nodes, MDS and MCDS. This suggests that
key genes identified in regulatory networks derived from systematic analysis of DE genes
may be a more robust basis for understanding diseases processes than simply inspecting
the lists of DE genes.
6.1 Introduction
RNA-Seq or whole transcriptome shotgun sequencing uses next-generation sequencing
technology to quantify the abundance of RNA in a biological sample at a given moment
in time. Despite a high correlation between gene expression profiles using the same set
of samples, RNA-Seq is capable of detecting low abundance transcripts and allowed for
the detection of more differentially expressed (DE) genes with higher fold-changes than
microarray data (Zhao et al., 2014).
A typical differential expression analysis consists of normalizing raw counts, dispersion
estimation and performing a statistical test. Statistical tests are performed to see if the
observed differences in read counts data between two groups are statistically significant.
The results returned by them typically in terms of p-values reject or accept a certain
null hypothesis which signifies that the mean values of the two groups are equal or that
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the read counts follow the same distribution. To obtain accurate significant results, an
assumption about the distribution of the underlying data is required (see section 2.3),
e.g, a t-test which is widely to process microarray data assumes that the data has a
normal distribution. This assumption does not work for RNA-Seq data with discrete
values. Several data distributions have been suggested to model the RNA-Seq values.
Among them, Poisson distribution and Negative Bionomial (NB) distribution are used
most often. The Poisson distribution does not account for over-dispersion in the data and
presumes that mean and variance are equal which leads to lots of false discovery rates.
Therefore, the NB distribution with considering both mean and dispersion parameters is
typically preferred to model RNA-Seq data. Although, several methods such as DESeq
(Anders and Huber, 2010) and edgeR (Robinson et al., 2010) assume that RNA-Seq data
can be modelled by the NB distribution, each of them has a different way to estimate
the model parameters, mean and dispersion. This lead to different results with different
sizes. The problem gets worse when the methods have different assumptions about the
data distribution. (Soneson and Delorenzi, 2013) conducted a comprehensive comparison
between the results of eleven differential expression analysis methods which take RNA-Seq
read counts as input on both simulated and real data. They demonstrated characteristics
and benefits of utilizing each method. There appears to be no general consensus among
the DE genes found by the different methods (Soneson and Delorenzi, 2013). Here, we
selected four methods such as DESeq, edgeR, voom and VST from the above-mentioned
methods which take read counts as input and return p-values. The methods have been
explained in details in section 2.3.
In this work, we applied these methods to the LIHC and BRCA datasets to get the
significant DE genes. Initially, we showed the overlap among their results. Then, we
showed that key regulatory players are highly consistent among different methods despite
generally low similarity among their sets of DE genes.
6.2 Materials and Methods
We tested our method on the processed RNA-Seq data obtained from TCGA for matched
tumor and normal samples of LIHC and the patients (see chapter 5). We exploited the
R packages of DESeq, edgeR, VST and voom methods (Anders et al., 2013; Law et al.,
2014) to identify the respective sets of DE genes. With TFmiR a TF-miRNA co-regulatory
network was constructed for each set of DE genes. Then we used MDS and MCDS tools
to get the topological features in the regulatory networks.
6.2.1 Network Construction with TFmiR
The networks were constructed using TFmiR web server, see chapter 4. In this work, we
focused on disease-specific network. In this study, we selected hepatocellular carcinoma
and breast neoplasms from the list of diseases for construction of the disease-specific
co-regulatory networks.
6.2.2 Topology Inference
We inferred network topologies of disease-specific networks involving TFs, microRNAs,
and target genes that we predicted with our TFmiR web server from a set of DE genes.
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We took the same strategy as TFmiR and selected the top 10% highest centrality nodes
as hub-degree nodes. A MDS was calculated based on the ILP formulation described in
(Nazarieh et al., 2016), where MDS in a regulatory network is the minimum number of
regulatory genes and miRNAs that control the whole network. A MCDS was computed
based on the heuristic approach mentioned in (Nazarieh et al., 2016), where MCDS in a
co-regulatory network is a set of genes and miRNAs that are connected and control the
LCC of the network.
6.3 Results
6.3.1 Inference of DE Genes
The processed matching tumor-normal samples of LIHC and BRCA consist of 100 and 226
samples with 20501 genes, respectively. The data were given as input to the R packages
DESeq, edgeR, voom and VST. We obtained adjusted p-values as output from all four
packages. Based on the adjusted p-value threshold 0.05, we determined if genes are DE.
The number of significant DE genes for the LIHC dataset with DESeq, edgeR, voom and
VST were 3872, 11399, 10610 and 10238, respectively and for the BRCA dataset 5231,
14722, 15559 and 13918, respectively. Venn diagrams in Figure 6.1 show the number of
genes which are common between these methods. The Venn diagrams were visualized
using the R package VennDiagram (Chen and Boutros, 2011).
6.3.2 Reconstructed Networks
In the case of LIHC dataset, analyzed by the DESeq method, 163 nodes and 199 edges
make up the hepatocellular carcinoma disease-specific network. The hubs, MDS and
MCDS of the network were visualized in Figure 6.2. In the case of breast neoplasms with
BRCA dataset and the same method, 227 nodes and 302 edges were retrieved from TFmiR
databases considering experimental resources. The TFmiR web server also was used to
construct disease-specific networks for the set of DE genes derived from edgeR, voom and
VST. Tables S23 and S27 show the number of nodes, edges, hubs, MDS and MCDS for
the LIHC and BRCA data sets for all the above-mentioned methods, respectively.
6.3.3 Topology Consistency
We performed pairwise comparisons between the topological features of these networks,
see Tables 6.1 and 6.2. The results demonstrate the percentage overlap of hubs, MDS and
MCDS between the aforementioned analysis methods. As shown in the tables, DESeq
has the highest overlap with edgeR than voom and VST in both the studies, whereas the
topological features of edgeR are highly overlapped with voom than VST.
Tables S24, S25, S26 show the list of consistent genes and miRNAs that are common
among all the methods for hepatocellular carcinoma and in Tables 6.3, 6.4, 6.5 for breast
neoplasms. The tables show a high number of consistent genes and miRNAs among the
topological features of the methods. 13 out of 17 hubs selected by DESeq were identified
by other methods in the case of LIHC dataset and 20 out of 23 for the case of BRCA
dataset. The common MDS and MCDS make up almost 70% to 75% of the selected MDS
and MCDS by the DESeq method. The number of consistent topological features among
edgeR, voom and VST could increase when we disregard DESeq method, as it has the
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Figure 6.1: A) Venn diagram describing the number of overlapped DE genes between the
results of DESeq with edgeR, voom and VST for the LIHC dataset. B) Venn diagram
describing the number of overlapped DE genes between the results of DESeq with edgeR,
voom and VST for the BRCA dataset.
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Figure 6.2: Topology consistency in the disease-specific networks for the LIHC dataset.
A) hub-degree genes and miRNAs colored pink. B) MDS nodes colored green. C) MCDS
nodes colored blue. The black circle borders mark the consistent genes and miRNAs
between DESeq, edgeR, voom and VST.
64
Table 6.1: Pairwise comparison of hubs(left), MDS(middle) and MCDS(right numbers)
for the networks constructed from the set of DE genes analyzed by DESeq, edgeR, voom
and VST methods for the LIHC dataset.
Methods edgeR voom VST
DESeq 82,84,77 88,81,74 82,81,71
edgeR - 80,82,78 70,75,68
voom - - 87,92,95
Table 6.2: Pairwise comparison of hubs(left), MDS(middle) and MCDS(right numbers)
for the networks constructed from the set of DE genes analyzed by DESeq, edgeR, voom
and VST methods for the BRCA dataset.
Methods edgeR voom VST
DESeq 96,83,81 91,80,79 96,83,80
edgeR - 86,83,83 70,72,75
voom - - 83,85,88
lowest number of DE genes, the smallest network size and subsequently smallest set of
hubs, MDS and MCDS among all the methods.
6.3.4 Robustness of the Results
To check the robustness and significance of the results, 100 random networks were con-
structed with 11000 and 14000 randomly selected genes as pseudo set of DE genes .
Related networks were constructed with TFmiR. Detection of hubs, MDS and MCDS
were performed as explained before. The results of DESeq were compared with the other
tools, edgeR, voom and VST. We used the widely used tool, DESeq (Anders and Huber,
2010) as the base line of comparison because it appears to be a very conservative method
to detect the set of DE genes (Soneson and Delorenzi, 2013; Anders et al., 2013). More-
over, we realized from the previous experiments that DESeq contains the highest number
of consistent topological features among all the methods. Figure 6.3, panels (A) and (C)
visualize the overlap percentage between DESeq and other methods, and panels (B) and
(D) show the percentage overlap of hubs, MDS and MCDS of DESeq with random net-
works for hepatocellular carcinoma and breast neoplasms, respectively. If one provides
more than half of all human genes as input and generates a regulatory disease-specific
network, one can expect that a considerable fraction of the real key genes are recovered
by chance. In the two studied cases, between 20 and almost 60% overlap with the DESeq
key genes. However, the results indicate that random selection of nodes does not reach to
Table 6.3: Consistent hub genes and miRNAs for the BRCA dataset.
JUN, hsa-mir-21, E2F1, TFAP2A, FOS, ESR1, CCND1, IFNB1, EGFR, STAT5A, IL6, ESR2, KIT, ERBB2, RARB,
MYC, ETS2, hsa-mir-21-5p, STAT1, BRCA1
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Table 6.4: Consistent MDS genes and miRNAs for the BRCA dataset.
EGR1, JUN, RARA, RARB, BMP6, hsa-mir-21-5p, ESR2, TCF7L2, TNFSF12, FOXA1, MEIS1, TCF3, PARP1,
ETV5, ESR1, TFDP1, NR2F6, TRERF1, FOXM1, THRA, ZEB1, USF1, SRF, EFNA2, GBX2, LEF1, HEY2, E2F1,
LMO2, hsa-mir-34a-5p, STAT5B, SREBF1, hsa-mir-21, WT1, TFF3, IRF7, TAL1, TEAD4, CEBPD, TFAP2A,
ETS2, KLF6, hsa-mir-145-5p, NR3C1, JUND, NR4A1, STAT5A, RPA3
Table 6.5: Consistent MCDS genes and miRNAs for the BRCA dataset.
FOXA1, THRA, BRCA1, BRCA2, FOXM1, NR3C1, ETS2, CCND1, HEY2, TEAD4, SREBF1, hsa-mir-21-5p,
LMO2, FOS, ETV5, TFDP1, TAL1, KIT, IRF7, TFF3, CEBPD, hsa-mir-145-5p, SRF, LEF1, EGFR, GBX2,
CYP11A1, hsa-mir-21, E2F1, STAT5A, TFAP2A, TCF7L2, STAT5B, EGR1, JUN, JUND, IFNB1, CAV1, TN-
FSF12, hsa-mir-34a-5p, TRERF1, ESR1, BMP6, USF1, ESR2, VEGFA, NR4A1, IL6, EFNA2, WT1, RPA3, TCF3
the same level of topological overlap compared to the topological overlap of DESeq with
edgeR, voom and VST. Since none of the 100 random networks reached the values for the
real networks, the significance is below p = 0.01.
6.4 Summary and Discussion
In this work, we showed that the sets of hubs, MDS and MCDS are well consistent in
disease-specific networks constructed from different sets of DE genes identified by dif-
ferent analysis methods. For this purpose, we used regulatory networks involving TFs,
microRNAs, and target genes that we predicted with our TFmiR web server from a set
of DE genes and identified the hub-degree nodes. Although the overlap between the sets
of significant DE genes was only 26% in liver cancer and 28% in breast cancer, we found
that the topology of the regulatory networks constructed using TFmiR for the different
sets of DE genes was highly consistent with respect to hub-degree nodes and MDS and
MCDS (70-90%). This suggests that key genes identified in regulatory networks derived
from DE genes may be a more robust basis for understanding diseases processes than
simply inspecting the lists of DE genes.
66
Figure 6.3: Panels (A) and (C) illustrate the percentage overlap of hubs, MDS and MCDS
in the DESeq network with other three (edgeR, voom and VST) networks for the LIHC
and BRCA datasets, respectively. Panels (B) and (D) stand for the overlap of the three
mentioned topological features of DESeq with 100 disease-specific networks derived of
11000 and 14000 randomly selected genes from the LIHC and BRCA datasets, respectively.
Chapter 7
Randomization Strategies Affect Motif
Significance Analysis in TF-miRNA-gene
Regulatory Networks
This chapter is based on our paper entitled "Randomization strategies affect motif sig-
nificance analysis in TF-miRNA-gene regulatory networks" by Sepideh Sadegh, Maryam
Nazarieh, Christian Spaniol and Volkhard Helms that was published in the journal of
Integrative Bioinformatics (Sadegh et al., 2017).
Sepideh Sadegh extended the Cytoscape plugin by adding cascade motifs, added conserved
method to the plugin (in java), performed the experiments and wrote the manuscript.
Maryam Nazarieh proposed the computational motivation of the paper (the number of
required iterations for edge switching in co-regulatory networks) and suggested to add
cascade motifs, implemented conserved method (in R) and integrated it to TFmiR2 web
server, analyzed the results and wrote the manuscript (I was advisor of Sepideh Sadegh
under supervision of Prof. Helms). We used the Cytoscape plugin that was developed by
Christian Spaniol as part of his PhD thesis. Prof. Volkhard Helms designed the study,
wrote and edited the manuscript.
Gene regulatory networks constitute an abstract way of capturing the regulatory connec-
tivity between TFs, microRNAs and target genes in biological cells. Here, we address
the problem of identifying enriched co-regulatory three-node motifs that are found signif-
icantly more often in the real network than in randomized networks. First, we compare
two randomization strategies, that either only conserve the global degree distribution of
the entire network, or that also conserve the degree distributions of different regulatory
edge types. We argue that the edge-type preserving method leads to biologically more
meaningful results. Then, we address the issue how convergence of randomization can
be measured. We show that after 3 ∗ |E| edge swappings, converged motif counts are
obtained and the memory of initial edge identities is lost.
7.1 Introduction
GRNs are typically formulated as directed graphs whereby nodes stand for target genes,
TFs, and microRNAs and arcs stand for activating or repressing regulatory interac-
tions. TFs either activate or repress the transcription of target genes. MicroRNAs typ-
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ically induce the degradation of messenger RNAs of their target genes. Hence, modern
GRNs address the regulation of messenger RNA levels at the transcriptional and post-
transcriptional levels (Hamed et al., 2015a; Zhang et al., 2015a). Our group recently
introduced a web server termed TFmiR (Hamed et al., 2015a) that enables users to con-
struct and analyze disease-specific TF and miRNA co-regulatory networks. Please see the
chapter 4 for more details on TFmiR.
Shen-Orr and Alon were the first to identify regulatory motifs in a GRN of E.coli that
only consisted of TFs and target genes (Shen-Orr et al., 2002). They discovered that
feed-forward loops (FFLs) involving two TFs whereby TF1 regulates TF2 and both TFs
jointly regulate a target gene are statistically significantly enriched in real GRNs with
respect to randomized GRNs. Besides, they also discovered that single-input modules
and densely overlapping regions are enriched too, but we will focus on FFL-type motifs
here. Recently, several authors have expanded the concept of FFL-motifs to GRNs with
TFs, miRNAs and target genes (Megraw et al., 2013; Zhang et al., 2015a; Hamed et al.,
2015a). In this context, proper randomization of GRNs becomes even more important
for determining which FFL motifs are enriched in the real GRN. In our original TFmiR
paper, we did not distinguish between the three possible types of regulatory links, TF →
gene, TF → miRNA, and miRNA → gene, during randomization. However, Ohler and
co-workers recently pointed out that an edge-type preserving randomization strategy may
be beneficial whereby switching of arc endpoints takes place only between two arcs that
both of which belong to either one of the three groups of regulatory links (Megraw et al.,
2013).
Another important technical question is how to properly quantify proper randomization.
In our original TFmiR paper, we randomized 2 ∗ |E| times, whereby E is the number of
links in the GRN. It was argued that 100 ∗ |E| switches of edge end points ensure proper
randomization (Milo et al., 2004). Based on two GRNs with different link densities, we
present here a thorough analysis of which motifs are statistically enriched in these GRNs
under the edge-type conserving and non-conserving randomization strategies and how
proper randomization can be quantified. For comparison, we also used the established
motif-discovery tool FANMOD (Wernicke and Rasche, 2006).
7.2 Related Works
There exist many motif finding tools including the well-known tools mfinder (Kashtan
et al., 2004) and FANMOD (Wernicke and Rasche, 2006). mfinder detects network motifs
either by full enumeration of subgraphs, or by sampling of subgraphs for estimation of
subgraph concentrations. The latter method is faster but has a bias in favor of sampling
certain subgraphs more frequently than others (Wernicke, 2005). mfinder provides several
methods to generate random networks including the switching method, the stub method,
and the "go with the winners" algorithm (Milo et al., 2004). FANMOD uses an algorithm
called RAND-ESU (Wernicke, 2005) that enables quick and accurate estimation of the to-
tal number of size-k subgraphs in a given network. A new randomization algorithm named
WaRSwap (Megraw et al., 2013) provides a practical network motif discovery method for
large multi-layer networks such as co-regulatory networks. However, this technique must
be used together with a motif discovery tool such as FANMOD, which limits its applica-
bility. WaRSwap generates randomized networks by preserving the indegree distribution
of target nodes with respect to each source-target type rather than the exact indegrees.
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Table 7.1: Density of BC-complete, BC-disease and GBM networks
|E| |V | density
BC-complete 378 258 0.0057
BC-disease 297 206 0.0070
GBM 4248 408 0.0256
This randomization method seems to be more compatible with multi-layer networks than
the universal method where only the in and outdegree of nodes are conserved.
7.3 Materials and Methods
7.3.1 Types of 3-node Motifs in miRNA-TF Synergistic Regulatory Networks
miRNA and TF co-regulatory networks contain four types of regulations, TF→ Gene, TF
→ miRNA, miRNA → Gene, and miRNA → TF, that can be combined in ten different
ways as 3-node motifs, see Figure 2.1. Eight of these are synergistic motifs consisting of
two different types of regulators (miRNA and TF), and their directly/indirectly synergis-
tically regulated target gene (first two rows of Figure 2.1). The last two motifs, where
the target gene is not cooperatively regulated, are not studied here.
7.3.2 Datasets
We used miRNA and TF co-regulatory networks for two different complex diseases as
input to our motif finding tool. The first network is associated with breast cancer (BC)
(Hamed et al., 2015a) and the second network with glioblastoma multiforme brain tumor
(GBM) (Sun et al., 2012). Table 7.1 lists topological properties of the two networks. The
GBM network is about four times denser than the BC networks. In a study on breast can-
cer using gene and miRNA expression data from the The Cancer Genome Atlas (TCGA)
portal, Hamed et al. (Hamed et al., 2015b) identified 1262 genes and 121 miRNAs that are
deregulated in cancer tissue with respect to matched normal tissue. With the TFmiR web
server (Hamed et al., 2015a) we identified regulatory interactions for the provided lists
of up- and down-regulated genes and miRNAs using data from established and curated
regulatory databases of both predicted and experimentally validated interactions. The re-
sulting network is termed BC-complete in table 7.1. Then we used TFmiR to intersect this
global network with genes associated with breast neoplasms based on the human miRNA
disease database (HMDD) (Lu et al., 2008) and DisGeNET, a database for gene-disease
association (Bauer-Mehren et al., 2010). This gave the breast cancer-specific subnetwork
that we termed BC-disease.
A co-regulatory network for GBM with 415 genes and 124 mature GBM-related miR-
NAs was retrieved from Sun et al. (Sun et al., 2012), who used a similar approach for
constructing GRN to the approach used in TFmiR. They retrieved 428 human TFs from
the TRANSFAC database (Matys et al., 2006) and predicted the regulatory interactions
between a TF, an miRNA and a gene using computational approaches.
The main difference between the construction of the two networks considered here is in the
last step. In the GBM network, the authors included only miRNA-TF co-occurring pairs
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that are significant based on the hypergeometric test. In contrast, TFmiR does not check
for significance here. Another difference is that in building the GBM-specific co-regulatory
network only predicted interactions were utilized, while in the BC-complete/disease co-
regulatory networks both predicted and experimentally validated interactions were taken
into account.
7.3.3 Motif Discovery Process
The steps used for the motif discovery are as follows: 1) A subgraph census is conducted
for the types of desired motifs on the original network. 2) An ensemble of N similar
random networks is generated and subgraph enumeration is applied to each of these
networks. 3) Finally, after calculating the frequency of each type of subgraph in all
networks (original and randomized), its significance metrics are calculated, with the over-
represented subgraphs being reported as motifs. We implemented the entire process of
motif finding as an in-house Cytoscape App (Shannon et al., 2003), which is an OSGi
Bundle style App. This functionality will be made publicly available in the next release
of TFmiR.
Enumeration of desired subgraphs
Typical algorithms for enumeration of subgraphs work on a connectivity matrix C, whose
elements (Cij) are equal to 1 if regulator i regulates target j and 0 otherwise. Then, they
scan all n by n submatrices of C, that represent topologies of each desired type of size
n motif. We modified this typical subgraph enumeration algorithm by using the data
models in Cytoscape (namely CyNetwork and CyTable).
Generating Random Networks
Randomization of networks must be conducted such that sampling is performed as uni-
formly as possible from the collection of all obtainable random networks. (Megraw et al.,
2013) suggested that low-variance distributions of motif counts in randomized networks
are a sign of inadequate randomization, and that they can happen due to edge switching
in large multi-layer networks. To evaluate the adequacy of sampling and uniformity of
randomly generated networks, variances of the subgraph counts of all types of possible
motifs in the randomized networks should be considered (see section 7.4.3).
The key aspect in assessing the statistical over-representation of motifs is to generate the
random networks such that their characteristics are as similar as possible to the original
network. The method using swapping of endpoints ensures that each node in the random-
ized networks has the same number of incoming and outgoing edges (in and outdegree) as
the corresponding node in the real network. The universal method used for this purpose is
the so-called switching method, employed for the first time in the field of motif detection
by (Shen-Orr et al., 2002). By construction, this method strictly conserves the degree
distribution of the graph and even of each node. The algorithm generates a Markov chain
of states by randomly selecting a pair of edges (A → B, C → D) and swapping their
endpoints to create the new edges (A→ D, C → B). Creation of self-edges and multiple
edges are not allowed and considered as failed attempts of switching. This process is
repeated Q ∗ |E| times, where |E| is the number of edges in the graph and Q is chosen
large enough so that sthe Markov chain shows good mixing. (Milo et al., 2004) found
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that for many networks, values of around Q = 100 appear to be more than adequate.
In our approach failed attempts are not counted, i.e. we repeat swapping as many times
as needed to reach Q ∗ |E| times successful attempts. This algorithm returns a shuﬄed
version of the original network as a randomized network. We suggest some measures to
assess proper mixing in section 7.3.4.
Different Strategies
We modified the current switching method to consider additional features of miRNA-TF
synergistic regulatory networks (different node and edge types). To deal with networks
with multiple types of connections, we use the terminology introduced by (Yeger-Lotem
et al., 2004) where the extended degree of a node stands for the number of edges per type
that point to/from a node. Two nodes have the same extended degree if they have the
same number of incoming and outgoing edges for each edge type.
Based on this definition, one can develop a new switching strategy, which allows only
swapping endpoints of edges with the same regulatory relationship among miRNAs, TFs
and target genes. Hence, we distinguish a conserving method that conserves the extended
degree of nodes, i.e. edges are switched only between edges of the same type, and a non-
conserving method that does not conserve the extended degree of nodes, i.e. switching
is performed without considering the edge type, consequently the frequency of each edge
type is not conserved. This method is equivalent to the original switching method. Note
that the non-conserving method can also create new edge types, which did not exist in
the original network, unless this is prevented (such as TF → TF, or miRNA → miRNA
edges).
An efficient algorithm for the conserving method can be implemented by grouping net-
work edges of different edge types into different lists and then randomly selecting the
second edge from the edge list of the first selected edge type. This helps to improve the
efficiency of the randomization algorithm in terms of runtime.
Comparison of Real and Randomized Networks by Significance Metrics
The goal of network motif discovery is to determine which subgraph types occur in the
original network at significantly higher frequencies than in random networks. For this
purpose, the occurrence of a particular subgraph in the network of interest is compared
to the distribution of counts for the same subgraph over a set of randomized networks
using p-value and z-score. The p-value represents the probability of a motif to appear an
equal or greater number of times in a random network than in the original network (Milo
et al., 2002). This probability should be smaller than a determined probability threshold
to reject the null hypothesis. This can be empirically determined using a large number of
randomized networks:
p-value = Nrh
Nt
whereNrh is the number of random networks in which a certain motif type is acquired more
than or equal to its number in the real network and Nt is the total number of randomized
networks. It has been suggested (Hamed et al., 2015a) that 100 is sufficiently large.
Alternatively, let freal be the frequency in the real network and frand be the frequency in
a random network. We can then define the z-score as follows (with σ being the standard
deviation):
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z-score = (freal-frand)
σ(frand) , σ(frand) =
√∑
i
(frandi -frand)2
Nt
Subgraphs with z-score ≥ 2 and p-value ≤ 0.05 are considered significant motifs as was
previously performed (Shen-Orr et al., 2002; Wernicke and Rasche, 2006; Megraw et al.,
2013).
7.3.4 Measures for Proper Mixing of Randomized Networks
One general drawback of randomizing networks by the switching method is that there
is no measure of how long one needs to iterate over the select two edges and swap their
endpoints routine to attain well randomized networks. Here we propose two measures to
characterize whether randomized networks are properly mixed.
First, we measure the similarity of networks before and after randomization. Ideally, edges
should be switched until there are no common edges between the original network and
each randomized network. In other words one should search for the maximum difference
between the given network and each randomized network to avoid situations of under-
shuﬄing (Liang et al., 2015). Under-shuﬄing means that only a small fraction of the
switchable edges were swapped. We defined a similarity metric to measure how similar is
the ensemble of randomized networks to the original network in terms of common edges:
Similarity = <Sim>|E|
Here, Sim is the number of common edges between the original and a particular ran-
domized network, <Sim> is its average in all randomized networks, and |E| is the total
number of edges in the original network. Lower Similarity values indicate better random-
ization. The lowest possible value of zero happens in case of no common edges. This
definition considers the size of the network as well as the number of randomized networks.
This enables comparison of the similarity metrics of randomization approaches applied to
different given networks. A value close to zero indicates that under-shuﬄing is avoided.
Another measure is the convergence of subgraph counts during randomization. For
0.01∗|E| to 100∗|E| randomization iterations, we recorded how often the investigated sub-
graph types occurred in the random networks and checked whether this number converged
to a specific value or whether it did not follow any pattern and changed erratically.
7.4 Results
7.4.1 Synergistic 3-node Motifs
Table 7.2 shows which co-regulatory 3-node motifs were significantly enriched in the real
GRN vs. randomized GRNs when either the edge-type conserving randomization strat-
egy was applied or the non-conserving one. 100 ∗ |E| iterations were used for this part of
our study. In the BC-complete network, no significant motif is found by the conserving
method. In contrast, the composite-miRNA-mediated and cascade-miRNA- mediated mo-
tifs are reported as significant by the non-conserving method. In the BC-disease network,
only the co-regulation type is identified as significant by the conserving method, whereas
the non-conserving method gives the same significant motifs as for the BC-complete net-
work. In the GBM network, TF-FFL and miRNA-FFL are reported as significant by
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Table 7.2: p-values for different 3-node subgraphs in the considered networks when either
the non-conserving or the conserving randomization strategy is used.
BC-complete BC-disease GBM
Subgraph type Non-cons. Cons. Non-cons. Cons. Non-cons. Cons.
Co- regulation 0.77 0.33 0.96 0.04 1.00 1.00
TF-FFL 1.00 0.77 0.98 0.61 0.00 0.00
miRNA- FFL 0.77 0.86 0.69 1.00 0.00 0.00
Composite- FFL 0.29 0.12 0.45 0.50 0.00 0.68
Composite- TF-Med. 0.62 0.26 0.66 0.42 0.00 0.55
Composite- miRNA-Med. 0.00 0.50 0.01 0.53 0.00 0.62
Cascade- TF-Med. 0.47 0.69 0.16 0.26 0.00 0.84
Cascade- miRNA-Med. 0.00 0.54 0.01 0.49 0.00 1.00
the conserving method; whereas by the non-conserving method all types of subgraphs ex-
cept co-regulation are identified as significant. In all three networks, subgraphs of types
composite-miRNA-mediated and cascade-miRNA-mediated are identified as statistically
significant by the non-conserving method. All subgraphs meeting the p-value criterion in
Table 7.2 also met the z-score criterion. Note that p-value is a probability and can be
slightly different in each run of the algorithm due to the generation of different random-
ized networks.
The non-conserving method leads to detecting more subgraph types as significant com-
pared with the conserving method. In randomization by the conserving method, swapping
happens between all edges of the same type, hence the chance of having the same types
of subgraphs in randomized networks compared to the original network is not decreased
that much. This could result in higher p-values and consequently fewer subgraphs will
show significant differences.
In the GBM network, we found 3-node FFLs to be significant while in BC networks they
are not. One reason for this could be the higher density of the GBM network than the
BC networks.
7.4.2 Motif Finding with FANMOD
FANMOD also employs the "switching method" for randomization of network. The ran-
domization step can optionally keep the color degree of a vertex constant by exchanging
edges only with edges of the same type. This is equal to randomization by the conserving
method in our approach. The same number of swappings per edge (Q = 100) and the
same criteria for p-value and z-score were chosen for both tools. FANMOD gave similar
motif finding results for all three miRNA-TF co-regulatory networks (Figure 7.1) to those
of our tool. The few dissimilarities can be due to slight differences of the randomization
algorithms. In the routine of randomly selecting edges for swapping, we only count suc-
cessful attempts until a pre-defined number of iterations is reached whereas FANMOD
tries a limited pre-defined number of times to find an appropriate candidate for swapping
irrespective of whether this is successful or not. By inspecting the output file of FAN-
MOD we found that ∼ 80% of the attempts were successful by randomization with the
conserving method and ∼ 50% with the non-conserving method.
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Figure 7.1: Significant 3-node motifs (highlighted in green) detected by the FANMOD
tool with two different randomization strategies. (A) BC-complete. (B) BC-disease. (C)
GBM.
7.4.3 Validation of Randomization
Uniform Sampling of Randomized Networks
(Megraw et al., 2013) observed many failed switches during the execution of FANMOD
randomization, which was also the case here. As mentioned, our approach counts only
the number of successful attempts until a pre-defined number of iterations is reached. By
close inspection of the resulting background histogram of significant motifs, we observed
in the miRNA-TF synergistic regulatory networks of BC and GBM a high variance of
count distributions of subgraphs in randomized networks for all significant 3-node motifs,
see Table 7.3 and Table 7.4. This indicates an adequate randomization of networks in our
approach. For the GBM network, much higher variances were obtained than for the BC
networks. It is suggestive to attribute this to the higher density of the network.
Measures for Proper Mixing of Randomized Networks
Similarity Metric
Two sets of 100 randomized networks were generated from the BC-complete network using
in one case the edge-type conserving strategy and in the other case the non-conserving
randomization strategy. Between 0.01 ∗ |E| and 100 ∗ |E| iterations of edge swapping
(Q∗|E|) were carried out. Figure 7.2 shows the similarity between original and randomized
GRNs for varying Q. The number of iterations required to reach values close to zero
depends on the randomization strategy. For the non-conserving method, the similarity
metric reaches zero at fewer iterations (Q = 7 for BC-complete and Q = 8 for GBM) than
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Table 7.3: Variance of count distributions of subgraphs in randomized networks for the
BC-complete/-disease networks. Significant motifs are marked in bold.
Non-conserving method Conserving method
Subgraph type Variance Variance
BC-disease BC-complete BC-disease BC-complete
Co- regulation 14.9 32.0 6.7 10.3
TF-FFL 5.5 7.5 2.4 2.6
miRNA- FFL 4.2 4.9 7.0 8.4
Composite- FFL 1.7 1.5 2.0 1.7
Composite- TF-Med. 298.8 339.1 177.6 130.0
Composite- miRNA-Med. 85.1 74.0 391.9 458.5
Cascade- TF-Med. 592.3 880.8 174.8 134.4
Cascade- miRNA-Med. 394.6 433.4 435.9 522.6
Table 7.4: Variance of count distributions of subgraphs in randomized networks for GBM
network. Significant motifs are marked in bold.
Non-conserving method Conserving method
Subgraph type Variance Variance
Co- regulation 18,335.7 4729.6
TF-FFL 4340.9 3298.5
miRNA- FFL 1526.1 2344.3
Composite- FFL 277.0 890.4
Composite- TF-Med. 10,282.2 38,169.3
Composite- miRNA-Med. 1690.0 6153.5
Cascade- TF-Med. 53,127.1 37,486.1
Cascade- miRNA-Med. 35,798.9 7742.2
the conserving method (Q = 14 for BC- complete and Q = 15 for GBM). Results for the
GBM network are very similar to those for the BC-complete network, only slightly more
iterations are needed to reach zero. Both methods of randomization for both networks
reach similarities below 0.01 afterQ = 3 iterations. This means that after 3∗|E| iterations,
less than 1 % of the edges in the ensemble of randomized networks are in common with
the original network. This low percentage of similarity seems to be a good threshold for
choosing a proper Q for our randomization method.
Convergence of Subgraph Counts
Figure 7.3 shows how often subgraph types occurred in the set of randomized BC-complete
networks after randomization when Q was varied between 0.01 and 100. With the non-
conserving method (Figure 7.3), the total subgraph count converged to a fixed value after
Q = 10 iterations and did not change erratically thereafter. With the conserving method
(Figure 7.3), the total number of subgraphs found in the randomized networks was quite
stable over the whole range of 0.1 < Q < 100.
Our empirical findings for both BC and GBM networks suggest that Q = 1 is adequate
to obtain properly mixed randomized networks by the conserving method; whereas for
the non-conserving method Q = 10 appears suitable for ensuring good mixing of the
randomized networks. Evaluation of network similarity for the BC-complete network
suggests Q ∼ 3 as a good balance for both conserving and non-conserving methods of
randomization.
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Figure 7.2: Similarity metric vs. number of iterations for (A) the BC-complete and (B)
the GBM networks.
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Figure 7.3: Total number of subgraphs vs. number of iterations for (A) the BC-complete
and (B) the GBM networks.
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Figure 7.4: Overlap of most central nodes (according to three different centralities) with
the set of genes and miRNAs in the statistically enriched motifs. (A) Conserving. (B)
Non-conserving.
7.4.4 Network Centrality of Gene and miRNA Sets
Here, we analyzed the overlap between the genes and miRNAs participating in the en-
riched 3-node motifs (here termed motif nodes) and the most central genes and miRNAs
with respect to degree, betweenness, and closeness centralities (here termed central nodes).
Using either edge-type conserving or non-conserving randomization gave 26 and 130 genes
and miRNAs in enriched motifs, respectively. These sets were compared to sets with the
same number of most central genes and miRNAs. The centralities were measured using
the igraph package (Csardi and Nepusz, 2006), considering only outdegree of nodes in the
directed network. The motif nodes identified by the conserving method had the highest
overlap with the central nodes defined according to closeness and betweenness central-
ity, respectively, see Figure 7.4 panel (A). In contrast, the motif nodes defined with the
non-conserving method showed a similar overlap with the central nodes identified by all
three centralities, see Figure 7.4 panel (B). This latter observation can be explained by
noting that only 57 genes and miRNAs have outdegree greater than or equal to 1 in the
BC disease networks. The overlap of around 45 % with the central nodes means that
essentially all these 57 motif nodes are hub nodes in this network. A larger fraction of
hub nodes (up to around 60 %) exists in the smaller set of 26 motif nodes defined by the
conserving method.
Next, we analyzed the overlap of the 26 motif nodes identified by the conserving method
with a MCDS of key regulatory genes and miRNAs that dominates the network. For
this, we solved the ILP formulation of the respective MCDS in the LSCC of this network
(Nazarieh et al., 2016) and obtained an MCDS of seven genes and miRNAs. Among these,
TGFB1, TP53, ESR1, and hsa-mir-22 belong to the motif nodes.
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7.4.5 Biological Relevance of the detected Motifs
The biological relevance of the genes among the motif nodes obtained by the conserv-
ing and non-conserving randomization methods was evaluated based on the functional
categories in GO Direct using the enrichment analysis via DAVID (version 6.8) (Huang
et al., 2009). p-values below the threshold 0.05 obtained by the hypergeometric test were
adjusted for multiple testing using the BH procedure (Benjamini and Hochberg, 1995).
Both methods returned almost the same number of significant GO terms, mostly involv-
ing transcription and apoptotic processes, although the non-conserving method considered
104 genes versus 14 genes considered by the conserving method, see Tables S28 and S29.
7.5 Summary and Discussion
If the network of interest contains more than one node or edge type, different randomiza-
tion strategies can be applied for motif discovery. In this study, different strategies led to
quite different enriched 3-node motif types.
The reason why FFLs were statistically significantly enriched only in the GBM network
could originate from the difference in constructing the GBM and BC networks, where
only significant TF-miRNA co-occurring pairs were considered in the regulatory network
of GBM. This means that the TF → gene ← miRNA triad is enriched a priori in this
network. Our study suggests that the way of network construction and also the density
of the network may affect the results of motif finding. For the considered BC-networks,
only subgraphs of types other than FFLs were found to be significantly enriched. Our
motif finding tool identified composite-miRNA-mediated and cascade-miRNA-mediated
as statistically significant motifs (by the non-conserving method). Although the results
are similar in BC-networks, the conserving method identified the co-regulation motif type
to be significant in the filtered BC-disease network that was not found significant in the
BC-complete network. We thus speculate that motif searches in filtered (i.e. more spe-
cific) networks may identify biologically more meaningful motifs.
We suggest variance of motif counts and similarity of original and randomized networks
as suitable auxiliary measures to judge whether randomization generates properly mixed
networks. Our study suggests that the density of networks does not affect the min-
imum required Q to obtain properly mixed randomized networks. In conclusion, the
non-conserving method leads to detecting more subgraph types as being statistically sig-
nificant compared with the conserving method. For the 2.5 networks studied here, we
noticed that (a) the conserving randomization method identified significant motifs con-
taining a larger fraction of the most central nodes (Figure 7.4) than the non-conserving
method, and (b) both methods gave the same number of significant GO terms, although
the conserving method considered much fewer genes for this than the non-conserving
method. Certainly, the same analysis should be extended to a representative number of
comparable GRNs. So far, it seems that the conserving method gives biologically more
meaningful results.
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Chapter 8
TFmiR2: Constructing and Analyzing
Disease-, Tissue- and Process-specific TF and
miRNA co-regulatory Networks
This chapter is based on the manuscript entitled "TFmiR2: Constructing and analyzing
disease-, tissue- and process-specific transcription factor and miRNA co-regulatory net-
works" by Nazarieh et al. (2017). The abstract of the work was published earlier as
mentioned in (Nazarieh et al., 2017).
Maryam Nazarieh developed both frontend and backend of the web server and extended
the TFmiR databases and wrote the manuscript. Mohamed Hamed provided the mouse
database. Christian Spaniol edited the frontend programs. Thorsten Will provided the
tissue data for human and mouse and disease-associated genes for mouse. All authors
including Prof. Volkhard Helms designed the study and edited the manuscript.
TFmiR2 is a freely available web server for constructing and analyzing integrated TF and
miRNA co-regulatory networks in human and mouse. Due to the availability of genome
scale data sets, the challenge is no longer to generate large regulatory networks, but rather
to determine the parts that are essential to a scientific question. TFmiR2 helps to solve
this issue by generating tissue- and biological process-specific networks as well as networks
with multiple specificity for the set of deregulated genes and miRNAs provided by the
user. Furthermore, the service can now aid the user to identify key driver genes and miR-
NAs in the constructed networks by utilizing the graph theoretical concept of a MCDS.
Especially when combined with experimental validation, these putative key players as
well as the newly implemented 4-node TF-miRNA motifs can potentially promote novel
insights that may assist in developing new therapeutic approaches through identification
of significantly enriched patterns of interactions between the components.
Availability: The TFmiR2 web server is available at http://service.bioinformatik.
uni-saarland.de/tfmir2.
8.1 Introduction
The regulatory networks involving TFs, genes and miRNAs control all cellular processes
and define tissue specificity (Nazarov et al., 2013). They are also tightly associated with
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cellular malfunctions and disease pathways (Lee and Young, 2013). Therefore, construc-
tion and analysis of the corresponding regulatory networks are central issues in systems
biology (Guzzi et al., 2015; Georgakilas et al., 2016). The predecessor of this new service,
the TFmiR web server (Hamed et al., 2015a) enables integrative analysis of combinatorial
regulatory interactions between TFs, miRNAs and deregulated target genes. TFmiR has
been successfully used in diverse areas of biological research, e.g. in hematopoiesis (Hamed
et al., 2017). We present here the significantly expanded new version TFmiR2. Added
core features comprise the support for mouse data, confinement to tissue- and process-
specific subnetworks, detection of 4-node motifs, and driver gene detection based on the
topology of the deregulated networks by, for example, the MCDS algorithm (Nazarieh
et al., 2016). Besides the disease-specific features of the original service, TFmiR2 now
enables the user to also select multiple gene ontology terms related to biological processes
as filters to generate process-specific networks around the set of user-specified deregulated
genes and miRNAs. Such networks can then be even further filtered to specific tissues to
arrive at tissue- and process-specific networks.
These new additions enable users to contextualize the data in a more specific setting
than before. This could, for example, reveal the regulatory dependencies among the
user-specified deregulated genes and/or miRNAs in a tissue of choice, or alternatively, to
consider the mutual effect of this deregulated set in a confined and potentially aberrant
biological process which ultimately causes a disease. Furthermore, the service can now
aid the user to identify key driver genes and miRNAs in the constructed networks by
utilizing the graph theoretical concept of the MCDS (Nazarieh et al., 2016). Such drivers
could possibly drive the pathogenic processes of diseases and thus appear potential drug
targets. TFmiR2 detects 4-node TF-miRNA motifs described in (Sun et al., 2012) by
considering different randomization methods as discussed in (Sadegh et al., 2017).
8.2 Methods
The basic workflow in TFmiR2 consists of three steps: 1) data upload and processing, 2)
construction of the networks, 3) network visualization and downstream analysis. Figure
8.1 depicts the overall workflow of TFmiR2. For the set of data provided by a user, a
variety of options exist to generate networks related to a user-specified biological process,
tissue and disease as well as combinations of them. In TFmiR2, the user can select a
tissue, disease and related process and also restrict the regulatory interactions that are
included to either experimental, predicted or both data sources. In addition to the disease-
specific network and the full interaction network which were already featured in TFmiR,
TFmiR2 constructs tissue-, process-, disease-tissue-, disease-process, and tissue-process
specific networks.
8.2.1 Functionality of TFmiR2
TFmiR2 combines the databases for human previously used in TFmiR with the reg-
Network database (Liu et al., 2015) which integrates gene regulatory networks from 25
selected databases as described in (Liu et al., 2015). If a tissue is selected, the full in-
teraction network is filtered to a tissue-specific subnetwork by confining the interactions
to those where both interaction partners are expressed in the selected tissue. This re-
striction is relaxed for miRNAs since we did not include evidence on tissue-specificity of
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Figure 8.1: A system level overview of the TFmiR2 architecture describing the incorpo-
rated databases (top left), workflow and output downstream analysis.
miRNAs. In Process-specific networks that are derived from the full interaction network,
we demand that at least one interactor is related to the selected biological process(es).
When multiple processes are selected, the constructed network is even capable to demon-
strate the cross-process interactions. The process of deriving a disease-specific network
was described in (Hamed et al., 2015a), see chapter 4. Moreover, TFmiR2 can generate
a disease-process specific network that corresponds to the set of mutual interactions be-
tween a disease gene and a potentially aberrant biological process. The interactions in
the network are selected such that either regulator nodes are known to be associated with
the selected disease found in (Bauer-Mehren et al., 2010) and target nodes are known to
be related to the user-specified biological process(es) or vice versa. To limit the effect of
disease genes to a specific tissue, disease-tissue specific networks can be constructed. Then
the interactions in the network are selected such that either regulator or target nodes are
known to be associated with the selected disease, but both regulator and target nodes
are known to be expressed in the selected tissue. The process-specific network may be
further confined to a tissue-process specific network by considering the interactions whose
regulators and targets correspond to the user-specified tissue and biological process.
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8.2.2 TFmiR2 user input Scenarios
TFmiR2 can be started from a set of deregulated miRNAs. In such a case, TFmiR2 iden-
tifies the set of genes whose target miRNAs as well as regulating miRNAs are significantly
enriched within the input miRNAs using a hypergeometric test followed by BH adjust-
ment (Benjamini and Hochberg, 1995). The user may also provide deregulated miRNAs
and mRNAs or just a list of deregulated mRNAs as described in TFmiR (Hamed et al.,
2015a). TFmiR2 enables users to determine the level of significance through adjusting
the enrichment threshold for the set of genes and miRNAs.
Furthermore, the user may optionally set the p-value cutoff (default is 0.05) for ORA on
the resulting network nodes (genes/miRNAs). Finally, the user can control the evidence
level (experimentally validated, predicted, or both) for the constructed regulatory inter-
actions that will be used in the subsequent network analysis.
TFmiR2 now enables the user to also select multiple GO terms (The-Gene-Ontology-
Consortium, 2017) related to biological processes as filters to generate process-specific
networks around the set of user-specified deregulated genes and miRNAs.
8.2.3 Identification of Network Key Nodes
In TFmiR2, a new method was added to find the key driver genes on the concept of based
on network controllability (Nazarieh et al., 2016), see chapter 3. If the network includes
a connected component, then the MCDS algorithm returns a set of genes and miRNAs
that control the whole network, see Figure 8.2. Due to the large overlap between MDS
and MCDS on the LCC as described in (Nazarieh et al., 2016), we focused here on the
essential component of the network, the LSCC and applied MCDS on it. In a strongly
Figure 8.2: A graphical representation that illustrates the MCDS solution in the LSCC
of an example TF and miRNA co-regulatory network. The red circle borders mark the
one TF and two miRNAs belonging to the solution.
connected component of a GRN, there is a path from each node in the component to all
other nodes. TFs and miRNAs constitute the dominators and connectors of the MCDS
solution.
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8.2.4 Tissue-exclusive Genes
Tissue-exclusive genes are the set of genes solely expressed in one tissue. TFmiR2 enables
the user to study the interacting neighbours of tissue-exclusive genes to better understand
the underlying regulatory network.
8.2.5 Identification of TF-miRNA 4-node Motifs
Integration of gene-gene and protein-protein interaction data from databases such as Men-
tha (Calderone et al., 2013) and String (Szklarczyk et al., 2015) enables TFmiR2 to detect
motifs of size 4 in addition to study further types of co-regulatory interactions. Addition-
ally, TFmiR2 allows a user to set a confidence threshold to retrieve the set of gene-gene
and protein-protein interactions which exceed the threshold. TFmiR2 detects 12 different
motifs of size 4 as shown in Figure 8.3 based on (Sun et al., 2012) where the gene-
gene/protein-protein interactions are regulated by a TF and a miRNA. The co-regulation
is defined by a regulatory pair of TF and miRNA (either in both directions or just in one
direction) that co-regulate at most two target interacting genes.
In Figure 8.3 part a) Com/TF/miRNA-FFL, one of the target genes is regulated by a
TF and just one of the target genes is repressed by a miRNA. If the TF regulates the
miRNA and the miRNA represses the TF, then it is a Com-FFL. If just the TF regulates
the miRNA, it is a TF-FFL and if just the miRNA represses the TF, it is a miRNA-FFL.
In Figure 8.3 part b) Com/TF/miRNA-FFL-miRNA, both target genes are regulated by
a TF and just one of the target genes is repressed by a miRNA. If the TF regulates the
miRNA and the miRNA repressed the TF, then it is a Com-FFL-TF. If just the TF
regulates the miRNA, it is a TF-FFL-TF and if just the miRNA represses the TF, it is a
miRNA-FFL-TF.
In Figure 8.3 part c) Com/TF/miRNA-FFL-miRNA, both target genes are repressed by
a miRNA and just one of the target genes is regulated by a TF. If the TF regulates the
miRNA and the miRNA represses the TF, then it is a Com-FFL-miRNA. If just the TF
regulates the miRNA, it is a TF-FFL-miRNA and if just the miRNA represses the TF,
it is a miRNA-FFL-miRNA.
In Figure 8.3 part d) Com/TF/miRNA-FFL-Full, both target genes are repressed by a
miRNA and regulated by a TF. If the TF regulates the miRNA and the miRNA represses
the TF, then it is a Com-FFL-Full. If just the TF regulates the miRNA, it is a TF-FFL-
Full and if just the miRNA represses the TF, it is a miRNA-FFL-Full.
8.2.6 Conserved Randomization Strategy
In TFmiR2, the user can select a randomization strategy which can be either edge-type
conserving or non-conserving, see chapter 7.3.3. The non-conserving method was realized
in the first version of TFmiR. If the conserved method is selected, then swapping the
edges is limited to the edge type. To do the swapping scheme, first all the interaction
types (TF-gene, TF-miRNA, miRNA-gene, miRNA-miRNA and gene-gene) are grouped
respectively. Then the endpoints are swapped inside each group. The number of swapping
events for each group depends on the group size, e.g. if it is supposed to have totally N
swappings in the network, then each group contributes proportionally.
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Figure 8.3: Schematic illustration of the four motif types detected in TFmiR2. All motifs
contain a TF, a miRNA, and at least one common target gene.
8.2.7 Data Retrieval and Processing
The miRNA-process association files were downloaded from the TAM web service (The
tool for annotations of human miRNAs) (Lu et al., 2010) and were matched literally to the
textual IDs of the general GO terms. The gene-process association files were retrieved from
UniProtKB (Ashburner et al., 2000; Barrell et al., 2009; The-Gene-Ontology-Consortium,
2017) with GOC validation date of 21.10.2017 for Go terms. Mapping of GO terms to
UniProtKnowledgebase keywords was performed on 26.10.2017. Here we considered 42
biological processes that are commonly annotated in both miRNA and gene association
files.
Tissue-specific genes in human were derived from the expression data of the GTEx project
(release V6p) on 53 tissues (Mele et al., 2015). As in (Mele et al., 2015), a gene was con-
sidered as abundant in a sample when its RPKM value was above 0.1 and a gene was
considered as abundant in a tissue if it was abundant in most of the samples of the re-
spective tissue. Mouse data on tissue expression was inferred from ENCODE expression
data on 30 tissues (release 3 of Sept 2012) (Pervouchine et al., 2015). Here, abundance
of genes was determined according to the protocol of the identically quantified data in
(Djebali et al., 2012). Thus, genes considered abundant in a tissue needed to be expressed
(RPKM > 0) in both biological replicates of the corresponding tissue and have an npIDR
value below 0.1. Several databases were used to generate networks for mouse. OregAnno
(Griffith et al., 2008) was included for TFs regulating genes. TransmiR (Wang et al., 2010)
and ChipBase (Yang et al., 2013) provided information on which TFs regulate miRNAs.
miRTarBase (Hsu et al., 2010), TarBase (Sethupathy et al., 2006), miRecords (Xiao et al.,
2009) and starBase (Yang et al., 2011) collect target genes of miRNAs. Gene-gene inter-
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actions were adopted from mentha (Calderone et al., 2013) and String (Szklarczyk et al.,
2015) databases. Moreover, our database for mouse was integrated with regNetwork (Liu
et al., 2015) which includes interaction data from many databases. RegNetwork is an
integrative database of transcriptional and post-transcriptional regulatory networks for
human and mouse from 25 selected databases. It covers three types of experimentally
validated and computationally predicted regulatory interactions including TF → gene,
TF → miRNA and miRNA → gene. (Liu et al., 2015). The mouse genome database
(MGD) is an integrative database of mouse genes and its features and functions. It is the
core component of consortium of mouse genome informatics (MGI) (Smith et al., 2018).
Mouse disease genes were mapped from human homologs using data of the MGI database.
8.3 Results
8.3.1 Case Study
To demonstrate the capabilities of the new features of TFmiR2, we considered the same
dataset that was used in the earlier version of TFmiR (Hamed et al., 2015b). The PPI
threshold was set to 80%. Cell proliferation, cell differentiation and apoptosis were se-
lected from the list of processes. Tissue was set to Breast-Mammary Tissue. The MCDS
algorithm was applied on the LSCC of the process-specific, tissue-specific and disease-
specific networks. Out of 5 MCDS nodes, 4 nodes (ESR1, hsa-mir-221, PDGFA, TGFB1)
were common among all the results. This indicates that these four nodes have significant
roles in causing and maintaining the disease. Moreover, TFmiR2 detected multiple FFL
motifs of size 4 in the disease-specific network. AAKT1, TP53, JAG1, PDGFA, NDRG3,
FLI1, BRCA2, GNA13, ELK3 and COL15A1 were the dominators of the disease-process
specific networks. These genes are associated mainly with the cell cycle and cell differen-
tiation.
8.4 Summary and Discussion
TFmiR2 reinforces the earlier version, TFmiR, through involving tissue-and process-
specific networks with whereby a disease-specific network can be restricted to a related
tissue and multiple biological processes. These tailored new networks enable a user to
analyse the mutual interaction between a disease gene and malfunctioned biological pro-
cess, where the MCDS method identifies the putative key driver genes and miRNAs that
control the LSCC of the network. Moreover, the co-regulatory PPI motifs represent the
most significant genes, miRNAs and proteins with respect to the predefined pattern of
interactions between them.
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Chapter 9
Conclusions
The dissertation addressed several open problems in the research field of gene regulatory
networks. Master regulatory genes are genes which either directly govern the particular
cellular identity or are at the inception of developmental lineages and regulate a cascade
of gene expressions to form specific lineages. The network in ESCs is spanned up by few
connected master regulatory TFs which share many target genes. Slight changes in the
expression levels of such a tightly interwoven network of transcription factors lead the
ESCs into differentiation. Cancer stem cells show a very similar behavior as stem cells.
They have the capability of generating an indefinite number of cells of the same type and
cause different types of tumors. In this dissertation, we exploited the regulatory mech-
anisms underlying ESCs to identify cancer biomarkers. We addressed the problem by
formulations of two combinatorial optimization problems which are based on the concept
of network controllability. In the MDS approach, we search for a minimum number of
dominators in directed graphs which control the whole network, whereas a MCDS returns
a dominating pathway in the connected component of regulatory networks. Based on the
success of these methods in achieving the master regulators which govern the global gene
regulatory network of E. coli and the cell cycle genes of S. cerevisiae in addition to the
gene regulatory network of mouse ESCs, we applied the methods to cancer networks. A
significant set of breast cancer drug targets were found among a dominating pathway of
the breast cancer network.
With respect to the fact that optimization problems usually do not have unique solutions
and we needed to use a heuristic approximate approach of MCDS for solving some problem
instances due to the long running time to achieve optimal solutions, a novel prioritization
method was proposed. This method, which does not rely on any prior knowledge, was
utilized to prioritize DE genes between two conditions. The proposed ranking system
gives priority to the DE genes which interact with each other and comprise a network.
The priority of the nodes in a network increases by the number of roles the respective
genes take either as dominators or when taking part in a dominating pathway or as hub-
degree nodes. DE genes with the same priority are sorted in descending order based on
the absolute value of their fold changes. Highest priority is given to a gene with highest
fold change with the same combination of topological scores.
The sets of DE genes identified by different bioinformatics tools do not agree with each
other in terms of size and content. A comprehensive comparison between eleven different
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tools took RNA-Seq read counts as input and showed that there is no general consensus
among them (Soneson and Delorenzi, 2013). In this dissertation, we showed that there is a
noticeable overlap between topological features of these methods. To explain this finding,
we selected four differential gene expression analysis methods which take read counts as
input and return p-values as output. We used our web server TFmiR to construct the
disease-associated network.
TFmiR is a freely available web server which takes at least one set of DE genes or miR-
NAs as input. Then it constructs a network with all the interactions existing in selected
regulatory databases for four types of interactions (TF → gene, TF → miRNA, miRNA
→ gene and miRNA → miRNA). If a disease is selected, then the network is pruned to a
disease-specific network by selecting those edges for which at least one of their endpoints
was reported in gene or miRNA disease databases.
TFmiR2 web server reinforces the functionality of TFmiR by pruning the complete net-
work to process-specific and tissue-specific networks and also a combination of them such
as disease-process, disease-tissue and process-tissue networks. Applying MCDS on the
LSCC of the (disease, tissue, process) networks identified a set of genes and miRNAs
of size five, where four of them were common in the dominating pathway of all of the
networks.
FFL motifs of size three and four can be detected by TFmiR and TFmiR2. In TFmiR2,
we offered two randomization strategies, an edge-type conserving method and a non-
conserving method. In a separate work, we showed that the conserving method detected
much fewer significant motifs compared to the non-conserving method in the breast cancer
network, while carrying almost the same number of biological process GO terms. More-
over, we showed that a considerable fraction of co-regulation FFL motif nodes (genes and
miRNAs) which are detected by the conserving method overlapped with the dominating
pathway of the network.
To summarize, the methods that we developed in this thesis have a variety of applications.
MDS is capable of identifying key regulators and master regulators in any network. De-
pends on the underlying network, the role of dominators are specified, e.g, if the network
is a differential network, the dominators are responsible for the transition. The key dom-
inating pathway in the network is detected by MCDS. Like MDS, the role of dominators
and connectors in the MCDS are defined by the underlying networks. TFmiR2 constructs
disease-, tissue-, process-specific networks or a combination of these networks by receiving
at least one set of dysregulated genes or miRNAs. The set of hotspot nodes and network
motifs can be detected by the web server tools.
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Appendix A
Supplementary materials
A.1 A Guide to use ILP formulations of MDS and MCDS
This guide contains instructions for users how to use the provided tools in sage software
system, MDS and MCDS in a directed network. The ILP formulations were written in the
Sage software system and use the glpk solver to find the solutions. The ILP formulation
for the directed form of MDS finds a minimum number of dominators in the directed
graph. The program is applied to the full network to find the optimal solution for the
MDS problem. The program takes two arguments (input file, output file). The first
argument is a tab-delimited file as an input network and the second argument is the
output text file to which the results are saved in the user-specified path. The program
can be executed in the terminal as follows:
. / sage MDS_direct . sage [ i npu t_ f i l e ] [ ou tput_f i l e ]
Suppose we have a network named black.csv, the following command outputs the MDS
result for the mentioned input network. .
. / sage MDS_direct . sage black . csv mds_result . txt
To find the optimal solution for the MCDS problem, we considered two types of compo-
nents in the network. The LCC and the LSCC. Because no feasible solution for MCDS
exists in graphs that are not connected. The ILP formulation for the directed form of
MCDS finds a set of minimum connected dominators in the directed graph. The pro-
gram takes three arguments (component type, input file, output file). The first argument
determines the type of component which can be either LCC or LSCC. The component
type needs to be specified explicitly in upper case or lower case as given in the example.
The other two arguments are a tab-delimited file as input network as in section 2 and the
output text file to which the results are saved in the user-specified path. The program
can be executed in the terminal as follows:
. / sage MCDS_direct . sage [ Component ] [ i npu t_ f i l e ] [ ou tput_f i l e ]
Suppose we have a network named black.csv, the following command outputs the MCDS
result for the mentioned input network.
. / sage MCDS_direct . sage LCC black . csv mcds_result . txt
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Figure S1: Cumulative distribution of the functional similarity scores between pairs of
MCDS nodes of the mouse pluripotency network (in red) against the similarity between
all pairs of genes in the pluripotency network (in black).
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Figure S2: MCDS is a Cytoscape application that allows users to find an approximate
MCDS solution in a directed graph. The user can choose to run the algorithm on the
largest connected component underlying directed graph (LCCD) and undirected graph
(LCC), as well as the LSCC of the network. The connectivity among the nodes in the
MCDS can then be visualized via Cytoscape.
Figure S3: Example of MCDS on the LCC underlying the undirected graph of the cell
cycle of S. cerevisiae. The associated table shows the role of the nodes in the solution
with the number of successors and predecessors.
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Figure S4: Example of MCDS on the LCC underlying directed graph (LCCD) of a toy
network. The associated table shows the role of the nodes in the solution with the number
of successors and predecessors.
Figure S5: Example of MCDS on the LSCC of a toy network. The associated table shows
the role of the nodes in the solution with the number of successors and predecessors.
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Figure S6: MCDS download statistics between February 2016 and April 2018.
Figure S7: MCDS geographical usage distribution between February 2016 and April 2018.
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Figure S8: Sample input file of deregulated TFs/genes. (1), and (-1) refer to up- and
down regulation, respectively.
Figure S9: Sample input file of deregulated miRNAs. (1), and (-1) refer to up-and down
regulation, respectively.
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Figure S10: (a) Co-targeted genes defined as genes that are targeted by the same TF and
miRNA pair. (b) Co-regulated genes defined as all genes regulated by the TF and the
miRNA of this TF-miRNA pair.
Figure S11: A composite FFL motif involves the TF SPI1, the miRNA has-mir-155,
and the target gene FLI1. The co-regulated nodes are also visualized and are further
tested whether they compose a cooperative functional module in breast cancerogenesis
(see Figure S12).
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Figure S12: Cumulative distribution of GO functional semantic scores of gene pairs of
co-regulated genes in the examined motif (red) versus randomly selected genes (black).
The p-value was calculated using the Kolmogorov-Smirnov test.
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A.3 Tables
Table S1: 34 MCDS genes of the E.coli LCC based taken from RegulonDB. ’D’ stands
for dominating node, ’C’ for connecting node. Only the largest component of the network
with 1198 genes was analyzed here.
Gene Role no. Target genes
feaR C 2
BolA D 2
zraR C 3
AsnC D 4
CreB D 5
stpA C 7
uxuR C 8
rbsR C 9
galS C 10
malT C 10
dpiA C 11
metJ D 15
ompR C 17
leuO D 20
nac C 21
csgD C 23
rob D 26
gadX C 28
gadE C 28
fhlA C 30
purR D 31
oxyR C 33
nagC C 36
marA C 38
soxS C 40
pdhR C 42
lrp D 105
narL C 121
fur C 129
ArcA C 173
IHF D 219
fis C 227
fnr D 296
CRP D 497
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Table S2: Enriched GO terms (top) and KEGG pathways with adjusted p-values < 0.05
for the 34 genes in the MCDS for the E.coli GRN. p-values were adjusted for multiple
testing using the BH procedure.
Enriched terms count adj. p-values
GO:0006350 ∼ transcription 32 4.845E-28
GO:0045449 ∼ regulation of transcription 33 4.043E-26
GO:0051171 ∼ regulation of nitrogen compound metabolic process 33 3.204E-26
GO:0019219 ∼ regulation of nucleobase, nucleoside, nucleotide and nucleic
acid metabolic process
33 3.204E-26
GO:0010556 ∼ regulation of macromolecule biosynthetic process 33 3.108E-26
GO:0009889 ∼ regulation of biosynthetic process 33 3.108E-26
GO:0031326 ∼ regulation of cellular biosynthetic process 33 3.108E-26
GO:0080090 ∼ regulation of primary metabolic process 33 2.843E-26
GO:0031323 ∼ regulation of cellular metabolic process 33 2.610E-26
GO:0006355 ∼ regulation of transcription, DNA-dependent 32 3.767E-26
GO:0051252 ∼ regulation of RNA metabolic process 32 3.572E-26
GO:0010468 ∼ regulation of gene expression 33 6.725E-26
GO:0060255 ∼ regulation of macromolecule metabolic process 33 7.117E-26
GO:0019222 ∼ regulation of metabolic process 33 7.779E-26
GO:0010467 ∼ gene expression 32 2.898E-25
GO:0050794 ∼ regulation of cellular process 33 1.280E-24
GO:0050789 ∼ regulation of biological process 33 6.833E-24
GO:0065007 ∼ biological regulation 33 1.549E-23
GO:0034645 ∼ cellular macromolecule biosynthetic process 32 1.114E-22
GO:0009059 ∼ macromolecule biosynthetic process 32 2.139E-22
GO:0044249 ∼ cellular biosynthetic process 32 3.984E-17
GO:0009058 ∼ biosynthetic process 32 3.175E-16
GO:0044260 ∼ cellular macromolecule metabolic process 33 2.886E-14
GO:0006139 ∼ nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process
32 7.960E-14
GO:0034641 ∼ cellular nitrogen compound metabolic process 33 4.637E-13
GO:0043170 ∼ macromolecule metabolic process 33 1.015E-12
GO:0006807 ∼ nitrogen compound metabolic process 33 1.708E-12
GO:0044238 ∼ primary metabolic process 34 7.490E-10
GO:0044237 ∼ cellular metabolic process 34 1.056E-9
GO:0009987 ∼ cellular process 34 2.724E-7
GO:0000160 ∼ two-component signal transduction system (phosphorelay) 10 1.913E-6
GO:0008152 ∼ metabolic process 34 4.584E-5
ecd02020:Two-component system 6 3.558E-7
ect02020:Two-component system 6 1.853E-7
ecr02020:Two-component system 6 1.853E-7
ecg02020:Two-component system 6 1.340E-7
eck02020:Two-component system 6 1.340E-7
ecq02020:Two-component system 6 1.088E-7
eum02020:Two-component system 6 9.060E-8
ecz02020:Two-component system 6 9.060E-8
ecf02020:Two-component system 6 9.060E-8
ecx02020:Two-component system 6 8.481E-8
ecj02020:Two-component system 6 8.481E-8
eco02020:Two-component system 6 7.553E-8
ecm02020:Two-component system 6 7.127E-8
ecv02020:Two-component system 6 6.576E-8
ecw02020:Two-component system 5 5.241E-6
eci02020:Two-component system 5 5.952E-6
ece02020:Two-component system 5 5.627E-6
ecc02020:Two-component system 5 5.688E-6
Table S3: Dominators in the identified MDS for the cell-cycle specific GRN of S. cerevisiae.
Genes
FKH1, GCR1, ORC1, YOX1, PHD1, ACE2, STB1, SWI5, STB5, SWI4, TEC1, RAP1
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Table S4: 14 TFs and 3 target genes in the identified MCDS for the cell-cycle specific
GRN of S. cerevisiae. ’C’ and ’D’ stand for the roles of connector and dominating nodes.
Gene Role no. Target genes
PMA2 C 0
TID3 C 0
CAR1 C 0
STP4 C 1
SRD1 C 3
GCR1 D 11
STB5 D 12
PHD1 D 18
YOX1 C 29
ACE2 C 31
RAP1 D 35
SWI5 C 43
SWI4 D 46
TEC1 C 47
ORC1 D 61
STB1 D 62
FKH1 D 96
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Table S5: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted p-
values < 0.05 for the 17 genes in the MCDS for the cell-cycle specific GRN of S. cerevisiae.
P-values were adjusted for multiple testing using the BH procedure.
Enriched terms count adj. P-values
GO:0006355 ∼ regulation of transcription, DNA-dependent 12 2.952E-6
GO:0051252 ∼ regulation of RNA metabolic process 12 1.813E-6
GO:0045449 ∼ regulation of transcription 12 4.110E-5
GO:0019219 ∼ regulation of nucleobase, nucleoside, nucleotide and nucleic
acid metabolic process
12 7.514E-5
GO:0051171 ∼ regulation of nitrogen compound metabolic process 12 6.098E-5
GO:0034645 ∼ cellular macromolecule biosynthetic process 15 1.015E-4
GO:0009059 ∼ macromolecule biosynthetic process 15 9.269E-5
GO:0010468 ∼ regulation of gene expression 12 2.122E-4
GO:0010556 ∼ regulation of macromolecule biosynthetic process 12 2.201E-4
GO:0006357 ∼ regulation of transcription from RNA polymerase II pro-
moter
8 2.219E-4
GO:0010467 ∼ gene expression 15 2.078E-4
GO:0031326 ∼ regulation of cellular biosynthetic process 12 1.921E-4
GO:0009889 ∼ regulation of biosynthetic process 12 1.878E-4
GO:0006350 ∼ transcription 10 2.838E-4
GO:0060255 ∼ regulation of macromolecule metabolic process 12 4.468E-4
GO:0031323 ∼ regulation of cellular metabolic process 12 4.545E-4
GO:0080090 ∼ regulation of primary metabolic process 12 4.592E-4
GO:0019222 ∼ regulation of metabolic process 12 8.004E-4
GO:0048522 ∼ positive regulation of cellular process 7 8.463E-4
GO:0044249 ∼ cellular biosynthetic process 15 0.001
GO:0048518 ∼ positive regulation of biological process 7 0.001
GO:0009058 ∼ biosynthetic process 15 0.001
GO:0010628 ∼ positive regulation of gene expression 6 0.001
GO:0045941 ∼ positive regulation of transcription 6 0.001
GO:0051173 ∼ positive regulation of nitrogen compound metabolic process 6 0.002
GO:0045935 ∼ positive regulation of nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
6 0.002
GO:0010557 ∼ positive regulation of macromolecule biosynthetic process
6 0.002
GO:0009891 ∼ positive regulation of biosynthetic process 6 0.002
GO:0031328 ∼ positive regulation of cellular biosynthetic process 6 0.002
GO:0051329 ∼ interphase of mitotic cell cycle 5 0.002
GO:0051325 ∼ interphase 5 0.003
GO:0010604 ∼ positive regulation of macromolecule metabolic process 6 0.003
GO:0009893 ∼ positive regulation of metabolic process 6 0.003
GO:0031325 ∼ positive regulation of cellular metabolic process 6 0.003
GO:0034641 ∼ cellular nitrogen compound metabolic process 14 0.004
GO:0050794 ∼ regulation of cellular process 12 0.005
GO:0006807 ∼ nitrogen compound metabolic process 14 0.005
GO:0006139 ∼ nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process
13 0.006
GO:0044260 ∼ cellular macromolecule metabolic process 16 0.006
GO:0065007 ∼ biological regulation 13 0.008
GO:0043170 ∼ macromolecule metabolic process 16 0.008
GO:0050789 ∼ regulation of biological process 12 0.010
GO:0000278 ∼ mitotic cell cycle 6 0.014
sce04111:Cell cycle 4 0.051
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Table S6: 29 MCDS genes of the mouse ESC pluripotency network identified in the LSCC.
Gene Role out_degree
Wnt5a C 1
Dvl1 D 1
Map2k1 D 1
Raf1 C 1
Dkk1 C 1
Smad3 D 1
Nedd4l D 2
Akt1 C 2
Fgfr1 D 2
Grb2 D 2
Ptpn11 C 2
I tgb1 C 2
Tcl1 D 2
Mapk3 D 3
Lifr D 3
Notch1 D 3
Hras1 D 3
Cdk2ap1 C 3
Cdx2 C 4
Gsk3b D 5
Smad1 D 8
Sall4 C 9
Tcf3 D 12
Esrrb D 14
Nr5a2 D 20
Stat3 D 20
Sox2 C 30
Nanog C 46
Pou5f1 D 82
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Table S7: Enriched GO terms and KEGG pathways with adjusted p-values < 0.05 for
the 29 genes in the MCDS for the mouse pluripotency network. p-values were adjusted
for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0009653 anatomical structure morphogenesis 19 5.814E-11
GO:0009790 embryonic development 16 9.890E-11
GO:0048513 organ development 21 7.347E-11
GO:0048731 system development 22 1.464E-10
GO:0032502 developmental process 24 2.106E-10
GO:0048519 negative regulation of biological process 19 1.957E-10
GO:0030154 cell differentiation 20 1.889E-10
GO:0048856 anatomical structure development 22 2.854E-10
GO:0048869 cellular developmental process 20 3.122E-10
GO:0048523 negative regulation of cellular process 18 3.431E-10
GO:0048518 positive regulation of biological process 19 8.095E-10
GO:0048522 positive regulation of cellular process 18 1.479E-9
GO:0048598 embryonic morphogenesis 12 2.233E-9
GO:0001701 in utero embryonic development 11 2.790E-9
GO:0007275 multicellular organismal development 22 2.957E-9
GO:0050793 regulation of developmental process 13 1.355E-8
GO:0051093 negative regulation of developmental process 10 1.501E-8
GO:0019827 stem cell maintenance 6 2.525E-8
GO:0048468 cell development 13 2.638E-8
GO:0048864 stem cell development 6 2.900E-8
GO:0009888 tissue development 13 3.913E-8
GO:0048646 anatomical structure formation involved in morphogenesis 11 3.778E-8
GO:0045596 negative regulation of cell differentiation 9 5.834E-8
GO:0045595 regulation of cell differentiation 11 5.952E-8
GO:0042127 regulation of cell proliferation 12 8.561E-8
GO:0048863 stem cell differentiation 6 1.114E-7
GO:0043009 chordate embryonic development 11 1.221E-7
GO:0009792 embryonic development ending in birth or egg hatching 11 1.289E-7
GO:0045165 cell fate commitment 8 3.238E-7
GO:0050789 regulation of biological process 28 3.465E-7
GO:0007167 enzyme linked receptor protein signaling pathway 9 1.042E-6
GO:0065007 biological regulation 28 1.328E-6
GO:0050794 regulation of cellular process 27 1.525E-6
GO:0009887 organ morphogenesis 11 2.550E-6
GO:0006357 regulation of transcription from RNA polymerase II promoter 11 3.481E-6
GO:0007243 protein kinase cascade 8 6.748E-6
GO:0045944 positive regulation of transcription from RNA polymerase II pro-
moter
9 7.026E-6
GO:0045893 positive regulation of transcription, DNA-dependent 9 2.135E-5
GO:0008284 positive regulation of cell proliferation 8 2.171E-5
GO:0051254 positive regulation of RNA metabolic process 9 2.141E-5
GO:0032501 multicellular organismal process 22 3.182E-5
GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway 7 3.416E-5
GO:0010604 positive regulation of macromolecule metabolic process 10 4.234E-5
GO:0031325 positive regulation of cellular metabolic process 10 4.771E-5
GO:0045941 positive regulation of transcription 9 4.873E-5
GO:0010628 positive regulation of gene expression 9 5.828E-5
GO:0044260 cellular macromolecule metabolic process 22 6.809E-5
GO:0009893 positive regulation of metabolic process 10 7.095E-5
GO:0045935 positive regulation of nucleobase, nucleoside, nucleotide and nu-
cleic acid metabolic process
9 7.588E-5
GO:0007242 intracellular signaling cascade 11 9.113E-5
GO:0051173 positive regulation of nitrogen compound metabolic process 9 9.160E-5
GO:0010557 positive regulation of macromolecule biosynthetic process 9 9.500E-5
GO:0048568 embryonic organ development 7 1.007E-4
GO:0031328 positive regulation of cellular biosynthetic process 9 1.234E-4
GO:0009891 positive regulation of biosynthetic process 9 1.294E-4
GO:0051239 regulation of multicellular organismal process 10 1.755E-4
GO:0000003 reproduction 9 2.858E-4
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Enriched terms count adj. p-values
GO:0007399 nervous system development 10 3.578E-4
GO:0001890 placenta development 5 3.527E-4
GO:0019222 regulation of metabolic process 17 3.675E-4
GO:0043170 macromolecule metabolic process 22 4.118E-4
GO:0040007 growth 6 4.679E-4
GO:0030326 embryonic limb morphogenesis 5 5.073E-4
GO:0035113 embryonic appendage morphogenesis 5 5.073E-4
GO:0048589 developmental growth 5 5.629E-4
GO:0001707 mesoderm formation 4 6.255E-4
GO:0006355 regulation of transcription, DNA-dependent 12 7.191E-4
GO:0051094 positive regulation of developmental process 6 7.089E-4
GO:0048332 mesoderm morphogenesis 4 7.045E-4
GO:0001710 mesodermal cell fate commitment 3 7.035E-4
GO:0051252 regulation of RNA metabolic process 12 7.834E-4
GO:0010468 regulation of gene expression 15 7.754E-4
GO:0031323 regulation of cellular metabolic process 16 7.767E-4
GO:0001704 formation of primary germ layer 4 7.666E-4
GO:0000165 MAPKKK cascade 5 8.128E-4
GO:0035107 appendage morphogenesis 5 8.297E-4
GO:0035108 limb morphogenesis 5 8.297E-4
GO:0048333 mesodermal cell differentiation 3 8.931E-4
GO:0000122 negative regulation of transcription from RNA polymerase II
promoter
6 8.864E-4
GO:0048736 appendage development 5 9.114E-4
GO:0060173 limb development 5 9.114E-4
GO:0010646 regulation of cell communication 9 9.341E-4
GO:0007166 cell surface receptor linked signal transduction 15 9.336E-4
GO:0048729 tissue morphogenesis 6 9.703E-4
GO:0030182 neuron differentiation 7 0.001
GO:0022414 reproductive process 8 0.001
GO:0006468 protein amino acid phosphorylation 8 0.001
GO:0060255 regulation of macromolecule metabolic process 15 0.002
GO:0001708 cell fate specification 4 0.002
GO:0007498 mesoderm development 4 0.002
GO:0007420 brain development 6 0.002
GO:0009966 regulation of signal transduction 8 0.002
GO:0042221 response to chemical stimulus 9 0.002
GO:0001892 embryonic placenta development 4 0.002
GO:0010556 regulation of macromolecule biosynthetic process 14 0.002
GO:0044237 cellular metabolic process 22 0.002
GO:0045892 negative regulation of transcription, DNA-dependent 6 0.002
GO:0051253 negative regulation of RNA metabolic process 6 0.002
GO:0006350 transcription 12 0.002
GO:0007439 ectodermal gut development 3 0.003
GO:0048567 ectodermal gut morphogenesis 3 0.003
GO:0031326 regulation of cellular biosynthetic process 14 0.003
GO:0048699 generation of neurons 7 0.003
GO:0009889 regulation of biosynthetic process 14 0.003
GO:0045597 positive regulation of cell differentiation 5 0.003
GO:0016310 phosphorylation 8 0.003
GO:0007369 gastrulation 4 0.003
GO:0001829 trophectodermal cell differentiation 3 0.003
GO:0006464 protein modification process 10 0.003
GO:0045995 regulation of embryonic development 3 0.004
GO:0022008 neurogenesis 7 0.004
GO:0045449 regulation of transcription 13 0.004
GO:0048732 gland development 5 0.004
GO:0043412 biopolymer modification 10 0.005
GO:0007417 central nervous system development 6 0.005
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Enriched terms count adj. p-values
GO:0016481 negative regulation of transcription 6 0.005
GO:0043687 post-translational protein modification 9 0.005
GO:0009987 cellular process 27 0.005
GO:0051726 regulation of cell cycle 5 0.005
GO:0080090 regulation of primary metabolic process 14 0.005
GO:0001825 blastocyst formation 3 0.006
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic
acid metabolic process
13 0.006
GO:0045934 negative regulation of nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
6 0.007
GO:0051171 regulation of nitrogen compound metabolic process 13 0.007
GO:0051172 negative regulation of nitrogen compound metabolic process 6 0.007
GO:0034645 cellular macromolecule biosynthetic process 13 0.007
GO:0010629 negative regulation of gene expression 6 0.007
GO:0009059 macromolecule biosynthetic process 13 0.007
GO:0006793 phosphorus metabolic process 8 0.008
GO:0006796 phosphate metabolic process 8 0.008
GO:0043066 negative regulation of apoptosis 5 0.008
GO:0045667 regulation of osteoblast differentiation 3 0.008
GO:0048547 gut morphogenesis 3 0.008
GO:0010558 negative regulation of macromolecule biosynthetic process 6 0.008
GO:0001568 blood vessel development 5 0.008
GO:0043069 negative regulation of programmed cell death 5 0.008
GO:0060548 negative regulation of cell death 5 0.008
GO:0008283 cell proliferation 5 0.008
GO:0001944 vasculature development 5 0.008
GO:0031327 negative regulation of cellular biosynthetic process 6 0.009
GO:0009890 negative regulation of biosynthetic process 6 0.009
GO:0031667 response to nutrient levels 4 0.009
GO:0007492 endoderm development 3 0.009
GO:0032526 response to retinoic acid 3 0.009
GO:0033189 response to vitamin A 3 0.010
GO:0003006 reproductive developmental process 5 0.010
GO:0033273 response to vitamin 3 0.011
GO:0060541 respiratory system development 4 0.011
GO:0001763 morphogenesis of a branching structure 4 0.011
GO:0048546 digestive tract morphogenesis 3 0.011
GO:0055123 digestive system development 3 0.012
GO:0016055 Wnt receptor signaling pathway 4 0.012
GO:0060711 labyrinthine layer development 3 0.012
GO:0009880 embryonic pattern specification 3 0.012
GO:0001501 skeletal system development 5 0.013
GO:0007389 pattern specification process 5 0.013
GO:0009991 response to extracellular stimulus 4 0.013
GO:0007398 ectoderm development 4 0.013
GO:0051049 regulation of transport 5 0.013
GO:0016043 cellular component organization 11 0.013
GO:0031324 negative regulation of cellular metabolic process 6 0.013
GO:0048565 gut development 3 0.015
GO:0010033 response to organic substance 6 0.015
GO:0010605 negative regulation of macromolecule metabolic process 6 0.015
GO:0044238 primary metabolic process 21 0.015
GO:0030030 cell projection organization 5 0.018
GO:0007165 signal transduction 13 0.018
GO:0009892 negative regulation of metabolic process 6 0.019
GO:0009725 response to hormone stimulus 4 0.022
GO:0030900 forebrain development 4 0.022
GO:0051716 cellular response to stimulus 6 0.022
GO:0050896 response to stimulus 12 0.024
GO:0032989 cellular component morphogenesis 5 0.024
GO:0030278 regulation of ossification 3 0.025
GO:0001824 blastocyst development 3 0.026
GO:0008152 metabolic process 22 0.026
GO:0009719 response to endogenous stimulus 4 0.028
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Enriched terms count adj. p-values
GO:0032870 cellular response to hormone stimulus 3 0.029
GO:0007049 cell cycle 6 0.031
GO:0006950 response to stress 8 0.034
GO:0050678 regulation of epithelial cell proliferation 3 0.034
GO:0010467 gene expression 12 0.034
GO:0044249 cellular biosynthetic process 13 0.036
GO:0009605 response to external stimulus 6 0.037
GO:0032879 regulation of localization 5 0.038
GO:0048852 diencephalon morphogenesis 2 0.038
GO:0000904 cell morphogenesis involved in differentiation 4 0.039
GO:0031175 neuron projection development 4 0.042
GO:0051051 negative regulation of transport 3 0.042
GO:0035270 endocrine system development 3 0.042
GO:0006366 transcription from RNA polymerase II promoter 3 0.044
GO:0007507 heart development 4 0.044
GO:0009058 biosynthetic process 13 0.044
GO:0007584 response to nutrient 3 0.045
GO:0051216 cartilage development 3 0.047
mmu05200:Pathways in cancer 13 1.902E-9
mmu05220:Chronic myeloid leukemia 8 7.787E-8
mmu05210:Colorectal cancer 8 1.252E-7
mmu05215:Prostate cancer 8 1.296E-7
mmu05213:Endometrial cancer 7 1.327E-7
mmu05221:Acute myeloid leukemia 7 1.952E-7
mmu05211:Renal cell carcinoma 7 5.896E-7
mmu04722:Neurotrophin signaling pathway 8 8.510E-7
mmu04662:B cell receptor signaling pathway 7 1.030E-6
mmu04012:ErbB signaling pathway 7 1.537E-6
mmu04916:Melanogenesis 7 3.216E-6
mmu05223:Non-small cell lung cancer 6 3.483E-6
mmu04062:Chemokine signaling pathway 8 5.253E-6
mmu04660:T cell receptor signaling pathway 7 6.742E-6
mmu05214:Glioma 6 6.581E-6
mmu04510:Focal adhesion 8 7.542E-6
mmu05218:Melanoma 6 9.775E-6
mmu05212:Pancreatic cancer 6 9.901E-6
mmu04910:Insulin signaling pathway 7 1.245E-5
mmu04664:Fc epsilon RI signaling pathway 6 1.702E-5
mmu04650:Natural killer cell mediated cytotoxicity 6 1.134E-4
mmu04320:Dorso-ventral axis formation 4 1.346E-4
mmu04370:VEGF signaling pathway 5 2.677E-4
mmu04010:MAPK signaling pathway 7 4.049E-4
mmu04540:Gap junction 5 3.992E-4
mmu04912:GnRH signaling pathway 5 6.119E-4
mmu05219:Bladder cancer 4 7.840E-4
mmu04810:Regulation of actin cytoskeleton 6 0.001
mmu04310:Wnt signaling pathway 5 0.002
mmu04630:Jak-STAT signaling pathway 5 0.002
mmu04720:Long-term potentiation 4 0.003
mmu04730:Long-term depression 4 0.003
mmu04914:Progesterone-mediated oocyte maturation 4 0.005
mmu04666:Fc gamma R-mediated phagocytosis 4 0.007
mmu05216:Thyroid cancer 3 0.007
mmu05020:Prion diseases 3 0.010
mmu04360:Axon guidance 4 0.015
mmu05217:Basal cell carcinoma 3 0.023
mmu04920:Adipocytokine signaling pathway 3 0.033
mmu04520:Adherens junction 3 0.041
mmu04350:TGF-beta signaling pathway 3 0.051
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Table S8: Runtime to determine an optimal solution for individual modules in the BC
network with differing number of nodes and edges. Listed is also the resulting component
density. All computations were conducted on a single threaded Intel XEON machine
running at 2.2 Ghz. The module (grey) could not be solved in appropriate time using
ILP (not even after a month)
Module Nodes Edges Density Running Time (s)
black 41 233 0.13 1.91
brown 195 18843 0.49 52.71
green 110 595 0.04 94.60
magenta 26 123 0.18 1.91
pink 30 149 0.16 1.82
red 93 473 0.05 3.02
yellow 132 663 0.03 3499.55
blue 247 30239 0.49 14287.19
turquoise 295 43213 0.49 266.18
grey 148 723 0.03 NA
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Table S9: Identified genes in the MCDS (heuristic approach) for 10 modules of the breast
cancer network. The genes, whose protein products are known to be targeted by drugs,
are marked in bold.
Method Mod-
ule
Net-
work
Size
Re-
sult
size
Key driver genes
MCDS black 41 8 ZNF254, SEC24B, ZNF681, ZZZ3, WNT5B, CEP350, ZNF426, ZNF137
MCDS blue 247 3 FAM54A,ACAN, PDGFA
MCDS brown 195 1 AATK
MCDS green 110 29 GCDH, HDAC10, FLII, PIGQ, CXXC1, CNDP2, DPP7, OS9, MAGOH, AKT1, E4F1,
UTP14A, SH3GLB2, ATPBD4, C9orf7, AP1B1, TIMM44, WDR13, USF2, USF1, CDK9,
UCK1, CDC34, PQLC1, KIAA0664, CDC37, C7orf27, CDK10, LTBR
MCDS grey 148 38 FAM59A, FBN2, COLEC10, FRMPD1, IL5RA, RORA, GEFT, RNF2, CACNA1H,
CLGN, CAMK2N1, CEP72, CA6, PRND, ZC3H14, OR7A17, PRPH, BRD1, TAF15,
ZRANB2, ZNF480, ANXA13, UPF3A , SNCAIP, HPCAL4, MR1, POU4F2, SYT6,
DHDDS, CXorf26, GRHPR, PHF16, CNTN4, LHX4, CCDC130, PPARA , ABCG4,
SPRR1B
MCDS ma-
genta
26 7 VPS72, BGLAP, SESN2, TAF7, MED26, ILF2, ATF6
MCDS pink 30 6 ZNF706 , TCEB1, CHRAC1, DHX35, ZNF250, TMEM70
MCDS red 93 22 TGIF1, ZNF485, ZNF691, TGFB1, DHX8, USP21, PHF20, GTF3A, FHL3, RPS3A ,
JOSD2 , ATP1B1, SUMF2, EPN3, HTR6, PPP4C, CCDC9, MYC, UBAP1, PCGF1,
C6orf134, TP53
MCDS tur
quoise
295 1 ABHD10
MCDS yel-
low
132 26 SPI1, TRAF3IP3, HDAC11, HTRA4, CXCR4, IL2RG, ETS1, FUT4, FAM129C,
FAM124B , CASP10, RASSF5, PHACTR2, TSPAN2, PAG1, SLAMF1, SLC31A2,
DAPK1, TNFRSF9, NFKB1, FLI1, GZMK, SLFN11, PRKD3, LCP2, DFNA5
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Table S10: Enriched GO terms and KEGG pathways with adjusted p-values < 0.05 for
the 141 genes in the aggregated MCDS for the modules of the breast cancer network.
p-values were adjusted for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0009059∼macromolecule biosynthetic process 43 0.001
GO:0010468∼regulation of gene expression 43 0.001
GO:0006357∼regulation of transcription from RNA polymerase II pro-
moter
20 0.001
GO:0032774∼RNA biosynthetic process 12 0.001
GO:0051254∼positive regulation of RNA metabolic process 15 0.001
GO:0006350∼transcription 37 0.001
GO:0010556∼regulation of macromolecule biosynthetic process 43 0.001
GO:0032583∼regulation of gene-specific transcription 9 0.001
GO:0009889∼regulation of biosynthetic process 43 0.001
GO:0009891∼positive regulation of biosynthetic process 18 0.001
GO:0045449∼regulation of transcription 40 0.001
GO:0010467∼gene expression 43 0.001
GO:0006351∼transcription, DNA-dependent 12 0.001
GO:0045893∼positive regulation of transcription, DNA-dependent 15 0.001
GO:0034645∼cellular macromolecule biosynthetic process 43 0.001
GO:0031326∼regulation of cellular biosynthetic process 43 0.001
GO:0051171∼regulation of nitrogen compound metabolic process 42 0.002
GO:0019219∼regulation of nucleobase, nucleoside, nucleotide and nucleic
acid metabolic process
41 0.002
GO:0060255∼regulation of macromolecule metabolic process 45 0.002
GO:0051173∼positive regulation of nitrogen compound metabolic process 17 0.002
GO:0000122∼negative regulation of transcription from RNA polymerase
II promoter
11 0.002
GO:0019222∼regulation of metabolic process 48 0.002
GO:0010557∼positive regulation of macromolecule biosynthetic process 17 0.002
GO:0006139∼nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process
46 0.002
GO:0043170∼macromolecule metabolic process 65 0.003
GO:0034641∼cellular nitrogen compound metabolic process 48 0.003
GO:0031323∼regulation of cellular metabolic process 46 0.003
GO:0031328∼positive regulation of cellular biosynthetic process 17 0.003
GO:0045935∼positive regulation of nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
16 0.003
GO:0010551∼regulation of specific transcription from RNA polymerase II
promoter
7 0.003
GO:0080090∼regulation of primary metabolic process 44 0.004
GO:0045941∼positive regulation of transcription 15 0.004
GO:0045944∼positive regulation of transcription from RNA polymerase II
promoter
12 0.004
GO:0044260∼cellular macromolecule metabolic process 60 0.004
GO:0044249∼cellular biosynthetic process 45 0.004
GO:0006807∼nitrogen compound metabolic process 48 0.004
GO:0010628∼positive regulation of gene expression 15 0.004
GO:0006355∼regulation of transcription, DNA-dependent 29 0.005
GO:0051252∼regulation of RNA metabolic process 29 0.006
GO:0009058∼biosynthetic process 45 0.008
GO:0045892∼negative regulation of transcription, DNA-dependent 11 0.013
GO:0006366∼transcription from RNA polymerase II promoter 9 0.014
GO:0051253∼negative regulation of RNA metabolic process 11 0.014
GO:0010629∼negative regulation of gene expression 13 0.014
GO:0043193∼positive regulation of gene-specific transcription 6 0.016
GO:0009893∼positive regulation of metabolic process 18 0.018
GO:0016070∼RNA metabolic process 18 0.021
GO:0031667∼response to nutrient levels 8 0.021
GO:0010604∼positive regulation of macromolecule metabolic process 17 0.022
GO:0016481∼negative regulation of transcription 12 0.022
GO:0031325∼positive regulation of cellular metabolic process 17 0.027
GO:0031327∼negative regulation of cellular biosynthetic process 13 0.031
GO:0045595∼regulation of cell differentiation 12 0.034
GO:0009890∼negative regulation of biosynthetic process 13 0.036
GO:0009991∼response to extracellular stimulus 8 0.037
GO:0019216∼regulation of lipid metabolic process 6 0.040
GO:0045934∼negative regulation of nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
12 0.044
GO:0051172∼negative regulation of nitrogen compound metabolic process 12 0.048
GO:0009892∼negative regulation of metabolic process 15 0.055
hsa05200:Pathways in cancer 12 0.004
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Table S11: The integrated databases and interaction types in TFmiR. (P) means predicted
interactions and (E) means experimentally validated interactions.
Interaction Databases (P/E)∗ Genes miRNAs Regulatory links Version /frozen data
TF → gene TRANSFAC (E) 1279 – 2943 V11.4
TF → gene OregAnno (E) 1132 – 1083 Nov 2010
TF → gene TRED (P) 3038 – 6462 2007
TF → miRNA TransmiR (E) 158 175 567 V1.2, Jan 2013
TF → miRNA PMID20584335 (E) 58 56 102 Apr 2009
TF → miRNA ChipBase (P) 119 1380 33087 V1.1, Nov 2012
miRNA→ gene miRTarBase (E) 2244 551 5640 V4.5, Nov 2013
miRNA→ gene TarBase (E) 422 79 492 V7.0
miRNA→ gene miRecords (E) 543 157 780 Mar 2009
miRNA→ gene starBase (P) 5720 249 56051 V2.0, Sep 2013
miRNA→ miRNA PmmR (P) – 312 3846 Mar 2011
Table S12: The most significant functions and diseases enriched in the miRNA nodes of
the breast cancer disease network (Hamed et al., 2015b).
Category Term miRNAs Count P-value
Function Epithelial-mesenchymal transition 17 0.022
Function glucose metabolism 4 0.048
Disease Breast Neoplasms 67 1.43E-25
Disease Lung Neoplasms 50 4.33E-17
Disease Neoplasms 44 3.15E-15
Disease Ovarian Neoplasms 43 1.30E-14
Disease Adenocarcinoma 27 2.59E-13
Disease Pancreatic Neoplasms 39 7.30E-13
Disease Prostatic Neoplasms 41 3.49E-12
Disease Melanoma 45 1.25E-11
Disease Colonic Neoplasms 32 4.6E-11
Disease Colorectal Neoplasms 45 5.69E-11
Table S13: Key genes and miRNAs in the breast cancer network (Hamed et al., 2015b).
Key genes E2F6, TP53, SPI1, TGFB1, SMAD4, ESR1, TERT, E2F3, BRCA2, AKT1
Key miRNAs hsa-mir-148a, hsa-mir-21, hsa-mir-93, hsa-mir-152, hsa-mir-106b, hsa-mir-
143, hsa-mir-200c, hsa-mir-27a, hsa-mir-23a, hsa-mir-22, , hsa-mir-146a, hsa-
mir-335
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Table S14: The identified key gene nodes in the breast cancer network (Hamed et al.,
2015b) whose protein products are targeted by anti-cancer drugs. (1) means that at least
one drug that targets this gene product is reported in this database, and (0) means no
drugs are reported for the respective gene in this database. Not included are substances
that are known to be cancerogenous or mutagenic.
Target gene Drug and antineoplastic agents CTD PharmGKB Cancer Resource
AKT1 U 0126;tyrphostin AG 1478; Ursodeoxycholic
Acid;Valproic Acid;tyrphostin AG 1024; trametinib;
Tretinoin
1 0 1
BRCA2 Tretinoin; trichostatin A; Estradiol; transplatin;
troglitazone; Tunicamycin; fulvestrant
1 0 1
ESR1 exemestane;tamoxifen 0 1 1
TGFB1 Doxorubicin; Fluorouracil; Thalidomide; Entinostat;
Hyaluronidase
0 0 1
TP53 4-biphenylmine; alliin; Apigenin; At-
ropine;bicalutamide;butylidenephthalide
0 0 1
APPENDIX A. SUPPLEMENTARY MATERIALS 127
Table S15: 82 Candidates for hepatocelular carcinoma in the fourth layer identified by
TopControl. They were sorted initially by their scores, then by LFC. D stands for degree
of the node and LFC for log2(fold change).
gene D hub mds mcds score LFC
E2F1 25 1 1 1 3 3.76
EGR1 18 1 1 1 3 2.33
ESR1 9 1 1 1 3 2.19
JUN 33 1 1 1 3 1.39
NR1I2 9 1 1 1 3 1.37
MYC 18 1 1 1 3 1.07
JUND 6 1 1 1 3 0.99
STAT3 10 1 1 1 3 0.81
USF1 15 1 1 1 3 0.73
NR1H4 7 1 1 1 3 0.63
ETS1 9 1 1 1 3 0.61
IRF1 5 1 1 1 3 0.61
NR1I3 8 1 1 1 3 0.6
hsa-let-7b 47 1 1 1 3 -
hsa-mir-26a-5p 16 1 1 1 3 -
hsa-mir-29a 21 1 1 1 3 -
hsa-mir-29a-3p 18 1 1 1 3 -
hsa-mir-34a-5p 28 1 1 1 3 -
POU3F2 2 0 1 1 2 7.44
TP73 4 0 1 1 2 3.92
FOXM1 3 0 1 1 2 3.69
MYCN 3 0 1 1 2 3.25
ETV4 4 0 1 1 2 3.02
FOS 23 1 0 1 2 2.93
IL1B 1 0 1 1 2 2.25
NOS2 5 1 0 1 2 2.2
NR4A1 3 0 1 1 2 2.13
HBB 6 1 0 1 2 2.05
FOXO1 3 0 1 1 2 1.84
CYP3A4 6 1 0 1 2 1.84
IRF8 2 0 1 1 2 1.76
KCNIP3 1 0 1 1 2 1.76
ETS2 5 0 1 1 2 1.68
JUNB 2 0 1 1 2 1.55
FOSL1 10 1 0 1 2 1.37
SATB1 1 0 1 1 2 1.32
CEBPD 1 0 1 1 2 1.3
KLF6 2 0 1 1 2 1.28
KLF4 2 0 1 1 2 1.27
MAFG 3 0 1 1 2 1.21
KLF11 3 0 1 1 2 1.15
PDGFB 1 0 1 1 2 1.11
HIVEP1 1 0 1 1 2 1.04
NME2 1 0 1 1 2 0.95
CYBB 5 1 0 1 2 0.95
TCF3 2 0 1 1 2 0.92
ZBTB7B 1 0 1 1 2 0.88
TNFRSF1A 1 0 1 1 2 0.82
MAZ 4 0 1 1 2 0.8
GATA4 2 0 1 1 2 0.76
F12 1 0 1 1 2 0.75
CREM 3 0 1 1 2 0.74
CNBP 1 0 1 1 2 0.73
FOXA3 1 0 1 1 2 0.7
HLTF 1 0 1 1 2 0.7
SREBF2 3 0 1 1 2 0.68
NFE2L2 4 0 1 1 2 0.66
COL2A1 2 0 0 1 1 10.97
TERT 6 1 0 0 1 9.17
HOXD10 1 0 1 0 1 5.57
OTX1 1 0 1 0 1 5.53
CDK1 2 0 0 1 1 3.41
RRM2 2 0 0 1 1 2.98
SERPINE1 4 0 0 1 1 1.76
HMGA1 5 0 0 1 1 1.65
IGFBP1 2 0 0 1 1 1.45
GTF2IRD1 1 0 1 0 1 1.3
WEE1 1 0 1 0 1 1.25
COL1A2 4 0 0 1 1 1.18
PLAU 8 1 0 0 1 1.1
APOH 6 1 0 0 1 1.09
APOA5 2 0 0 1 1 1.05
ABCA1 2 0 0 1 1 1.02
AR 3 0 1 0 1 1
GATA6 1 0 1 0 1 0.9
HSF1 1 0 1 0 1 0.85
RORA 1 0 1 0 1 0.81
OAS1 1 0 1 0 1 0.8
NFKB2 2 0 1 0 1 0.76
HTATIP2 2 0 0 1 1 0.68
CCND1 12 1 0 0 1 0.67
ALDOC 2 0 0 1 1 0.67
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Table S16: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted
p-values < 0.05 for the hubs in the hepatocellular carcinoma network. P-values were
adjusted for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0045944 positive regulation of transcription from RNA polymerase II
promoter
15 5.185E-10
GO:0006366 transcription from RNA polymerase II promoter 10 1.908E-6
GO:0045893 positive regulation of transcription, DNA-templated 10 1.316E-6
GO:0042493 response to drug 8 1.016E-5
GO:1902895 positive regulation of pri-miRNA transcription from RNA
polymerase II promoter
4 2.219E-4
GO:0032355 response to estradiol 5 4.619E-4
GO:0000122 negative regulation of transcription from RNA polymerase II
promoter
8 0.001
GO:0032870 cellular response to hormone stimulus 4 0.001
GO:0051591 response to cAMP 4 0.001
GO:0034097 response to cytokine 4 0.002
GO:0048146 positive regulation of fibroblast proliferation 4 0.002
GO:0043401 steroid hormone mediated signaling pathway 4 0.002
GO:0009612 response to mechanical stimulus 4 0.002
GO:0001666 response to hypoxia 5 0.002
GO:0051412 response to corticosterone 3 0.008
GO:0051726 regulation of cell cycle 4 0.017
GO:0045787 positive regulation of cell cycle 3 0.026
GO:0006367 transcription initiation from RNA polymerase II promoter 4 0.027
GO:0030522 intracellular receptor signaling pathway 3 0.029
GO:0007568 aging 4 0.031
GO:0008285 negative regulation of cell proliferation 5 0.037
GO:0042127 regulation of cell proliferation 4 0.039
GO:0042542 response to hydrogen peroxide 3 0.043
GO:0071277 cellular response to calcium ion 3 0.043
GO:0006357 regulation of transcription from RNA polymerase II promoter 5 0.048
hsa05166:HTLV-I infection 9 9.692E-6
hsa05161:Hepatitis B 6 0.001
hsa04917:Prolactin signaling pathway 5 8.985E-4
hsa04380:Osteoclast differentiation 5 0.007
hsa05200:Pathways in cancer 7 0.006
hsa05210:Colorectal cancer 4 0.008
hsa05133:Pertussis 4 0.012
hsa05222:Small cell lung cancer 4 0.015
hsa05205:Proteoglycans in cancer 5 0.016
hsa05219:Bladder cancer 3 0.046
hsa04310:Wnt signaling pathway 4 0.043
hsa05206:MicroRNAs in cancer 5 0.043
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Table S17: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted
p-values < 0.05 for the MDS in the hepatocellular carcinoma network. P-values were
adjusted for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0045944 positive regulation of transcription from RNA polymerase II
promoter
43 3.867E-38
GO:0006366 transcription from RNA polymerase II promoter 25 1.062E-19
GO:0045893 positive regulation of transcription, DNA-templated 24 1.923E-18
GO:0000122 negative regulation of transcription from RNA polymerase II
promoter
22 6.235E-13
GO:0006351 transcription, DNA-templated 30 1.904E-11
GO:0010628 positive regulation of gene expression 12 9.784E-8
GO:0045892 negative regulation of transcription, DNA-templated 13 6.778E-6
GO:0030522 intracellular receptor signaling pathway 6 1.504E-5
GO:0006367 transcription initiation from RNA polymerase II promoter 8 5.651E-5
GO:0043401 steroid hormone mediated signaling pathway 6 9.578E-5
GO:0051726 regulation of cell cycle 7 2.341E-4
GO:0008285 negative regulation of cell proliferation 10 3.478E-4
GO:0006357 regulation of transcription from RNA polymerase II promoter 10 7.629E-4
GO:0006355 regulation of transcription, DNA-templated 17 9.599E-4
GO:0048146 positive regulation of fibroblast proliferation 5 0.001
GO:0070301 cellular response to hydrogen peroxide 5 0.001
GO:0009612 response to mechanical stimulus 5 0.002
GO:0042493 response to drug 8 0.002
GO:0050728 negative regulation of inflammatory response 5 0.005
GO:0032873 negative regulation of stress-activated MAPK cascade 3 0.006
GO:0045597 positive regulation of cell differentiation 4 0.009
GO:0071499 cellular response to laminar fluid shear stress 3 0.010
GO:0042127 regulation of cell proliferation 6 0.012
GO:2000188 regulation of cholesterol homeostasis 3 0.012
GO:0032870 cellular response to hormone stimulus 4 0.014
GO:0051591 response to cAMP 4 0.014
GO:0045766 positive regulation of angiogenesis 5 0.016
GO:0010941 regulation of cell death 3 0.016
GO:0034097 response to cytokine 4 0.018
GO:0008284 positive regulation of cell proliferation 8 0.021
GO:0010629 negative regulation of gene expression 5 0.027
GO:0007165 signal transduction 12 0.030
GO:0060337 type I interferon signaling pathway 4 0.029
GO:0006006 glucose metabolic process 4 0.033
GO:0045444 fat cell differentiation 4 0.040
GO:1902895 positive regulation of pri-miRNA transcription from RNA
polymerase II promoter
3 0.043
GO:0032496 response to lipopolysaccharide 5 0.044
GO:0007568 aging 5 0.044
hsa05166:HTLV-I infection 11 6.294E-5
hsa04010:MAPK signaling pathway 8 0.0181
hsa04380:Osteoclast differentiation 6 0.021
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Table S18: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted
p-values < 0.05 for the MCDS in the hepatocellular carcinoma network. P-values were
adjusted for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0045944 positive regulation of transcription from RNA polymerase II
promoter
40 5.582E-30
GO:0006366 transcription from RNA polymerase II promoter 25 3.745E-18
GO:0045893 positive regulation of transcription, DNA-templated 23 1.051E-15
GO:0000122 negative regulation of transcription from RNA polymerase II
promoter
19 1.414E-8
GO:0010628 positive regulation of gene expression 12 5.040E-7
GO:0042493 response to drug 12 1.973E-6
GO:0006351 transcription, DNA-templated 25 5.148E-6
GO:0045892 negative regulation of transcription, DNA-templated 13 2.690E-5
GO:0051591 response to cAMP 6 7.307E-5
GO:0009612 response to mechanical stimulus 6 2.315E-4
GO:0006357 regulation of transcription from RNA polymerase II promoter 11 3.759E-4
GO:0008285 negative regulation of cell proliferation 10 0.001
GO:0032870 cellular response to hormone stimulus 5 0.001
GO:0034097 response to cytokine 5 0.002
GO:0048146 positive regulation of fibroblast proliferation 5 0.002
GO:1902895 positive regulation of pri-miRNA transcription from RNA
polymerase II promoter
4 0.003
GO:0043401 steroid hormone mediated signaling pathway 5 0.003
GO:0070301 cellular response to hydrogen peroxide 5 0.003
GO:0042127 regulation of cell proliferation 7 0.003
GO:0045766 positive regulation of angiogenesis 6 0.003
GO:0051726 regulation of cell cycle 6 0.004
GO:0010629 negative regulation of gene expression 6 0.006
GO:0032873 negative regulation of stress-activated MAPK cascade 3 0.008
GO:0006367 transcription initiation from RNA polymerase II promoter 6 0.009
GO:0007568 aging 6 0.013
GO:0030522 intracellular receptor signaling pathway 4 0.013
GO:0071499 cellular response to laminar fluid shear stress 3 0.013
GO:0045429 positive regulation of nitric oxide biosynthetic process 4 0.018
GO:0010941 regulation of cell death 3 0.023
GO:0071222 cellular response to lipopolysaccharide 5 0.025
GO:0071277 cellular response to calcium ion 4 0.026
GO:0006915 apoptotic process 9 0.032
GO:0030194 positive regulation of blood coagulation 3 0.033
GO:0008284 positive regulation of cell proliferation 8 0.043
hsa05166:HTLV-I infection 12 3.013E-5
hsa04380:Osteoclast differentiation 8 7.793E-4
hsa05133:Pertussis 6 0.003
hsa05142:Chagas disease (American trypanosomiasis) 6 0.012
hsa04010:MAPK signaling pathway 8 0.020
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Table S19: 140 candidates for breast neoplasms in the fourth layer identified by TopCon-
trol. They were sorted initially by their scores, then by LFC. D stands for degree of the
node and LFC for log2(fold change).
gene D hub mds mcds score LFC
EGR1 19 1 1 1 3 2.59
ESR2 7 1 1 1 3 2.58
FOS 20 1 1 1 3 2.47
E2F1 25 1 1 1 3 2.34
CEBPA 17 1 1 1 3 2.1
ESR1 19 1 1 1 3 1.79
JUN 45 1 1 1 3 1.6
STAT5A 7 1 1 1 3 1.6
RUNX2 5 1 1 1 3 1.4
STAT1 34 1 1 1 3 1.28
ETS2 6 1 1 1 3 1.15
MITF 8 1 1 1 3 0.94
NR1H3 8 1 1 1 3 0.9
TFAP2A 24 1 1 1 3 0.9
IRF1 16 1 1 1 3 0.65
ARHGEF7 11 1 1 1 3 0.62
USF1 16 1 1 1 3 0.61
SRF 5 1 1 1 3 0.58
TFDP1 10 1 1 1 3 0.58
hsa-mir-1 86 1 1 1 3 -
hsa-mir-145-5p 39 1 1 1 3 -
hsa-mir-146a 31 1 1 1 3 -
hsa-mir-21 44 1 1 1 3 -
hsa-mir-21-5p 32 1 1 1 3 -
hsa-mir-34a-5p 27 1 1 1 3 -
EFNA2 2 0 1 1 2 Inf
CGA 5 1 0 1 2 7.25
GBX2 1 0 1 1 2 5.7
GATA4 3 0 1 1 2 5.6
WT1 2 0 1 1 2 5.39
LHX2 1 0 1 1 2 4.88
HBB 5 1 0 1 2 4.73
BMPR1B 1 0 1 1 2 4.41
POU3F2 1 0 1 1 2 4.14
IFNB1 9 1 0 1 2 4.13
RRM2 2 0 1 1 2 3.69
FOXM1 1 0 1 1 2 3.54
KIT 6 1 0 1 2 2.79
IL6 7 1 0 1 2 2.76
HOXA5 2 0 1 1 2 2.55
OTX1 1 0 1 1 2 2.49
TFF3 1 0 1 1 2 2.35
NR4A1 4 0 1 1 2 2.17
TAL1 1 0 1 1 2 1.92
BMP6 1 0 1 1 2 1.87
FOXA1 3 0 1 1 2 1.87
GATA3 3 0 1 1 2 1.75
SOX10 1 0 1 1 2 1.66
IRF7 5 0 1 1 2 1.6
NR3C1 8 1 0 1 2 1.57
PLAU 8 1 0 1 2 1.49
THRB 3 0 1 1 2 1.33
NR5A2 1 0 1 1 2 1.29
LMO2 1 0 1 1 2 1.26
MAZ 4 0 1 1 2 1.24
STAT5B 4 0 1 1 2 1.24
SATB1 1 0 1 1 2 1.16
FLI1 5 0 1 1 2 1.14
JUNB 2 0 1 1 2 1.12
KLF8 1 0 1 1 2 1.11
SERPINE1 7 1 0 1 2 1.11
RARB 6 1 1 0 2 1.1
ETV5 4 0 1 1 2 1.09
TRERF1 1 0 1 1 2 1.08
MYC 21 1 0 1 2 1.07
THRA 2 0 1 1 2 1.07
HEY2 1 0 1 1 2 1.06
NFATC2 3 0 1 1 2 1.06
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TNFSF12 3 0 1 1 2 1.05
IRF9 1 0 1 1 2 1.03
MECOM 1 0 1 1 2 1.03
FOXO4 1 0 1 1 2 1.02
SREBF1 7 1 0 1 2 1.02
MEIS1 1 0 1 1 2 1.01
TCF7L2 3 0 1 1 2 1.01
KLF11 4 0 1 1 2 1
NR2F6 2 0 1 1 2 1
CEBPD 4 0 1 1 2 0.97
HMGB2 1 0 1 1 2 0.97
PBX1 2 0 1 1 2 0.93
TEAD4 1 0 1 1 2 0.91
KLF13 2 0 1 1 2 0.88
JUND 5 0 1 1 2 0.87
KRAS 1 0 1 1 2 0.83
RPA3 1 0 1 1 2 0.82
MYEF2 1 0 1 1 2 0.8
TFCP2L1 1 0 1 1 2 0.76
TFE3 1 0 1 1 2 0.68
VEGFA 7 1 0 1 2 0.66
TCF3 3 0 1 1 2 0.65
AR 5 0 1 1 2 0.63
ICAM1 6 1 0 1 2 0.62
MMP1 5 1 0 0 1 6.92
HBG1 4 0 0 1 1 5.42
INSM1 2 0 1 0 1 4.93
APOB 4 0 0 1 1 4.73
ADIPOQ 3 0 0 1 1 4.71
SLC2A4 2 0 0 1 1 4.54
PF4 2 0 0 1 1 4.45
ACACB 1 0 1 0 1 3.71
TYRP1 2 0 0 1 1 3.65
ZBTB16 2 0 0 1 1 3.31
ISG15 4 0 0 1 1 2.95
MUC1 4 0 0 1 1 2.77
CDC25A 5 1 0 0 1 2.32
ALDOC 2 0 0 1 1 2.24
ATF3 6 1 0 0 1 2.21
LEF1 4 0 0 1 1 2.06
PIGR 4 0 0 1 1 2.05
ABCB1 3 0 0 1 1 1.94
ERBB2 6 1 0 0 1 1.89
COL1A2 5 1 0 0 1 1.88
CYP11A1 3 0 0 1 1 1.86
BRCA2 4 0 0 1 1 1.81
EPAS1 1 0 1 0 1 1.73
FOXO1 1 0 1 0 1 1.69
APOC2 2 0 0 1 1 1.5
RFX2 1 0 1 0 1 1.46
ZNF219 1 0 1 0 1 1.43
AFP 1 0 1 0 1 1.43
EGFR 8 1 0 0 1 1.4
PPARA 3 0 0 1 1 1.36
HMGA1 3 0 0 1 1 1.34
PDGFA 2 0 0 1 1 1.33
BRCA1 5 0 0 1 1 1.24
KLF6 1 0 1 0 1 1.24
HDGF 1 0 1 0 1 1.21
PARP1 1 0 1 0 1 1.2
RARA 3 0 1 0 1 1.13
BCL6 3 0 0 1 1 1.09
HOXD9 2 0 1 0 1 1.09
CCND1 15 1 0 0 1 1.01
MYB 6 1 0 0 1 0.99
CCL5 6 1 0 0 1 0.94
SOX4 1 0 1 0 1 0.89
PGR 5 0 0 1 1 0.87
ZEB1 1 0 1 0 1 0.72
ZNF444 1 0 1 0 1 0.65
FUS 2 0 1 0 1 0.64
NR1D1 3 0 1 0 1 0.62
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Table S20: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted
p-values < 0.05 for the hubs in the breast neoplasms network. P-values were adjusted for
multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0045944 positive regulation of transcription from RNA polymerase II
promoter
27 5.900E-20
GO:0045893 positive regulation of transcription, DNA-templated 16 1.506E-10
GO:0000122 negative regulation of transcription from RNA polymerase II
promoter
17 8.232E-10
GO:0006366 transcription from RNA polymerase II promoter 15 1.345E-9
GO:0048661 positive regulation of smooth muscle cell proliferation 6 5.457E-5
GO:0050679 positive regulation of epithelial cell proliferation 6 5.457E-5
GO:0010628 positive regulation of gene expression 8 3.862E-4
GO:0045429 positive regulation of nitric oxide biosynthetic process 5 4.226E-4
GO:0061029 eyelid development in camera-type eye 4 4.089E-4
GO:0042493 response to drug 8 6.854E-4
GO:0006357 regulation of transcription from RNA polymerase II promoter 9 7.250E-4
GO:0048146 positive regulation of fibroblast proliferation 5 6.762E-4
GO:0008284 positive regulation of cell proliferation 9 9.027E-4
GO:0070374 positive regulation of ERK1 and ERK2 cascade 6 0.004
GO:0030335 positive regulation of cell migration 6 0.004
GO:0051091 positive regulation of sequence-specific DNA binding tran-
scription factor activity
5 0.006
GO:0001541 ovarian follicle development 4 0.007
GO:0051591 response to cAMP 4 0.009
GO:0034097 response to cytokine 4 0.013
GO:0008285 negative regulation of cell proliferation 7 0.015
GO:0043406 positive regulation of MAP kinase activity 4 0.017
GO:0006367 transcription initiation from RNA polymerase II promoter 5 0.020
GO:0060337 type I interferon signaling pathway 4 0.019
GO:0071347 cellular response to interleukin-1 4 0.025
GO:0035458 cellular response to interferon-beta 3 0.024
GO:0001666 response to hypoxia 5 0.026
GO:0060749 mammary gland alveolus development 3 0.025
GO:0007623 circadian rhythm 4 0.025
GO:0030324 lung development 4 0.025
GO:0007596 blood coagulation 5 0.029
GO:1902895 positive regulation of pri-miRNA transcription from RNA
polymerase II promoter
3 0.031
GO:0045892 negative regulation of transcription, DNA-templated 7 0.032
GO:0046427 positive regulation of JAK-STAT cascade 3 0.035
GO:0007165 signal transduction 10 0.037
GO:0006351 transcription, DNA-templated 13 0.039
GO:0002053 positive regulation of mesenchymal cell proliferation 3 0.045
hsa05200:Pathways in cancer 16 8.489E-8
hsa05166:HTLV-I infection 13 3.355E-7
hsa05219:Bladder cancer 7 2.695E-6
hsa04917:Prolactin signaling pathway 8 2.475E-6
hsa05161:Hepatitis B 9 2.010E-5
hsa05323:Rheumatoid arthritis 7 1.346E-4
hsa05212:Pancreatic cancer 6 4.0173E-4
hsa05221:Acute myeloid leukemia 5 0.003
hsa05223:Non-small cell lung cancer 5 0.003
hsa05142:Chagas disease (American trypanosomiasis) 6 0.002
hsa04620:Toll-like receptor signaling pathway 6 0.002
hsa04151:PI3K-Akt signaling pathway 9 0.004
hsa05205:Proteoglycans in cancer 7 0.006
hsa05206:MicroRNAs in cancer 8 0.006
hsa04630:Jak-STAT signaling pathway 6 0.008
hsa04012:ErbB signaling pathway 5 0.009
hsa04066:HIF-1 signaling pathway 5 0.013
hsa04915:Estrogen signaling pathway 5 0.013
hsa05164:Influenza A 6 0.015
hsa04668:TNF signaling pathway 5 0.015
hsa05213:Endometrial cancer 4 0.015
hsa05168:Herpes simplex infection 6 0.016
hsa04110:Cell cycle 5 0.023
hsa05210:Colorectal cancer 4 0.022
hsa04510:Focal adhesion 6 0.023
hsa05230:Central carbon metabolism in cancer 4 0.022
hsa04380:Osteoclast differentiation 5 0.023
hsa05162:Measles 5 0.024
hsa05160:Hepatitis C 5 0.024
hsa05218:Melanoma 4 0.027
hsa05220:Chronic myeloid leukemia 4 0.027
hsa05133:Pertussis 4 0.029
hsa04060:Cytokine-cytokine receptor interaction 6 0.028
hsa04932:Non-alcoholic fatty liver disease (NAFLD) 5 0.031
hsa05222:Small cell lung cancer 4 0.037
hsa05215:Prostate cancer 4 0.040
hsa05202:Transcriptional misregulation in cancer 5 0.041
hsa05143:African trypanosomiasis 3 0.043
hsa05020:Prion diseases 3 0.043
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Table S21: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted
p-values < 0.05 for the MDS in the breast neoplasms network. P-values were adjusted
for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0045944 positive regulation of transcription from RNA polymerase II
promoter
60 7.919E-48
GO:0006366 transcription from RNA polymerase II promoter 39 3.038E-31
GO:0000122 negative regulation of transcription from RNA polymerase II
promoter
38 1.036E-24
GO:0045893 positive regulation of transcription, DNA-templated 33 1.777E-23
GO:0006351 transcription, DNA-templated 44 3.246E-15
GO:0006357 regulation of transcription from RNA polymerase II promoter 22 2.381E-12
GO:0045892 negative regulation of transcription, DNA-templated 22 2.294E-11
GO:0006367 transcription initiation from RNA polymerase II promoter 14 2.058E-10
GO:0043401 steroid hormone mediated signaling pathway 10 2.195E-9
GO:0030522 intracellular receptor signaling pathway 8 1.236E-7
GO:0006355 regulation of transcription, DNA-templated 29 2.346E-7
GO:0008285 negative regulation of cell proliferation 16 2.543E-7
GO:0045597 positive regulation of cell differentiation 7 3.505E-6
GO:0034097 response to cytokine 7 2.672E-5
GO:0045666 positive regulation of neuron differentiation 7 2.814E-4
GO:0045669 positive regulation of osteoblast differentiation 6 0.001
GO:0001938 positive regulation of endothelial cell proliferation 6 0.002
GO:0042493 response to drug 10 0.002
GO:0048469 cell maturation 5 0.002
GO:0003215 cardiac right ventricle morphogenesis 4 0.002
GO:0035855 megakaryocyte development 4 0.004
GO:0032870 cellular response to hormone stimulus 5 0.004
GO:0051591 response to cAMP 5 0.005
GO:0071277 cellular response to calcium ion 5 0.007
GO:0009612 response to mechanical stimulus 5 0.012
GO:0060337 type I interferon signaling pathway 5 0.016
GO:0042127 regulation of cell proliferation 7 0.019
GO:0051726 regulation of cell cycle 6 0.021
GO:0071773 cellular response to BMP stimulus 4 0.020
GO:0045444 fat cell differentiation 5 0.023
GO:0045647 negative regulation of erythrocyte differentiation 3 0.035
GO:0043065 positive regulation of apoptotic process 8 0.039
GO:0033148 positive regulation of intracellular estrogen receptor signaling
pathway
3 0.041
GO:0030218 erythrocyte differentiation 4 0.041
GO:0048646 anatomical structure formation involved in morphogenesis 3 0.047
GO:0010941 regulation of cell death 3 0.047
GO:0008584 male gonad development 5 0.049
hsa05202:Transcriptional misregulation in cancer 13 1.158E-6
hsa05200:Pathways in cancer 16 3.003E-5
hsa04917:Prolactin signaling pathway 8 7.036E-5
hsa05161:Hepatitis B 9 7.276E-4
hsa05166:HTLV-I infection 11 0.001
hsa05221:Acute myeloid leukemia 6 0.001
hsa04380:Osteoclast differentiation 8 0.001
hsa04919:Thyroid hormone signaling pathway 7 0.005
hsa05220:Chronic myeloid leukemia 5 0.039
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Table S22: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted
p-values < 0.05 for the MCDS in the breast neoplasms network. P-values were adjusted
for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0045944 positive regulation of transcription from RNA polymerase II
promoter
66 5.561E-50
GO:0006366 transcription from RNA polymerase II promoter 40 3.410E-29
GO:0045893 positive regulation of transcription, DNA-templated 36 2.942E-24
GO:0000122 negative regulation of transcription from RNA polymerase II
promoter
35 1.772E-18
GO:0006357 regulation of transcription from RNA polymerase II promoter 22 1.264E-10
GO:0045892 negative regulation of transcription, DNA-templated 23 1.268E-10
GO:0006367 transcription initiation from RNA polymerase II promoter 14 2.797E-9
GO:0043401 steroid hormone mediated signaling pathway 10 1.531E-8
GO:0030522 intracellular receptor signaling pathway 8 6.067E-7
GO:0006351 transcription, DNA-templated 36 7.362E-7
GO:0042127 regulation of cell proliferation 12 3.413E-6
GO:0042493 response to drug 14 7.937E-6
GO:0010628 positive regulation of gene expression 13 1.161E-5
GO:0008285 negative regulation of cell proliferation 15 2.143E-5
GO:0006355 regulation of transcription, DNA-templated 28 4.631E-5
GO:0045669 positive regulation of osteoblast differentiation 7 2.024E-4
GO:0035855 megakaryocyte development 5 2.355E-4
GO:0060337 type I interferon signaling pathway 7 2.640E-4
GO:0045597 positive regulation of cell differentiation 6 2.768E-4
GO:0001938 positive regulation of endothelial cell proliferation 7 3.703E-4
GO:0032870 cellular response to hormone stimulus 6 6.743E-4
GO:0051591 response to cAMP 6 7.186E-4
GO:0034097 response to cytokine 6 0.001
GO:0008284 positive regulation of cell proliferation 13 0.002
GO:0042593 glucose homeostasis 7 0.002
GO:0051091 positive regulation of sequence-specific DNA binding tran-
scription factor activity
7 0.003
GO:0071356 cellular response to tumor necrosis factor 7 0.003
GO:0048469 cell maturation 5 0.004
GO:0001666 response to hypoxia 8 0.005
GO:0035162 embryonic hemopoiesis 4 0.006
GO:0006978 DNA damage response, signal transduction by p53 class me-
diator resulting in transcription of p21 class mediator
4 0.006
GO:0060749 mammary gland alveolus development 4 0.007
GO:0001701 in utero embryonic development 8 0.008
GO:0032332 positive regulation of chondrocyte differentiation 4 0.010
GO:0030318 melanocyte differentiation 4 0.011
GO:0008584 male gonad development 6 0.014
GO:0048146 positive regulation of fibroblast proliferation 5 0.015
GO:0045648 positive regulation of erythrocyte differentiation 4 0.018
GO:0030878 thyroid gland development 4 0.020
GO:0048589 developmental growth 4 0.020
GO:0030097 hemopoiesis 5 0.020
GO:0009612 response to mechanical stimulus 5 0.020
GO:0002053 positive regulation of mesenchymal cell proliferation 4 0.021
GO:0032496 response to lipopolysaccharide 7 0.022
GO:0045931 positive regulation of mitotic cell cycle 4 0.026
GO:0001569 patterning of blood vessels 4 0.026
GO:0071773 cellular response to BMP stimulus 4 0.031
GO:0030855 epithelial cell differentiation 5 0.034
GO:0060333 interferon-gamma-mediated signaling pathway 5 0.035
GO:0007596 blood coagulation 7 0.036
GO:0051726 regulation of cell cycle 6 0.036
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway
via death domain receptors
4 0.036
GO:0045444 fat cell differentiation 5 0.036
GO:0007623 circadian rhythm 5 0.039
GO:0030509 BMP signaling pathway 5 0.040
GO:0045647 negative regulation of erythrocyte differentiation 3 0.040
GO:0030501 positive regulation of bone mineralization 4 0.039
GO:0032869 cellular response to insulin stimulus 5 0.040
GO:0045666 positive regulation of neuron differentiation 5 0.041
hsa05202:Transcriptional misregulation in cancer 16 5.609E-8
hsa05200:Pathways in cancer 20 3.179E-6
hsa05221:Acute myeloid leukemia 9 8.284E-6
hsa05161:Hepatitis B 12 2.050E-5
hsa05166:HTLV-I infection 15 2.333E-5
hsa04917:Prolactin signaling pathway 9 2.708E-5
hsa04380:Osteoclast differentiation 9 0.002
hsa05210:Colorectal cancer 6 0.011
hsa05160:Hepatitis C 8 0.011
hsa05220:Chronic myeloid leukemia 6 0.018
hsa04919:Thyroid hormone signaling pathway 7 0.023
hsa05215:Prostate cancer 6 0.036
hsa05162:Measles 7 0.041
hsa05216:Thyroid cancer 4 0.042
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Table S23: Specifications of disease-specific networks for the LIHC dataset.
method # nodes # edges # hubs # MDS # MCDS
DESeq 163 199 17 37 35
edgeR 454 579 46 87 98
voom 483 608 49 94 105
VST 475 586 48 93 99
Table S24: Consistent hub genes and miRNAs for the LIHC dataset.
hsa-let-7b, JUN, E2F1, FOS, MYC, CCND1, ESR1, TERT, STAT3, NFE2L2, HBB, APOH, MIER1
Table S25: Consistent MDS genes and miRNAs for the LIHC dataset.
NFE2L2, NME2, MAZ, MYCN, JUN, NR1H4, KCNIP3, NR4A1, TCF3, FOS, ETV4, ESR1, CREM, CNBP,
FOXM1, hsa-let-7b, STAT3, USF1, LEF1, SREBF2, HIVEP1, MYC, JUND, CEBPD, ETS2, KLF6, AR, E2F1
Table S26: Consistent MCDS genes and miRNAs for the LIHC dataset.
LEF1, MAZ, CREM, FOXM1, ETS2, MYC, HIVEP1, E2F1, hsa-let-7b, EGR1, JUN, RRM2, JUND, KCNIP3,
CNBP, STAT3, NME2, FOS, ETV4, ESR1, USF1, NR4A1, TCF3, NFE2L2
Table S27: Specifications of disease-specific networks for the BRCA dataset.
method # nodes # edges # hubs # MDS # MCDS
DESeq 227 302 23 64 70
edgeR 864 1185 87 145 173
voom 756 1065 76 144 169
VST 851 1199 86 147 168
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Table S28: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted
p-values < 0.05 for the conserved method in breast cancer disease. P-values were adjusted
for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0042771 intrinsic apoptotic signaling pathway in response to DNA
damage by p53 class mediator
4 7.463E-4
GO:0045944 positive regulation of transcription from RNA polymerase II
promoter
8 6.630E-4
GO:0045893 positive regulation of transcription, DNA-templated 6 0.004
GO:0010165 response to X-ray 3 0.014
GO:0006366 transcription from RNA polymerase II promoter 5 0.044
GO:0042981 regulation of apoptotic process 4 0.039
hsa05212:Pancreatic cancer 6 2.201E-6
hsa05220:Chronic myeloid leukemia 6 1.855E-6
hsa05200:Pathways in cancer 8 1.301E-5
hsa05161:Hepatitis B 6 3.130E-5
hsa05166:HTLV-I infection 6 4.079E-4
hsa04110:Cell cycle 5 3.893E-4
hsa05210:Colorectal cancer 4 0.001
Table S29: Enriched GO terms (top) and KEGG pathways (bottom line) with adjusted
p-values < 0.05 for the non-conserved method in breast cancer disease. P-values were
adjusted for multiple testing using the BH procedure.
Enriched terms count adj. p-values
GO:0045892 negative regulation of transcription, DNA-templated 15 0.001
GO:0051092 positive regulation of NF-kappaB transcription factor activity 8 0.006
GO:0008340 determination of adult lifespan 4 0.018
GO:0006468 protein phosphorylation 12 0.018
GO:0045944 positive regulation of transcription from RNA polymerase II
promoter
17 0.034
GO:0045893 positive regulation of transcription, DNA-templated 12 0.035
GO:0000122 negative regulation of transcription from RNA polymerase II
promoter
14 0.040
GO:0016032 viral process 9 0.046
hsa05200:Pathways in cancer 14 2.495E-4
hsa05212:Pancreatic cancer 7 3.700E-4
hsa05166:HTLV-I infection 11 3.851E-4
hsa05210:Colorectal cancer 6 0.002
hsa05220:Chronic myeloid leukemia 6 0.003
hsa05145:Toxoplasmosis 6 0.031
hsa04110:Cell cycle 6 0.033
hsa05162:Measles 6 0.039
hsa04350:TGF-beta signaling pathway 5 0.042
hsa05222:Small cell lung cancer 5 0.040
hsa04064:NF-kappa B signaling pathway 5 0.040
hsa05215:Prostate cancer 5 0.038
hsa05161:Hepatitis B 6 0.035
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Abbreviations:
• GRN: Gene Regulatory Network
• TF: Transcription Factor
• DE: Differentially Expressed
• MDS: Minimum Dominating Set
• MCDS: Minimum Connected Dominating Set
• LCC: Largest Connected Component
• LSCC: Largest Strongly Connected Component
• VST: Variance-Stabilizing Transformation
• GO: Gene Ontology
• ESC: Embryonic Stem Cell
• BH: Benjamini-Hochberg
• ILP: Integer Linear Programming
• DAVID: The Database for Annotation, Visualization and Integrated Discovery
• ORA: Over Representation Analysis
• HMDD: Human miRNA Disease Database
• DisGeNET: A Database for Gene-Disease Association
• FFL: Feed Forward Loop
• IPSC: Induced Pluripotent Stem Cell
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